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Abstract
The discovery of the genetic basis of neurodegenerative disorders has enabled the 
generation of models to study their pathogenesis.
In part one, human embryonic kidney cells with inducible expression of wild-type or 
mutant G209A a-synuclein modelled increased a-synuclein expression and a 
familial form of Parkinson’s disease, respectively. Both wild-type and mutant a- 
synuclein were localised to vesicles, some of which were catecholaminergic. Over­
expression of wild-type or mutant (G209A) a-synuclein alone did not reduce cell 
viability, cause oxidative stress or impair mitochondrial function. However, mutant a- 
synuclein expression enhanced the susceptibility to dopamine toxicity causing 
increased oxidative stress and cell death. This effect was similar to that of reserpine, 
an inhibitor of vesicular monoamine uptake, in controls. These results suggest that 
a-synuclein may play a role in dopamine compartmentalisation. Loss of function 
conferred by the G209A mutation could therefore increase cytoplasmic dopamine 
concentrations with subsequent cell damage or death.
In part two, myoblast cell lines were established, and characterised, from the R6/2 
mouse model of Huntington’s disease (HD). Mutant N-terminal huntingtin transgene 
over-expression was associated with significantly greater numbers of myotubes 
suggesting a role of huntingtin in muscle differentiation. In long-term culture, 
differentiated R6/2 myotubes, but not controls, formed nuclear huntingtin inclusions. 
Inclusion number depended upon culture medium conditions suggesting that 
environmental factors might be relevant. This model of HD in non-neuronal post­
mitotic cells may be useful to study the pathophysiology of, and possibly the effect of 
therapeutics on, huntingtin aggregate formation.
The third part examined the suggestion that codon 129 homozygosity of the prion 
protein (PrP) gene may predispose to sporadic inclusion body myositis (sIBM).
2
Codon 129 zygosity in 41 sIBM muscle biopsies was not significantly different to 
results published in population studies in several Western countries suggesting 
sIBM is not linked to homozygosity at codon 129 of the PrP gene.
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CHAPTER 1: General introduction
1.1. Introduction
Neurodegenerat ive diseases are common diseases; in the United States an 
estimated 4 million people have the most common neurodegenerative disease, 
Alzheimer’s disease, and about 1 million suffer from Parkinson’s disease (Kawas 
and Katzman, 1999; Lilienfeld, 1994), with a similar prevalence in Europe (de Rijk et 
al., 2000). Other neurodegenerative diseases such as Huntington’s disease, 
Amyotrophic Lateral Sclerosis, prion disease, or fronto-temporal dementia are less 
common.
The increase in life expectancy across the world has raised further concern 
about the incidence of neurodegenerative diseases, in particular Alzheimer’s 
disease and Parkinson’s disease. The incidence of these diseases rises with age so 
that the prevalence of Alzheimer’s disease is about 1 in 10,000 at the age of 60 and 
1 in 3 among individuals at the age of 85 (Evans et al., 1989; Katzman, 1986). It has 
been estimated that in the United States by 2025 more than 10 million people will 
suffer from Alzheimer’s disease and this number may rise to 20 million by 2050 
(Kawas and Katzman, 1999). Age was also found to be the most important risk 
factor for Parkinson’s disease with an estimated prevalence of 1 to 2% in the 
population over 65 years of age (de Rijk et al., 2000). Close to 50% of individuals at 
the age of 85 in the community showed at least one symptom or sign of Parkinson’s 
disease (Bennett et al., 1996).
The death of neurones characterises many neurodegenerative diseases 
including Parkinson’s disease, Huntington’s disease, stroke, prion disorders, and 
amyotrophic lateral sclerosis. Since the capacity of the central nervous system for 
regeneration is severely limited it is paramount to prevent neuronal death. Research 
into what causes neuronal cell death in neurodegenerative diseases promises
23
valuable insight into their pathogenesis, which may ultimately help design 
treatments. This is important not only because it would help treat millions of patients 
but also because of the socio-economic burden associated with neurodegenerative 
diseases.
This thesis investigated the molecular pathology of 3 neurodegenerative 
diseases. The first part describes a cell culture model of Parkinson’s disease using a 
stable inducible system, the Ecdysone Mammalian Expression system. This model 
allowed the investigation of a-synuclein gene expression, both wild-type and G209A 
mutant, and it’s relationship to cellular dysfunction, in particular oxidative stress, 
dopamine toxicity and mitochondrial function. The second part of the thesis 
describes a cell culture model of Huntington’s disease established in myoblast cell 
cultures from transgenic Huntington’s disease mice (R6/2). In this model, the 
relevance of over-expression of the human transgene for protein aggregation and 
myotube differentiation was examined. Finally, the last part of the thesis tested the 
hypothesis that homozygosity at the common polymorphism at codon 129 of the 
prion protein gene might be more common in sporadic inclusion body myositis.
This introductory chapter reviews basic mechanisms underlying, and pathways 
leading to, neuronal cell death. These include mitochondrial function, oxidative 
stress and excitotoxicity, and protein aggregation and the ubiquitin-proteasome 
pathway.
1.1.1. Mitochondrial function
Mitochondria are present in every cell. The mitochondrial respiratory chain and 
oxidative phosphorylation provide the majority of energy in the form of ATP. The 
mitochondrial respiratory chain complexes are located on the inner mitochondrial 
membrane. Of the five complexes, complex I (NADH CoQ10 reductase) is the
24
largest with 41 subunits, complex III (ubiquinol cytochrome c reductase) has 11 
subunits, complex IV (cytochrome oxidase, COX) has 13 subunits and complex V 
(ATPase) has 14 subunits. Complex II (succinate ubiquinone oxidoreductase) with 4 
subunits is the only complex completely encoded by the nucleus.
Tissues with high energy demands such as brain, skeletal and cardiac 
muscle contain the greatest number of mitochondria. Mitochondria contain the only 
source of extranuclear DNA. Each mitochondrion harbours 2 to 10 molecules of 
mitochondrial DNA (mtDNA), which is a 16.5 kilobase circular double-stranded 
molecule consisting of a heavy (H) and a light (L) chain. Mt DNA encodes 22 
transfer RNAs (tRNAs) and 12S and 16S ribosomal RNA as well as 13 proteins all 
part of the respiratory chain and oxidative phosphorylation system. Of these13 
polypeptides 7 are subunits of complex I, one is a subunit of complex III, three are 
subunits of complex IV and 2 are subunits of complex V. The remaining 70 subunits 
of mitochondrial respiratory chain are encoded by the nucleus and imported into 
mitochondria. Nuclear DNA also encodes proteins for mtDNA replication, 
transcription, translation, repair and regulation of mitochondrial respiratory chain 
assembly.
MtDNA is very compact, with 93% of the sequence encoding genes and 
virtually no introns. There is no protective histone coat and mtDNA repair may be 
slower than nuclear DNA repair with subsequent accumulation of base damage 
(Yakes and Van Houten, 1997). Mitochondria are highly active metabolically. Fuel 
molecules such as carbohydrates, fatty acids and amino acids are oxidised in the 
citric acid cycle within the mitochondrial matrix leading to the production of NADH 
and FADH2. Glycolysis and fatty acid oxidation are other sources of NADH and 
FADH2, which contain a pair of electrons with high transfer potential. The transfer of 
these electrons from NADH or FADH2 to 0 2 through protein complexes located in 
the inner mitochondrial membrane generates a pH gradient and a transmembrane
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electric potential. Subsequently ADP is phosporylated to ATP when electrons flow 
back to the mitochondrial matrix. This process is called oxidative phosphorylation. 
The citric acid cycle and oxidative phosphorylation also generate free radicals in the 
form of superoxide ions. Reactive oxygen species are thought to contribute to the 
high mutation rate of mtDNA (Shenkar et al., 1996).
Mitochondria serve a variety of functions within the cell other than the 
oxidative phosphorylation of ADP to ATP. A number of metabolic processes take 
place in the mitochondrial matrix including fatty acid oxidation, amino acid 
metabolism, heme synthesis, iron-sulfur synthesis, ubiquinone syntheses, and 
mitochondrial DNA replication and repair. Mitochondria play a critical role in the 
regulation of programmed cell death with pro- and antiapoptotic proteins being 
localised at the outer mitochondrial membrane and proapoptotic cytochrome c and 
apoptosis inducing factors (AIFs) located in the mitochondrial matrix (see next 
section). In addition, free radicals are produced within mitochondria, which also 
contain anti-oxidant defences. An excess of free radical production or diminished 
anti-oxidant defences can lead to oxidative stress within cells (see section 1.1.3). 
Mitochondria maintain a protonelectrochemical gradient (Ap) across their inner 
membrane and serve to buffer cellular calcium levels, key factors for ATP production 
and mitochondrial integrity (see section 1.1.5).
1.1.2.Types of cell death
1.1.2.1. Necrosis
Neuronal necrotic cell death occurs with abrupt cessation of the supply of oxygen 
and/or glucose, for example in anoxia, ischaemia, or associated with trauma (Emery 
et al., 1998; Linnik et al., 1993). Cells are unable to produce the ATP necessary to 
maintain their integrity and function; histologically, nucleus and mitochondria swell
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followed by rapid lysis of cellular organelles. The DNA is degraded enzymatically at 
random.
1.1.2.2. Programmed cell death
Programmed cell death occurs following the activation of an intrinsic cellular 
programme. In multicellular organisms development, organ morphogenesis, and the 
regulation of defence mechanisms to remove infected or otherwise damaged cells 
require programmed cell death. Apoptosis describes one morphological form of cells 
undergoing programmed cell death. It is characterised morphologically by reduced 
cell volume, condensation of chromatin and fragmented nuclei with preservation of 
cellular membranes. Apoptotic cells exhibit “apoptotic bodies” containing cellular 
material and are recognised and removed by phagocytes.
Programmed cell death needs to be tightly regulated. Diseases such as 
neurodegenerative diseases and immunodeficiency may be linked to an excess of 
programmed cell death with the untimely death of important cells such as neurones 
or lymphocytes. Indeed, evidence to suggest involvement of programmed cell death 
has been provided for diseases such as Alzheimer’s disease, Amyotrophic Lateral 
Sclerosis, Parkinson’s disease and Huntington’s disease (for a review see (Vila and 
Przedborski, 2003), and sections 3.1.10 and 4.1.9). Understanding the mechanisms 
of programmed cell death in neurodegeneration may be relevant to the development 
of treatment for these devastating diseases.
The caspase family
Key to programmed cell death is the activation of a cascade of proteolytic enzymes 
called caspases. Caspases exist in almost all cells. Intracellular signalling processes 
triggered by intracellular damage or lack of trophic factors can activate caspases. In 
mammals, 15 members of the caspase family have been identified; procaspases 2,
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8, 9 and 10 are known as initiators whereas procaspases 3, 6 and 7 are known as 
effectors. Initiator caspase activation precedes effector caspase activation. 
Eventually, activated caspase-3 cleaves an inhibitory protein of the caspase 
activated DNAase (ICAD), which can then act as an endonuclease to digest DNA 
(Enari et al., 1998; Sakahira et al., 1998). This is followed by mitochondrial damage, 
chromatin condensation, DNA fragmentation and nuclear membrane disruption, and 
ultimately cell death.
Mitochondrial involvement
Mitochondria play a pivotal role in programmed cell death (Green and Kroemer, 
2004) (Figure 1.1). One mechanism involves the inner mitochondrial membrane 
while the other involves the Bel 2 family of programmed cell death regulating 
proteins situated at the outer mitochondrial membrane. In the first mechanism a 
pore in the inner mitochondrial membrane, the permeability transition pore (PT) 
opens and allows the flow of water and molecules smaller than about 1.5kD. This 
leads to an equilibration of ions across the inner mitochondrial membrane and thus 
to a loss of the mitochondrial membrane potential (A'Fm). The entry of water leads to 
swelling of the mitochondrial matrix, and subsequently the outer mitochondrial 
membrane may become permeable. Situated at the outer mitochondrial membrane, 
the Bel 2 family helps regulate programmed cell death. Some of its members 
promote programmed cell death (Bax and Bak) whereas others have anti­
programmed cell death activities (Bel 2 and Bel XL) (Gross et al., 1999). They play 
an important part in the regulation of mitochondrial integrity, particularly 
mitochondrial outer membrane permeabilisation (Green and Kroemer, 2004), and 
the release of mitochondrial pro-apoptotic factors such as cytochrome c, apoptosis- 
inducing factor (AIF) or Smac/Diablo (Gross et al., 1999).
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Initiation of programmed cell death
Programmed cell death can be initiated following extracellular or intracellular signals 
(Figure 1.1). In the extrinsic pathway activation of cell surface receptors such as 
Fas/CD95 or tumour necrosis factor receptor 1 (TNFR 1) are activated when they 
bind their respective ligands (Fas ligand for Fas/CD95 or tumour necrosis factor a 
for TNFR 1). This leads to the association of an intracellular death domain that is 
part of the receptor with a death effector domain (FADD, Fas associated death 
domain, and TRADD, tumour necrosis factor receptor associated death domain 
respectively). Subsequently, procaspase 8 is activated followed by downstream 
caspase activation and cell death. In the intrinsic, receptor independent pathway, in 
response to e.g. oxidative stress or the formation of toxic aggregates pro-apoptotic 
molecules such as Bax translocate to mitochondria to induce mitochondrial outer 
membrane permeabilisation and release of mitochondrial pro-apoptotic cytochrome 
c, AIF, or Smac/Diablo. In the cytosol cytochrome c and AIF form a complex with 
procaspase 9 and Apaf 1 and then activate the effector caspase 3. Endoplasmatic 
reticulum stress induced by abnormal calcium homoeostasis or increase in the 
concentration of unfolded proteins within the endoplasmatic reticulum can also 
induce programmed cell death by activation of caspase 12 and subsequent 
activation of caspase 9 (Morishima et al., 2002; Nakagawa et al., 2000).
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Figure 1. Mitochondria and programmed cell death
Figure 1.1. Mitochondria and programmed cell death.
Mitochondria play a central part in pathways leading to programmed cell death. 
Intracellular death signals (e.g. oxidative damage or toxic aggregates) can initiate a 
cascade of events including transfer of pro-apoptotic Bax or Bak to the outer 
mitochondrial membrane, opening of the permeability transition pore (PT) and loss 
of the mitochondrial transmembrane potential. This leads to the entry of water and 
ions into the mitochondrial matrix, swelling and subsequent mitochondrial outer 
membrane permeabilisation (MOMP). Cytochrome c, apoptosis inducing factor (AiF) 
and Smac/Diablo can then leak into the cytoplasm activating executioner caspases, 
which leads to programmed cell death. Extracellular death signals activate cellular 
death receptors such as Fas with subsequent activation of caspase 8 and then 
executioner caspases leading to programmed cell death. Apaf: apoptosis associated 
factor. BID: BCI2-interacting domain. IAF: inhibitor of apoptosis. FasL: Fas ligand.
1.1.3. Free radicals and anti-oxidant cellular defence systems
Any independent species that contains one or more unpaired electron is a free 
radical. Free radicals are generally unstable and therefore highly reactive with a 
half-life of only nanoseconds (Halliwell and Gutteridge, 1999). They are normal by­
products of cellular aerobic metabolism (Halliwell and Gutteridge, 1999). The most 
prominent biological free radicals are the reactive oxygen species (ROS) superoxide 
(0 2*‘), hydroxyl (OH*), and hydrogen peroxide (H20 2), and the reactive nitrogen 
species (RNS). These result from nitric oxide (NO*), which also possesses an 
unpaired electron and can either via a series of reactions give nitrous oxide (N20) 
and hydroxyl radical (OH*) or, following one-electron reduction to nitroxyl anion, 
react with 0 2 to give peroxynitrite (ONOO'). NO* reacts with 0 2 on exposure to air to 
form the gas nitrogen dioxide (N02*), which is a more reactive free radical than NO*. 
NO*, ONOO' and N 02*. Nitric oxide is synthesised in living organisms by enzymes 
called nitric oxide synthases (NOS). Three different types of NOS, neuronal NOS 
(nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS) help regulate NO* 
synthesis. NOS and NO* production serve physiological functions, e.g. blood vessel
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tonus and thus blood pressure regulation. Apart from iNOS NOS are dependant on 
Ca2+ levels, which links free radical production to mitochondria, which buffer 
cytoplasmic calcium.
Experiments on isolated mitochondria exposed to high levels of oxygen 
indicate that mitochondria convert 1 -2% of oxygen into ROS (Boveris and Chance, 
1973). The main source of free radical production is the mitochondrial respiratory 
chain complex I and particularly complex III (ubiquinone-cytochrome c reductase) 
(Turrens, 1997). In the regeneration of co-enzyme Q the intermediate free radical 
semiquinone (Q-) is formed. -Q-can transfer electrons non-enzymatically to oxygen 
thus generating 0 2". Cytosolic enzyme systems contribute to ROS production, in 
particular the NADPH oxidase family (Suh et al., 1999).
Free radicals can be counteracted by the cellular antioxidant defence 
systems, which are particularly strong in mitochondria. These defence systems 
include the enzymatic scavengers superoxide dismutase (SOD), catalase and 
glutathione peroxidase. SOD exists in three forms: a cytoplasmic copper/zinc 
(Cu/Zn) form (SOD 1), a mitochondrial manganese form (SOD 2) and an 
extracellular form (SOD 3)(Fridovich, 1995). All forms catalyse the rapid conversion 
of 0 2*‘ + 2H+ to H20 2. Catalase and glutathione peroxidase convert H20 2 to water. 
Other non-enzymatic low molecular weight compounds contribute to ROS 
scavenging. These include ascorbate (vitamin C), pyruvate, flavonoids (vitamin E), 
carotenoids (vitamin A), co-enzyme Q and glutathione (GSH). The latter is likely the 
most important of this group and present in all cells with high metabolic demands 
such as neurones in combination with glutathione peroxidase and glutathione 
reductase. Glutathione can reduce H20 2 and lipid hydroperoxides, which results in 
oxidised glutathione (GSSG). Subsequently, GSSG is reduced to GSH by 
glutathione reductase in a NADPH dependent conversion.
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1.1.4. Cellular consequences of oxidative stress
If ROS/RNS production is not balanced by the cellular defence mechanisms 
oxidative stress occurs. Consequently this can result in oxidative damage to lipids, 
proteins and DNA with subsequent functional impairment. If oxidative stress is 
severe it may cause cell death by necrosis or by programmed cell death. This may 
involve oxidative damage to mitochondria with Ca2+ release, opening of the 
mitochondrial permeability transition pore and release of pro-apoptotic factors (see 
section 1.1.2.2. and Figure 1.1.). ROS/RNS damaged proteins may be more prone 
to ubiquitination and degradation within the ubiquitin-proteasom system (UPS, see 
section 1.1.6.). Additional abnormal function of the UPS can further promote 
accumulation of damaged proteins leading to the formation of aggregates and 
possibly triggering the initiation of programmed cell death (see section 1.1.2.2. and 
Figure 1.1.).
Lipid peroxidation
The decomposition of H20 2 produces OH*, which can react with polyunsaturated 
fatty acids (PUVA) abstracting a hydrogen atom from a methyl group. This results in 
an unpaired unstable electron on the carbon atom (-HC-) that stabilises itself 
through electron re-arrangements forming a conjugated diene radical in the process. 
This can react with 0 2 to form a peroxyl radical (-COO -) that can abstract an 
electron from another lipid molecule creating a cycle of lipid peroxidation and the 
generation of lipid hydroxyperoxide products such as malonaldehyde (Gutteridge 
and Halliwell, 1990). Functionally, lipid peroxidation can affect membranes leading 
to loss of membrane fluidity, reduced membrane potential or changes in 
permeability to ions such as Ca2+ (Simonian and Coyle, 1996).
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Oxidative damage to DNA
Hydroxyl radicals can react with sugars, purins and pyrimidines of DNA. For 
example, OH* can add on to guanine at positions 4,5 or 8 in the purine ring; addition 
at position 8 leads to a C-8 OH-adduct radical that can be reduced to 8-hydroxy-7,8- 
dihydroguanine; it can also be oxidised to 8-hydroxyguanine or the imidazol ring 
may be opened with subsequent one-electron reduction and protonation resulting in 
2,6-diamino-4-hydroxy-5-formidopyrimidine (abbreviated as FAPyG). In a similar 
manner OH* can add on to adenine, cytosine or thymine (Halliwell and Gutteridge,
1999). Deoxyribose sugars are vulnerable to fragmentation by OH* where hydrogen 
abstraction by OH* can result in carbon centred-radicals, which in the presence of 
0 2 convert rapidly into sugar peroxyl radicals followed by the generation of carbonyl 
products in subsequent reactions. Consequences of ROS damage to DNA include 
base and sugar modifications, single- and double-strand breaks, and, if there is 
additional damage to proteins, DNA-protein cross links within the chromatin. This 
can interfere with chromatin unfolding, DNA repair, replication and transcription. In 
addition, the generation of single-strand breaks can activate poly(ADP)ribose 
polymerase (PARP) a process that requires ATP and can lead to depletion of NAD+ 
with subsequent impairment of mitochondrial function, glycolysis and ATP synthesis.
Oxidative damage to proteins
Proteins are particularly vulnerable to attacks by reactive nitrogen species such as 
ONOO', N 02* and N02CI; an attack upon tyrosine leads to the production of 3- 
nitrotyrosine. In addition, peroxides can be generated on the peptide backbone and 
side-chains of aminoacid residues, and carbonyls can also form. The consequences 
of oxidative damage to proteins can be widespread depending on the protein 
involved. It can change the function of enzymes including those involved in DNA 
replication and repair, receptors, signal transduction pathways and transport
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proteins. In addition, protein alterations may trigger an immune response with 
antibody formation, which has been hyothesised for example in scleroderma (Peng 
et al., 1997).
1.1.5. Excitotoxicity
Mitochondria maintain a protonelectrochemical gradient (Ap) across their inner 
membrane. This gradient consists of a transmembrane potential of about 150mV 
(A^m) and a small pH gradient, which controls ATP synthesis through oxidative 
phosphorylation (see section1.1.2). The mitochondrial membrane potential (A'Fm) is 
the component of the proton electrochemical potential (Ap), which determines Ca2+ 
sequestration and also the generation of reactive oxygen species.
Abnormal mitochondrial respiratory chain function may affect the energy 
dependent maintenance of the cellular transmembrane resting potential. 
Depolarisation of the cell membrane from the normal -90mV to between -60 and - 
30mV relieves the voltage dependent block of N-methyl-D-aspartate (NMDA) 
receptors by magnesium (Nicholls and Ward, 2000) and leads to their activation by 
ambient levels of glutamate. Calcium influx follows NMDA receptor activation. 
Mitochondria serve to buffer intracellular calcium. Failure of cytoplasmic Ca2+ 
homeostasis in the wake of mitochondrial dysfunction represents an early step 
towards excitotoxicity and necrotic cell death (for a review see Nicholls and Ward,
2000). Increased levels of cytoplasmic Ca2+ trigger the activation of nitric oxide 
synthase (NOS), and the ensuing increase in superoxide and nitric oxide potentially 
leads to the generation of peroxynitrite (Dawson et al., 1991). Both intra- 
mitochondrial calcium accumulation followed by mitochondrial depolarisation and 
peroxynitrite formation have been demonstrated to be associated with excitotoxic 
cell death (Schinder et al., 1996; White and Reynolds, 1995).
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1.1.6. The ubiquitin-proteasome system (UPS)
The UPS degrades intracellular proteins in a highly specific, complex and tightly 
regulated process. The UPS plays an important role in a variety of cellular 
processes such as the regulation of immune responses, regulation of the cell-cycle, 
growth and cell differentiation (Pickart, 2001; Voges et al., 1999). It also serves as a 
quality control instrument to ensure that abnormal, e.g. misfolded or damaged (e.g. 
by ROS) proteins are disposed of to prevent the formation of potentially toxic 
aggregates (Pickart, 2001; Voges et al., 1999). Abnormalities of the UPS have been 
linked to neurodegenerative diseases such as Parkinson’s disease, Huntington’s 
disease, Amyotrophic Lateral Sclerosis or Prion Diseases (for a review see 
(Ciechanover and Brundin, 2003), and also sections 3.1.9 and 4.1.7.2). It is not 
always clear whether abnormal UPS function is a primary cause of disease or 
involved secondary to another pathological process. For example mutations of 
Parkin, a ubiquitin ligase, that cause autosomal recessive Parkinson’s disease may 
be considered a primary cause (see section 3.1.11.2) whereas ubiquitin mediated 
aggregate formation and its consequences in Huntington’s disease could be 
considered secondary involvement of the UPS (see sections 4.1.7.2 and 4.1.7.3).
In the first step of the degradation process, in an ATP-dependent reaction a 
ubiquitin activating enzyme, E1, activates ubiquitin monomers. A ubiquitin 
conjugating enzyme (E2) binds activated ubiquitin which is then in an ATP- 
dependent reaction covalently linked to the targeted protein by a ubiquitin ligase 
(E3). This is repeated until several ubiquitin molecules are tagged onto the abnormal 
protein. It is not fully understood how abnormal proteins are recognised. Clearly, the 
E3-ligase family plays an important role but there may be other factors that 
contribute to the specificity of substrate recognition.
The UPS degrades poly-ubiquitinated proteins and non-ubiquitinated 
proteins are degraded in the 26S and 20S proteasome. These multicatalytic
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proteases are present in the cytoplasm, endoplasmatic reticulum, perinuclear region 
and within the nucleus of eukaryotic cells. The 20S proteasome (700kDa) forms the 
28-subunit catalytic core of the 26S proteasome. The 20S proteasome consists of 
two outer and two inner heptameric rings which assume the shape of a hollow 
cylinder. Within this structure 7p subunits of each of the two inner rings catalyse 
proteolysis at the C-terminus of acidic, hydrophobic and basic residues; they are 
referred to as peptidylglutamyl-, chymotrypsin- and trypsin-peptide hydrolytic 
activities. Seven a-subunits without proteolytic activity compose the outer ring of the 
20S proteasome. Here the 700kDa multisubunit ATPase containing PA700 activator 
(19S) is anchored to form the larger 26S proteasome. Upon binding of the PA700 
activator to the 20S proteasome the gate to the inner channel opens so that proteins 
destined for degradation can enter. Before proteins enter the proteolytic core of the 
20S proteasome C-terminal hydrolases detach and recycle the polyubiquitin chains 
so that single ubiquitin molecules again become available for E1 mediated 
ubiquitination (Pickart, 2001; Voges etal., 1999).
The degradation process in the proteasome generates small peptides, which 
can be re-used as building blocks in the synthesis of proteins, or can be presented 
on major-histocompatibility-complex I molecules as antigens to cells of the immune 
system. If the function of the proteasome or the ubiquitin labelling system is 
compromised abnormal proteins can accumulate and may aggregate to form 
insoluble inclusion bodies. This may disrupt cellular homeostasis and integrity, and 
may even lead to apoptosis (Sherman and Goldberg, 2001).
1.1.7. Models of neurodegenerative diseases
Disease models are a useful tool to help further our understanding of the 
pathogenesis of the respective disease, in particular, causes of the relative selective 
loss of dopaminergic neurones in PD or medium spiny striatal neurones in HD at the
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molecular level. Ultimately, these models may aid the development of therapeutic 
strategies. Models can be generated by using toxins, either in animals or in cell 
culture, or by genetically modifying animals or cells, or a combination of both.
Ideally, an animal model should reproduce the characteristic clinical and 
pathological features of a disease; for example in PD this should include a L-Dopa 
responsive movement disorder, a chronically progressive loss of dopaminergic 
neurones, and LB-like inclusions. This may simplify the complexity of human 
diseases, and no animal or cell culture model is likely to be an exact phenocopy of 
the human disease. Nonetheless, these models are vital in helping to dissect the 
many different molecular and biochemical pathways that converge on the final 
clinico-pathological phenotype of a given disease.
1.1.7.1. Toxin models
Toxins models utilise a specific toxin to model a disease, e.g. if mitochondrial 
involvement in a given disease is thought to play a role in the pathogenesis of this 
disease a mitochondrial toxin can be used. Toxins can be applied systemically to 
animals or injected under stereotactical guidance directly into the area of interest, 
e.g. the substantia nigra in PD. In addition, toxins can be used in cell culture models 
to investigate their effects at a subcellular level.
1.1.7.2. Knock-out models
In ‘knock-out’ mouse lines the genome is manipulated to remove or alter DNA 
sequences so a gene cannot function. For the generation of knock-out mouse lines, 
firstly embryonic stem (ES) cells are genetically modified in culture to introduce the 
desired changes into the genome, and successfully transformed ES cells are 
selected. Secondly, these ES cells are injected into recipient blastocysts from wild- 
type mice, which results in a mixture of normal and genetically modified cells
38
(chimera). Thereafter, the chimeric blastocysts are implanted into the reproductive 
tracts of normal mice that subsequently give birth to a number of chimeric mice. If 
these chimeric mice have incorporated the modified genes into their germ line, then 
a new strain of mice can be created that carries the targeted mutation. Knock-out 
mice model recessive disorders where the phenotype results from the loss of the 
protein encoded by the dysfunctional gene. In addition, the pathological 
consequences of the absence of the protein of interest may indirectly help to 
understand its function.
1.1.7.3. Transgenic animal models
Transgenic animals express a gene of interest foreign to their own DNA. DNA of the 
gene of interest under the control of a promoter sequence is constructed with 
recombinant DNA techniques and injected into the male pronucleus of fertilised 
uncleaved eggs from a donor animal. At the two-cell stage the injected eggs are 
transferred into the reproductive tract of a female animal. After confirmation of the 
successful incorporation of the transgene, heterozygous offspring are re-mated to 
generate a homozygous transgenic animal. The quality of the animal model is 
reflected in the expression of the gene of interest in the appropriate anatomical site, 
e.g. the substantia nigra in PD models. This depends upon the intrinsic efficiency of 
the promoter of the transgene, the number of transgene copies introduced into the 
host genome, and possibly upon the site of incorporation of the transgene into the 
host genome (for a review see Shuldiner, 1996).
1.1.7.4. Cell culture models
Cells can be genetically modified to express specific genes of interest, and the 
structural, biochemical and functional consequences of gene expression can be 
analysed at the level of the individual cell. Genes of interest are introduced into the
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host cell by a process called transfection. Most commonly, the cDNA of the gene of 
interest is inserted into a plasmid or viral cloning vector, and following transfection 
into a host cell line, the gene may be expressed transiently (transient transfection) or 
becomes incorporated into the host cell genome (stable transfection). Cells can also 
be modified to loose expression of a gene of interest, e.g. by using anti-sense 
mRNA.
Cell models of diseases can be generated in several ways:
Transient transfection. A plasmid of interest is transfected into cells and the gene 
of interest is transiently expressed. This type of model is useful for morphological 
analysis of protein expression in individual cells. However, the disadvantages are 
that the level of protein expression cannot be controlled, only a proportion of cells 
(usually 20-30%) express the protein and protein expression is short-lived (about 7- 
10 days).
Constitutive and stable expression. In these models the protein of interest is 
expressed permanently. However, often the transfected gene is markedly over­
expressed so that the physical load of over-expressed protein may be harmful for 
the cells. In addition, the continuous expression of the transfected gene may lead to 
a selection of cells that are able to grow in its presence thus introducing an 
important confounding factor.
Inducible and stable expression. In these models not only is the transfection 
stable but the inducing agent allows for more control over the amount of protein 
expressed from the transgene. Contrary to constitutive and stable expression 
systems, cells grow unselected for their ability to grow in the presence of the 
expressed protein and the comparison of the same cells with and without protein
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expression can identify relatively small differences. This can be more problematic 
with constitutive protein expression in particular because clonal cell lines, even 
when derived from the same precursor cell line, may show important differences per 
se. This could be an important confounding factor for comparisons between clones 
that express different proteins. A problem with inducible models is that the inducing 
agent itself can introduce artefactual changes compared with the non-induced 
controls. Using as inducer for example an insect hormone, which has no homologue 
in mammalian cells, can circumvent this.
Cell culture models are useful to selectively investigate pathological and biochemical 
aspects of diseases at the sub-cellular level. The quality of a cell culture model 
depends on the cell line in which the model was established. This should ideally 
reflect properties of the cell type affected in the disease it models, e.g. dopaminergic 
neurones in PD. Other factors that determine the quality of a cell culture model 
include the number of cells successfully transfected, the amount of protein 
expressed from the transfected cDNA and the control over the levels of protein 
expression. These factors may limit the types questions that can be addressed with 
a given model. With transient transfection, for example, only about 30% of cells will 
be successfully transfected (this may be higher with viral vectors) and the cells may 
not contain the transfected cDNA for longer than 10 days. This means that 
experiments are limited to those cells that have been transfected and will have to be 
short.
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CHAPTER 2
Material and Methods 
2.1 Materials
Unless otherwise stated the following equipment was used.
Tissue culture and human tissue handling equipment
ICN-Flow Automatic C02 Incubator model 320 (ICN-Flow Ltd., High Wycombe, 
Bucks, UK); Gelair (ICN-Flow) for tissue culture; Class I ICN Flow hood.
Centrifuges
Beckman GPR bench-top centrifuge with GH-3.7 horizontal rotor (Beckman Ltd., 
High Wycombe, Bucks, UK), Kontron T-124 high-speed centrifuge with 8.24 8 x 
50ml fixed angle rotor (Kontron Instruments, Watford, Herts, UK), Biofuge 13 with 18 
x 1.5ml fixed angle rotor (Heraeus, Germany), Fresco Microcentrifuge (Heraeus).
Molecular Biology equipment
Hybaid mini hybridisation oven (Hybaid Ltd., Middx, UK), Perkin-Elmer 2400 thermal 
cycler (Perkin-Elmer, Warrington, Cheshire UK), Infors-HAT orbital shaker (Infors 
Ltd., Crewe, UK), G25 Incubator shaker (New Brunswick Scientific Co. Inc. Edison, 
NJ, USA), Gel Dryer (BioRad Lab. Ltd., Hemel Hempstead, Herts, UK).
Electrophoresis equipment
BioRad 200/2.0 constant voltage power packs (BioRad Lab. Ltd.), BRL horizontal 
system for agarose gel electrophoresis (Bethesda Res Lab, Life Technologies Inc., 
Gaithsburg, MD, USA), BioRad vertical system for polyacrylamide gel
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electrophoresis (BioRad), UV transilluminator (GRI Ltd., Dunmow, Essex, UK), 
Polaroid camera.
Cell homogenisers
Uni-form 5ml and 10ml glass/Teflon homogeniser (Jecons Ltd., Leighton Buzzard, 
Bedforshire, UK), 5ml glass homogeniser and Glass-Col stirrer (CamLab Ltd., 
Cambridge, UK).
Spectrophotometers
Hitachi U-3210 (Hitachi Scientific Instruments, Wokingham, Berks, UK) and Kontron 
Uvikon 940 (Kontron Instruments, Watford, Herts, UK) split beam 
spectrophotometers.
Microscopy and photography
Zeiss Axiophot fluorescence microscope with FITC, UV and rhodamine filters (Carl 
Zeiss Microscope Division, Oberkochen, Germany), MRC 600 confocal microscope 
(BioRad Microscience Division, Herts, UK), Kodak Ektachrome 400ASA for 
immunofluorescence.
Flow cytometer
FACScalibur (Becton Dickinson, UK) flow cytometer using an argon 488nm laser 
and 500nm long-pass filter (FL1 channel) for DiOC6(3) and 578nm (FL2 channel) for 
propidium iodide. This flow cytometer runs on a MAC computer platform using 
Cellquest 4 (Becton Dickinson) software.
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PCR equipment
Peltier Thermal Cycler (PTC 200), MJ Research Inc., Watertown, Mass, USA or 
GeneAmp PCR Systems 2400, Perkin Elmer, Norwalk, CT, USA.
UV-transilluminator
Chromato-UVE, transilluminator model TM-20, San Gabriel, CA, USA.
Chemicals
Unless otherwise stated all chemicals were purchased from Sigma (Poole, Dorset, 
UK) or Merck Ltd. (Dagenham, Essex, UK).
2.2. Ceil lines and cell culture
2.2.1. EcR 293 cell line (Invitrogen, UK)
Human embryonic kidney cells (HEK293) with stable transfection of the pVgRxR 
plasmid (EcR 293) were purchased from Invitrogen (Invitrogen, UK). This plasmid 
confers resistence to the antibiotic Zeocin (400pg/ml).
Cells were grown at 37°C in a humidified atmosphere containing 5% C02in growth
medium consisting of Dulbecco’s modified Eagle medium (DMEM, Life 
Technologies, Paisley, UK) and 4.5 pg/L glucose, 10% fetal calf serum, 50 units/ml 
penicillin, 50 pg/ml streptomycin (all Life Technologies), 400 pg/ml Zeocin 
(Invitrogen), 50 pg/ml uridine and 110 pg/ml sodium pyruvate.
2.2.2. NT2 cells (Ntera2/D1)(Stratagene, UK)
NT2 cells are neuronal precursor stem cells derived from a human teratocarcinoma. 
They differentiate into post-mitotic mature neurones (hNT2 neurones) following 
treatment with retinoic acid (Pleasure and Lee, 1993; Pleasure et al., 1992).
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Cells were grown at 37°C in a humidified atmosphere containing 5% C02in growth
medium consisting of Dulbecco’s modified Eagle medium (DMEM) and 4.5 pg/L 
glucose, 10% fetal calf serum, 50 units/ml penicillin, 50 pg/ml streptomycin.
2.2.3. SH-SY5Y neuroblastoma cells
SH SY5Y neuroblastoma cells (Ross et al., 1983) were purchased from ECACC 
(Wiltshire, UK). SH SY5Y cells were grown in growth medium consisting of Minimal 
Essential Medium (MEM)/F12 supplemented with 15% foetal calf serum, 50 units/ml 
penicillin and 50 pg/ml streptomycin. For differentiation, SH-SY5Y cells were plated 
out at about 10% confluency (approximately 5000 cells/ml); 10 pM retinoic acid (all - 
trans retinoic acid, Sigma) was added to SH SY5Y cells every 2-3 days for 14 days.
2.2.4. R6/2 transgenic mice and myoblast cell lines
Transgenic mice, and littermate control mice, were bred by Professor Gillian Bates, 
Department of Medical Genetics, UMDS, London. Mice were maintained on a SDS 
No.3 breeders diet. The R6/2 transgenic mouse colony was maintained by 
backcrossing with C57BL/6 X CBA) F1 mice. Genotyping and CAG repeat sizing 
was performed by Professor Bates as described previously (Mangiarini et al., 1996).
Mice were sacrificed at 12 weeks of age by cervical dislocation. Quadriceps 
and gastrocnemius muscles were dissected under sterile conditions from 6 
transgenic R6/2 mice and 6 normal littermate mice. Muscle tissue was teased apart 
on 10cm Petri dishes using sterile needles and incubated for 12 minutes in 10ml 
filter sterilised dissociation medium (40ml DMEM with 12000 units of collagenase, 
40mg bovine serum albumin and 3.2 ml trypsin solution (2.5% diluted 1/20 in 
Versene, Gibco) at 37°C in a humidified atmosphere containing 8% C02. Growth 
medium (10ml, DMEM supplemented with 4.5 g/L glucose, 20% foetal calf serum,
50 units/ml penicillin, 50 pg/ml streptomycin, 50 pg/ml uridine, 110 pg/ml sodium
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pyruvate) was added and the suspension was triturated repeatedly through a 10ml 
tissue culture pipette. The supernatant was filtered through a cell strainer (40pm 
mesh, Falcon) and spun at 1000rpm for 10 minutes. The supernatant was aspirated 
and the cell pellet resuspended in growth medium. The entire procedure was 
repeated three times and the combined cell pellets were cultured on a plastic dish 
coated with laminin (Sigma, 10pg/ml physiologically buffered saline (PBS)) in growth 
medium at 37°C in a humidified atmosphere containing 8% C02. The medium was 
changed daily until cells were 50-70% confluent when they were harvested with 
trypsin solution and plated out on laminin (10pg/ml PBS) coated glass coverslips at 
70% confluency (Melo et al., 1996; Vachon et al., 1996). After 24 hours growth 
medium was replaced with differentiation medium (growth medium with either 2% 
horse serum instead of foetal calf serum or no serum). Once myotubes formed 
(usually within one week of differentiation) coverslips were examined weekly for 6 
weeks by immunocytochemistry.
2.2.5. Myotube desmin stain and myotube counts
For semi-quantitative analysis myoblast cultures were differentiated for 1 week and 
stained with desmin and DAPI. On each cover-slip, 4 randomly selected 
representative areas were photographed using a times 20 objective. Images were 
digitised and the total number of nuclei stained with DAPI, the number of desmin 
positive cells and the number of nuclei stained with DAPI within desmin positive 
cells were counted using Sigma Scan Pro5 image analysis software package 
(Jandel Scientific, San Rafael, CA, USA). For semi-quantitative analysis of 
inclusions myoblast cultures (n=3 for controls, and R6/2 cultured with and without 
serum) were differentiated for 6 weeks, and immunostained with ubiquitin and 
huntingtin with DAPI nuclear stain, followed by analysis as described above.
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2.3. Cell culture
All cell lines were grown on 10cm plastic culture dishes (Life Technologies Ltd., 
Paisley, UK). Growth medium was changed at least twice weekly following a wash in 
sterile phosphate buffered saline (PBS, Sigma, UK, consisting of 137mM NaCI, 
2.7mM KCI, 10mM Na2 HP04 and 1.8mM KH2 P04 pH 7.4). Cells were harvested 
and subcultured once they had become confluent. First, they were washed in PBS. 
Then, 1ml of 2.5 % trypsin (25g trypsin and 8.5g NaCI per litre, Gibco) solution (10% 
v/v in Versene) was added for 1-2 minutes at 37°C in a humidified atmosphere until 
cells could be dislodged easily by gentle tapping of the plate against the bench. The 
trypsin was then inactivated by the addition of 9ml of fresh growth medium and the 
cells divided for further growth onto new culture dishes or frozen down for storage.
2.3.1. Cell freezing and defrosting
A confluent plate of cells was harvested as described above. Cells were then 
centrifuged at 350g for 10 minutes at room temperature. The medium was aspirated 
and the cell pellet resuspended in freezing medium. This consisted of 90% growth 
medium and 10% filter sterilised DSMO except for hNT2 and EcR 293 cells where 
the growth medium was substituted with fetal calf serum. Cells resuspended in 
freezing medium in 1ml cryotubes were placed in a sealed polystyrene rack and 
frozen slowly overnight at -70°C before they were transferred into liquid nitrogen for 
long term storage.
Vials of frozen cells were defrosted rapidly at 37°C in a water bath. The cells 
were transferred to 10ml of pre-warmed growth medium in a 20ml universal 
container. Cells were pelleted by centrifugation at 300g for 10 minutes. The medium 
was aspirated, the cells resuspended in 8ml of fresh growth medium and plated onto 
a fresh culture dish. 24 hours later the cells were washed in PBS and the growth 
medium renewed.
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2.4. Molecular biology
2.4.1. The Ecdysone Mammalian Expression System
The Ecdysone-lnducible Mammalian Expression System (Figure 2.1) utilises the 
ability of the insect hormone 20- OH Ecdysone to induce gene expression via the 
ecdysone receptor. The system uses a heterodimer consisting of the ecdysone 
receptor (VgEcR from drosophila modified with the VP16 transactivation domain) 
and the retinoid X receptor (RxR from mammalian cells). This receptor contains a 
modified “Ecdysone response element" (EcRE), which is activated in the presence 
of a ligand such as ecdysone or its analogue ponasterone A. Binding of the 
heterodimer to the EcRE activates transcription. Mammalian cells do not contain the 
ecdysone receptor and therefore do not usually respond to ecdysone or its analogs 
and do not express the ligand. Therefore, there is no basal gene transcription. The 
plasmid pVgRxR contains the VgEcR and RxR genes while the pIND plasmid 
contains the modified ecdysone response element and the “multiple cloning site". 
PIND confers resistence against the antibiotic Zeocin, pVgRxR confers resistence 
against the antibiotic G418.
48
pVgRxR
plasmid
pIND
plasmid
pRSY >
RxR
RxR
I
toCMV> H V gE cf
/
VgEcR
ponasterone A
inserted cDNAPHSP
Ecdysone response element
(EcRE)
Figure 2.1. Schematic illustration of the Ecdysone Mammalian Expression system. 
For an explanation of abbreviations see the main text.
2.4.2. Generation of vectors
The pIND constructs for transfection, containing wild-type a-synuclein or G209A 
mutant a-synuclein, were generated by Dr. Sarah Tabrizi (Department of Clinical 
Neurosciences, Royal Free and University College Medical School London). In brief, 
total RNA was isolated from lymphoblasts from a male PD patient with the G209A a- 
synuclein mutation (kind gift from M. Polymeropoulos, NIH, Bethesda, USA) and 
control lymphoblasts with wild-type a-synuclein (from ECACC, Wiltshire, UK) as 
described by (Chomczynski and Sacchi, 1987). cDNA was generated by RT-PCR 
using the cDNA Cycle Kit (Invitrogen, The Netherlands) according to the 
manufacturer’s instructions. The High Fidelity system (Boehringer Mannhein, 
Germany) was used for all subsequent PCR. Alpha-synuclein cDNA was amplified
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using 5’-CAT TCG ACG ACA GTG TGG TGT (nucleotide 16-37) as a forward primer 
and 5’ CTG CTG ATG GAA GAC TTC GAG (nucleotide 586-607) as a reverse 
primer. In a subsequent PCR the open reading frame of a-synuclein and its 31-nt 5’ 
untranslated region was amplified using 5’-AAG GTA CC GAC AGT GTG GTG TAA 
AGG AAT as a forward primer (G65; nucleotide 26-44 with a 5’ Kpn I site) and 5’-AA 
TGA TCA AGC GTA GTC TGG GAC GTC GTA TGG GTA GGC TTC AGG TTC 
GTA GTG T 3’ as a reverse primer (G66; nucleotide 456-478 with a 3’- 
haemagglutinin (HA) epitope coding sequence and Bel I site, the stop codon of the 
a-synuclein sequence was changed to allow translation of HA). Both mutated 
G209A and wild-type a-synuclein amplified fragments were digested with Kpn I and 
Bel I and ligated into the Kpn I and BamH I sites of pIND (Invitrogen, The 
Netherlands). The correct sequence was confirmed by BIG DYE automated 
sequencing (AB1 310, Perkin Elmer, UK).
This yielded two vector constructs for transfection: pIND containing wild-type 
a-synuclein with a haemagglutinin tag (pIND. a-syn-HA) and pIND containing 
G209A mutant a-synuclein with an haemagglutinin tag (pIND. a-syn/G209A-HA).
2.4.3. Transfection of cDNA
CDNA was transfected using the Escort™ lipofection method according to the 
manufacturer’s instructions (Sigma). Two days before the transfection a confluent 
plate of cells was harvested and split 1:1. One day before the transfection, the cells 
were harvested, counted using a haemocytometer and seeded at a concentration of 
2 X 105 per well in a 6 well plate (35mm well diameter). Just before the transfection 
15fil of the Escort™ reagent were mixed with 230pl of DMEM and 5pg of vector 
cDNA and incubated for 15 minutes at room temperature. Thereafter, 2ml of growth 
medium was added to the Escort™-vector cDNA solution. Following aspiration of 
growth medium from each well containing the cells 0.7ml of Escort™-vector cDNA
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solution was added to each well. Cells were incubated for 5-6 hours at 37°C in a 
humidified chamber with 5% C 02. The Escort™-cDNA solution was then removed 
and replaced by growth medium; after a further 24 hours cells from each well were 
harvested, plated out onto a 10cm Petri dish and grown in growth medium 
containing the selection antibiotics Zeocin (400pg/ml), if the pVgRxR plasmid was 
transfected, or G418 (400pg/ml) if the pIND plasmid was transfected. Varying 
concentrations of antibiotics (0, 50, 125, 250, 300, 400, 500, 750 and 1000(ig/ml) 
were used to determine the minimum concentration required to kill (as assessed 
visually under a light microscope) all untransfected HEK293 cells after 7 days in 
culture when cells were plated out at 25% confluency with change of selection 
medium every 3 days.
Individual clones were generated as described (see section 2.4.4.) and 
grown in selection antibiotics.
2.4.4. Ring cloning
Cells were plated out at very low density so that clones could grow from individual 
cells. Sterile plastic rings were cut from the tops of 0.5ml Eppendorf tubes and then 
autoclaved. After clones were observed by microscopy the medium was aspirated 
and the cells washed in PBS. A sterile plastic ring dipped into UV sterilised high 
vacuum silicone grease was placed around a given clone creating a well, and 100pl 
of trypsin solution was added to this well. Subsequently, 100pl of growth medium 
was added to the well and the cells were transferred to a 35mm culture dish.
2.4.5. DNA extraction from cells
Cells were grown on 10cm tissue culture dishes, harvested by trypsinisation and 
washed in PBS. DNA was extracted using the Nucleon I DNA extraction kit (Scotlab, 
UK) following the manufacturer’s instructions. In brief, cell lysis was followed by
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deproteinisation with sodium perchlorate. Then, DNA was extracted using 
chloroform treatment and recovered with cold absolute ethanol. The DNA was then 
washed using 70% ethanol, centrifuged at 15000g, dried in a heating block at 37°C 
and dissolved in T10Ei buffer (10mM Tris-HCI and 1mM K2-EDTA, pH 7.4) at room 
temperature.
2.4.6. DNA extraction from muscle tissue
The method described here follows that previously described (Sambrook et al., 
1989). In a class I hood, muscle tissue the size of 1-3 matchstick heads was 
chopped up on a microscope slide with a scalpel. The tissue was transferred to a 
1.5ml Eppendorf tube that contained 600pl of 0.1 M Sodium EDTA, 0.01 M Tris-HCI 
(pH 8), 40pl of 10%SDS and 100pl proteinase K (20mg/ml). Tissue was left to digest 
for 3 hours at 56°C rotating in a Hybaid incubator. The samples were then stored at 
-20°C until further processing.
All the following steps were performed at room temperature. 750pl of phenol 
(commercially available liquefied phenol washed in Tris buffer, PhiBio, 
Loughborough, UK) were added to each sample in a class I hood and samples were 
rotated for 15 minutes. Thereafter, the samples were centrifuged at 15000g for 15 
minutes and then the upper, aqueous phase was carefully pipetted to a new 1.5ml 
Eppendorf tube. This was followed by adding 700pi of phenol/bromo- 
chloropropane/isoamyl alcohol (ratio 25:24:1) to each sample and rotation for 15 
minutes. Samples were then centrifuged at 15000g for 15 minutes with subsequent 
transfer of the upper aqueous phase into a new 1.5ml Eppendorf tube. This step 
was repeated 3 times on the upper aqueous phase; the last aqueous phase was 
pipetted into a fresh Eppendorf tube, 650pl of bromo-chloropropane/isoamyl alcohol 
(ratio 24:1) were added and samples rotated for 15 minutes. Samples were
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centrifuged at 15000g for 15 minutes and 500pl of the aqueous phase were pipetted 
into a new 1.5ml Eppendorf tube.
To each of these samples, 50pl of 3M sodium acetate (NaOAC, pH 4.8) and 
1ml ethanol were added in order to precipitate DNA. The precipitate was hooked out 
using a clean plastic stick and transferred into a new 1.5ml Eppendorf tube 
containing 1ml of 70% ethanol. If the precipitate was small the original tube was 
centrifuged at 15000g for 5 minutes and the supernatant aspirated. Then, 1ml 70% 
ethanol was added to the tube. This was repeated twice. The pellet was then dried 
in a heat block (37°C) for about 5 minutes and dissolved in 30-100pl of T^Ei at 
room temperature for several hours.
2.4.7. Estimation of DNA concentration and purity
Once the DNA was fully dissolved the DNA concentration and purity was estimated. 
For this purpose, 5pl of DNA solution was added to 995pl of ddH20  in a 1 ml silica 
quartz cuvette and mixed by inverting. The solution was scanned on a 
spectrophotometer to measure the absorbance pattern between 310nm and 210nm. 
The DNA concentration (pg/pl) was calculated assuming that a 1 mg/ml DNA 
solution has an absorbance of 20 at 260nm. The purity of the DNA was accepted 
when the A260/A280 ratio was between 1.7 and 2.0.
2.4.8. Polymerase chain reaction (PCR)
DNA primers, dATP, dGTP, dCTP, dTTP, Tag polymerase and polymerase buffers 
were obtained from Perkin-Elmer Ltd (Buckinghamshire, UK). All reactions were 
carried out in 0.3ml thin walled PCR tubes.
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2.4.8.1. Amplification of cDNA in pIND constructs
The multiple cloning site of pIND plasmid was amplified using the Ecdyson Forward 
and Reverse primers (Invitrogen).
Ecdysone Forward (G49): 5’CTC TGA ATA CTT TCA ACA AGT TAC 3’
Ecdysone Reverse (G50): 5’ TAG AAG GCA CAG TCG AGG 3’
The PCR mixture consisted of 1^g DNA extracted from samples, 40pmol of each 
oligonucleotide primer, 50mM KCI, 10mM Tris-HCI (pH 8.3), 1.5mM MgCI2, 200pM 
of each deoxynucleoside triphosphate, 5% dimethylsulphoxide and 2.5U Taq 
polymerase in a total volume of 25pl (all concentrations are final concentrations). 
PCR conditions were: 94°C for 4 minutes, 72°C for 1 minute, followed by 35 cycles 
of 94°C (1 minute), 56°C (1 minute, 72°C (1 minute), final extension at 72°C for 10 
minutes. The PCR product was then stored at -20°C until further analysis.
2.4.8.2. Prion protein gene (PRNP) PCR
The PRNP gene open reading frame was amplified as described by Palmer et al 
(Palmer Nature 1991). The PCR mixture consisted of 1pg DNA extracted from 
samples, 25pmol of each oligonucleotide primer, 50mM KCI, 10mM Tris-HCI (pH 
8.3), 1.5mM MgCI2, 200pM of each deoxynucleoside triphosphate, 5% 
dimethylsulphoxide and 2.5U Taq polymerase in a total volume of 50pl (all 
concentrations are final concentrations). PCR cycling conditions were 94°C for 30 
seconds, 57°C for 30 seconds, and 72°C for 1 minute for a total of 35 cycles. The 
PCR product was then stored at -20°C until further analysis.
The following primers were used: forward 5’-ACT GAG AAT TCT CTG ACA TTC 
TCC TCT CTT CA and reverse 5’TAC TGA GGA TCC CTC AAG CTG GAA AAA 
GA.
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2.4.9. PCR clean-up and sequencing
PCR products were cleaned using a commercially available kit following the 
manufacturer’s instructions (QIAquick PCR purification kit, Qiagen, UK). This kit 
utilises spin-column technology and the selective binding properties of a silica-gel 
membrane designed by Qiagen. DNA adsorbs to these silica membranes in the 
presence of high salt concentrations while contaminants pass through the column. 
Impurities are washed away and the DNA is eluted with Tris buffer or water. The 
purified DNA was dried and stored at -20°C until further analysis.
DNA was sequenced by the company MWG (MWG, Germany).
The sequence of the samples was compared with the sequence of human a- 
synuclein (SNCA, NM 000345, gi 6806896) obtained from
www.ncbi.nlm.nih.gov/LocustLink/ website. Sequences were aligned using SeqMan 
II software (DNASTAR Inc., USA).
2.4.10. DNA digestion by restriction endonucleases
All enzymes and buffers were from Promega (Chilworth Science Park, 
Southampton, UK). PCR products were digested with the restriction endonucleases 
MaeII (2 units, MBI, Fermentas, Lithuania) at 56°C or A/sPI (2 units, Boehringer- 
Mannheim, Germany) at 65°C for two hours. All reactions were performed in 
SuRE/Cut buffer M (Boehringer-Mannheim) in a total volume of 25pl.
2.4.11. Detection of DNA
PCR reaction or restriction digests were separated on agarose gels using the BRL 
horizontal system for agarose gel electrophoresis (Bethesda Res Lab., Life 
Technologies Inc., USA). Agarose gels (0.8-2% (w/v)) were prepared in 1 x Tris 
borate EDTA buffer (TBE, 0.9M Tris borate, 1mM EDTA, pH8) containing 1pg/ml 
ethidium bromide. The DNA and the DNA size markers (Smartladder containing
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DNA size markers from 200bp to 10kB, Eurogentic, Belgium) were diluted in 6 x 
loading buffer (Promega UK Ltd., Hants, UK) and loaded onto the gel. DNA was 
separated by electrophoresis in 1 x TBE buffer at 100V for 1 hour. The DNA bands 
on the gel were visualised using a UV transilluminator and then photographed with a 
Polaroid camera.
2.5. Cytochemical staining
2.5.1. Histochemical staining
Histochemical analyses were conducted on muscle tissue mounted on a piece of 
cork so that the muscle fibres were orientated perpendicular to the cork. Samples 
were immediately snap-frozen in isopentane chilled in liquid nitrogen and stored in 
liquid nitrogen. 7-9 pm sections were cut at -25°C with a cryotome (Reichert-Jung 
2800 Frigocut, Germany).
2.5.1.1. Haematoxylin and eosin
The staining protocol followed established histological staining techniques 
(Dubowitz, 1985; Engel, 1994). Sections were stained for 5 minutes in Meyer’s 
haemalaun (Merck, UK), rinsed carefully under running water and left in tap water 
for 10 minutes. Sections were then stained in 0.1% (w/v) eosin for 1 minute followed 
by dehydration in 70-100% ethanol, clearing in xylene and mounting in DPX (Agar 
Scientific Ltd, Cambridge, UK).
2.5.1.2. Gomori Trichrome
The Gomori Trichrome stain is an established histological staining technique 
(Dubowitz, 1985; Engel, 1994). The staining protocol followed the method described 
by Engel (Engel and Cunningham, 1963). Sections were first stained in 
haematoxylin for 5 minutes, rinsed thoroughly under running tap water and left in tap
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water for 10 minutes. Sections were then briefly rinsed in distilled water and stained 
in Gomori solution (0.6g chromotrope, 0.3g Fast Green, 0.6g tungstophosphoric 
acid, 1ml glacial acetic acid in a total volume of 100ml with tap H20, pH 3.4). 
Sections were dipped into 0.2% (v/v) glacial acetic acid, dehydrated in 70-100% 
ethanol, cleared in xylene and mounted in DPX.
2.5.1.3. Modified Congo red stain
This method followed the method described by Mendell et al (Mendell et al., 1991). 
Frozen sections were cut onto glass slides washed with methanol. After air-drying 
they were stained for 10 minutes with haematoxylin followed by three washes in 
distilled water for 5 minutes each. Sections were then placed in 80% isopropanol 
(saturated with NaCI, pH 10.5-11) for 5 minutes. Thereafter, sections were stained 
for 60 minutes with Congo red solution (0.2g Congo red in 80% isopropanol 
saturated with NaCI pH 10.5-11). Sections were dehydrated in 70-100% ethanol, 
cleared in xylene and mounted in DPX.
2.5.2. Immunocytochemistry
Irrespective of cell line, cells were grown on glass coverslips in a 35 mm dish with
2 ml of growth medium. Myoblasts were grown on glass coverslips coated with 
laminin (10|ig/ml in PBS) overnight at 37°C. The medium was aspirated and the 
coverslips were washed in PBS. Cells were fixed for 20 minutes in 4% (w/v) 
paraformaldehyde in PBS and then for 15 minutes at -20°C in methanol. All the 
following incubations took place in a humid chamber at 37°C. Fixation was followed 
by blocking with 10% normal goat serum in PBS for 1 hour; PBS was removed 
followed by incubation with the primary antibody (see section 2.5.4. for dilutions) for
3 hours. After 3 washes in PBS, primary antibodies raised in mouse were developed 
for 1 hour with goat anti-mouse Alexa 488 conjugates respectively (Molecular
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Probes, Oregon, USA, dilution 1/200 in PBS) while the rabbit or goat primary 
antibodies were detected with goat anti-rabbit or donkey anti-goat Alexa 568 
conjugates, respectively (Molecular Probes, Oregon, USA, 1/1000). After 3 washes 
in PBS, coverslips were mounted on glass slides in Citifluor (Agar Scientific, UK) 
with 1pg/ml DAPI or 1pg/ml propidium iodide. Dual labeling consisted of incubation 
with a mouse monoclonal antibody and development with anti-mouse secondary 
antibody followed by incubation with either rabbit or goat primary antibody and the 
appropriate fluorescent secondary antibody. In control experiments the primary 
antibody was omitted.
Cells were also labelled with MitoTracker® (CMXRos-H2, Molecular Probes,
3pM). To this end cells growing on coverslips were cultured for 45 minutes in 
prewarmed growth medium containing MitoTracker®; the medium was then replaced 
by normal growth medium and cells were cultured for a futher 30 minutes. Cells 
were then fixed and immunostained as described above.
2.5.3. Immunohistochemistry
For immunohistochemical analysis of frozen muscle sections, glass slides were 
coated in 3-aminopropyltriethoxysilane (APES). Slides were degreased in 100% 
ethanol, rinsed in ddH20  and air dried for 10 minutes. The slides were then 
immersed in 2% APES solution in aceton for 2 minutes followed by two washes in 
ddH20. Slides were then dried overnight at 40°C.
Muscle sections (7pm) were cut on a cryotome (Reichert-Jung 2800 
Frigocut, Germany) at -25°C and air-dried for 30 minutes, fixed in aceton at -20°C 
for 10 minutes and air-dried again for 30 minutes. Immunohistochemical analyses of 
frozen muscle sections followed the protocol as outlined above. After three washes 
in PBS, mouse monoclonal antibodies were incubated with biotinylated horse anti­
mouse secondary antibodies (Vector Laboratories, Burlingame, USA). After another
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three washes in PBS the sections were incubated with an avidin-biotin-complex 
followed by developing for 5 minutes with 0.5 mg/ml 3,3’diaminobenzidine in PBS 
and 1pl/ml H20 2 using the Vectastain-Kit (Vector Laboratories). Alternatively, 
alkaline phosphatase conjugates were used and peroxidase demonstrated using 
alkaline phophatase (Vector SK5100 kit with 0.1M levamisole). Sections were 
dehydrated in 70-100% ethanol, cleared in xylene and mounted in DPX.
2.5.4. Antibodies
The following primary antibodies were used: a-synuclein either mouse monoclonal 
antibody (MAB) (Zymed, San Francisco, USA, dilution 1/200) or rabbit polyclonal 
antibody (Chemicon, 1/2000), haemagglutinin (MAB anti-HA, Boehringer, Germany, 
1/200), cytochrome-c-oxidase (MAB anti-COX I subunit, Molecular Probes, Oregon, 
USA, 1/200), lysosomes (MAB anti-lysosomal associated membrane protein 1, 
PharMingen, 1/400) or Golgi zone (MAB anti-Golgi zone, Chemicon, 1/200), vesicle 
associated membrane protein (VAMP) (MAB anti-VAMP, Chemicon 1/200), 
vesicular monoamine transporter (VMAT) 1 or 2 (goat polyclonal antibody, anti- 
VMAT 1 and anti-VMAT2 (Santa Cruz Biotechnology, 1/50), desmin (Dako, 1/500), 
ubiquitin (MAB anti-ubiquitin, Chemicon, 1/300), CD-8 (MAB anti-CD-8, Novocastra, 
UK, 1/200), tyrosine hydroxylase (rabbit polyclonal antibody, anti-tyrosine 
hydroxylase, Biogenesis, UK 1/500), neurofilament (MAB anti-neurofilament, Dako, 
1/100), and rabbit polyclonal anti-N-terminal huntingtin (675 antibody, gift from Dr L. 
Jones, Cardiff 1/2000).
2.5.4. Catecholamine stain
Cells were stained for catecholamines using glyoxylic acid fluorescence 
cytochemistry following the method described by Lindvall and Bjorklund (Lindvall 
and Bjorklund, 1974). In brief, HEK293 cells were plated out on coverslips at a
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density of approximately 25000 cells/ml, washed in PBS and incubated for 5 
minutes at 37°C with a solution containing 5% BSA in 0.1 M phosphate buffer (pH 7) 
and 2% glyoxylic acid (Fluka, UK). Coverslips were mounted in PBS and visualised 
using a fluorescence microscope and FITC filter (see next section).
2.5.5. Image analysis and photography
Slides were evaluated with a Zeiss Fluorescence Axiophot microscope (Carl Zeiss 
Microscope Division, Oberkochen, Germany) using the appropriate filters to 
visualise FITC, DAPI and rhodamine with an attached Zeiss MC80 photocamera. 
For confocal mircroscopy a Krypton-Argon laser (Bio Rad MRC 600, Herts, UK) 
attached to an Olympus BH2-RFCA fluorescence microscope was used.
Photographs of conventional fluorescence microscopy were taken using a 
Zeiss Fluorescence Axiophot microscope with an attached Zeiss MC80 
photocamera and Kodak Ectachrome film (400 ASA). Slides were digitised using a 
laser scanner and processed with Adobe Photoshop software version 6.0. Images 
generated with the confocal microscope were digitally stored and processed using 
Confocal Assistent™ software and Adobe Photoshop software version 6.0.
2.6. Protein assays
2.6.1. Protein extraction
In general, one plate of confluent cells of the relevant cell line was washed in PBS 
and harvested using a cell scraper. Cells were washed twice in PBS and solubilised 
in dissociation buffer containing 50mM TRIS/HCI, 4% (w/v) SDS, 12% (w/v) glycerol, 
0.5% (v/v), pH 6.9 containing a cocktail of protease inhibitors (final concentration: 
1fig/ml leupeptin, 1 pg/ml pepstatin, 1pg/ml antipain, 100pg/ml PMSF, 5pg/ml 
chemostatin). In order to break up genomic DNA samples were sheared using a 
19G needle and 1ml syringe until the viscosity of the sample was reduced.
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2.6.2. Protein determination
Protein concentrations were determined with the bicinchoninic acid copper assay 
(Pierce-Warriner BCA™ kit, USA) kit or with the BioRad kit (Bio-Rad, Munich, 
Germany).
2.6.2.1. The bicinchoninic acid copper assay (BCA)
Protein concentrations were determined using a commercially available kit (Pierce- 
Warriner BCA™ kit, USA). Protein reduces Cu2+ to Cu+ which is detected by 
bicinchoninic acid (BCA). The purple reaction product is water soluble and exhibits 
strong absorbance at 562nm. For each assay a set of protein standards was 
prepared using dilutions of bovine serum albumine (BSA) in the same diluent as the 
samples. The standards were made to cover the range of protein concentrations 
expected in the respective samples; typically, 0, 25, 50, 75, 100, 125 and 150pg/ml 
were used. Assays were performed according to the manufacturer’s instructions 
using the protocol requiring 30 minutes incubation at room temperature. Each assay 
was performed in triplicate. The readings of the samples were interpolated against 
the BSA standard curve.
2.6.2.2. The BioRad protein determination kit
This kit determines protein concentrations of samples against an albumin standard 
curve following the Bradford method. The protein standard curve was prepared 
using BSA as described above for the BCA assay. The protein solution was diluted 
1/50 with the protein assay solution (Bio-Rad, Munich, Germany) according to the 
manufacturer’s instructions, and the absorbance was read at 540nm. The readings 
of the samples were interpolated against the BSA standard curve.
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2.6.3. Protein separation
Proteins were separated using standard techniques (Towbin et al., 1979) on 
gradient SDS-PAGE gels of varying percentage of acrylamide (between 4-15% w/v) 
depending on the size of the protein of interest. The recipes and the buffers used 
are listed in appendix 1. Separating and stacking gels were prepared in BioRad 
Mini-Protean II gel systems. Samples were heated at 37°C for 10 min and then 
centrifuged at 6000g for 10 minutes. Prior to loading of the samples onto the gel, 
0.01% (w/v) bromophenol blue was added. 20-50[ig of protein in dissociation buffer 
were loaded per well. For small proteins pre-stained low molecular weight markers 
3-43kDa (Life Technologies), or for larger proteins rainbow wide range molecular 
weight markers (2350-46000kDa, Sigma) were used. The gel was run at 100V until 
the bromophenol blue had run through the stacking gel. Thereafter, the gel was run 
at 200V until the bromophenol blue had reached the bottom of the separating gel.
2.6.4. Staining of protein gels
Equal protein loading was quantitatively verified on gels stained overnight with 0.1% 
(w/v) Phastgel blue R250 dye in 40% methanol and 10% (v/v) glacial acetic acid. 
Gels were then rinsed in ddH20  for 5-20 hours to destain.
2.6.5. Immunostaining of blots
After separation, gels were equilibrated in transfer buffer (Towbin’s buffer, see 
appendix 1) for 30 minutes. A polyvinylidene difluoride (PVDF, Millipore, Bedford,
MA, USA) membrane was “wetted” in methanol and placed onto the gel. This 
“sandwich” was placed between two sheets of blotting paper (Whatman No1, 
Whatman Ltd, UK) and then placed in a BioRad mini-blotting tank containing 
Towbin’s transfer buffer. Proteins were blotted for 1 hour at 100V. The post blot gel 
was stained with Phastgel blue R250 dye as described to control for equal loading of
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protein (section 2.6.4.).
The PVDF was blocked for two hours in 10% (w/v) proprietary milk powder in 
PBS at room temperature. The membrane was washed in 0.3% Tween/PBS for 10 
minutes at room temperature and incubated with the primary antibody diluted in 
0.3% Tween/PBS overnight. After three washes in 0.3% Tween/PBS for 5 minutes 
each gels were incubated with the secondary antibody diluted in 0.3% Tween/PBS 
for 2 hours at room temperature. All blots were developed by chemiluminescence 
detection (NEN, Life Science Products, Boston, USA) following the manufacturer’s 
instructions. The membranes were then exposed to ECL film (Amersham, UK) for 
varying times (between 5 seconds and 2 minutes) before development and fixation.
The following antibodies were used: anti-HA rat monoclonal antibody 
(Boehringer, Mannheim, Germany, 1/3000) as primary and sheep anti-rat Ig-HRP 
(Fab fragments, Boehringer, Germany, 1/3000) as the secondary antibody; anti-a- 
synuclein (Zymed, USA, 1/4000) and anti-porin (Calbiochem, USA, 1/25,000) mouse 
monoclonal antibodies as primary and rabbit anti-mouse HRP (Bio Rad, UK, 1/3000) 
as secondary antibody; (anti-tyrosine hydroxylase rabbit polyclonal antibody 
(Biogenesis, UK, 1/500) and donkey anti-rabbit (Dako, UK, 1/200) as secondary 
antibody.)
2.7. Enzyme analysis
All assays were performed in a final volume of 1ml on either a Hitachi U3210 or a 
Kontron 940 dual-beam spectrophotometer at 30°C. Enzyme assays were 
performed in triplicate for each sample. Results were accepted if they were within 
15% of each other. The chemicals necessary for the assays were from Sigmal 
Chemical Company and from Boehringer Mannheim (Boehringer Mannheim, 
Germany).
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2.7.1. Preparation of mitochondrial enriched fractions (MEFs)
MEFs were prepared from 10 X 10cm nearly confluent culture dishes of HEK293 
cells according to the method described by Krige et al. (Krige et al., 1992). Cell were 
harvested, the cell pellet resuspended in 10ml of PBS and centrifuged at 300g for 10 
minutes. This procedure was repeated three times. The last cell pellet was frozen at 
-70°C overnight. The cell pellet was then thawed and resuspended in 2ml ice-cold 
homogenisation buffer (0.25M sucrose, 10mM Tris-HCI, 1mM EDTA-K2, pH 7.4). 
Each sample was homogenised on ice with 20 strokes using a Potter homogeniser 
at 1000rpm, and then centrifuged at 1500g for 10 minutes at 4°C. The resultant 
post-nuclear supernatant (PNS) was collected into a fresh tube and kept on ice. The 
homogenisation and centrifugation steps were repeated twice resulting in three 
PNSs for each sample. These were combined and centrifuged for another 10 
minutes at 1500g; any residual pellet was discarded. The final PNS was centrifuged 
at 10000g for 12 minutes in a Kontron Centrikon T-124 centrifuge resulting in a 
brown MEF pellet. This pellet was resuspended in 200-800^1 of ice-cold 
homogenization buffer, aliquoted and snap-frozen in liquid nitrogen and stored at -  
70°C for up to a week until assaying. Before assaying mitochondrial respiratory 
chain activities all samples were freeze-thawed in liquid nitrogen three times to 
brake up mitochondrial membranes.
2.7.2. Mitochondrial respiratory chain activities
2.7.2.1. NADH CoQ reductase (Complex I)
The assay is based on the method described by Ragan et al (Ragan et al., 1987). It 
measures the rotenone sensitive CoC^ dependant oxidation of NADH at 340nm.
The CoQt was a gift from the Eisai Chemical Co, Japan. The stock solution of CoQi 
was diluted in ethanol followed by measuring the absorbance of CoQ^ at 275nm. To 
completely reduce quinone to quinol an excess of sodium borohydrate was added to
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the reference cuvette. The change in absorbance was used to calculate the 
concentration of C0 Q1 using a molar extinction coefficient of 2.25x103 (Redfearn, 
1967).
The sample and the reference cuvettes contained 20mM K+ Phosphate buffer 
with 8mM MgCI2 at pH7.2, 150pM NADH, 1mM KCN 2.5mg/ml BSA in a total 
volume of 1ml. To the sample cuvette the mitochondrial enriched fraction of the 
sample was added with the volume depending on the concentration; adjusting for 
the volume of sample and ubiquinone the volume of H20  was calculated to give a 
total volume of 1ml. The test and the sample cuvette were loaded into the 
photospectrometer followed by the addition of 50pM CoQi to the sample cuvette in 
order to start the reaction. The linear change of absorbance was recorded for 3-4 
minutes. Then, 10pl of rotenone was added to both cuvettes leading to a decrease 
in the rate of the reaction due to the inhibition of the rotenone sensitive component 
of the complex I activity. Complex I activity was defined as the rotenone sensitive 
reaction rate.
The rate was expressed as absorbance units per ml of sample. The molar 
extinction coefficient of 6.81 x103 (adjusted for the concentration of CoQO for NADH 
was used to calculate the enzyme activity in nmol/m in/m I. Enzyme activity was 
expressed relative to the protein concentration of the sample in nmol/min/mg and as 
a ratio with citrate synthase activity.
2.7.2.2. Succinate Cytochrome C reductase (Complex ll/lll)
The assay is based on the method described by King (King, 1967) and measures 
the antimycin A sensitive, succinate dependant reduction of cytochrome c at 550nm.
The test and the reference cuvette were loaded with 100mM K+ Phosphate 
buffer (pH 7.4), 300pM (K2) EDTA, 100pM cytochrome c and 2.5mg/ml BSA in a 
total volume of 1ml. In order to activate the enzyme, the sample was incubated in an
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Eppendorf tube for 4-5 minutes with 40pl of succinate and 10pJ of KCN (to block 
cytochrome oxidase activity). After 4 minutes of incubation, 1 OjliI of KCN were added 
to the reference cuvette, both cuvettes were placed into the spectrophotometer and 
assayed at 550nm. After another minute the entire contents of the Eppendorf tube 
were added to the test cuvette, which was then thoroughly mixed. After 4-5 minutes, 
antimycin A (complex III inhibitor) was added to the test cuvette, which was 
thoroughly mixed again, and the assay was continued for a further 4-5 minutes.
From the recording two reaction rates were calculated. The antimycin A 
independent rate (usually near zero) was subtracted from the total reaction rate.
This resulted in the reaction rate of cytochrome c reductase, which was expressed 
as absorbance units per ml of sample. Using the molar extinction coefficient of 
cytochrome c, 19.2x103, the activity was calculated as nmol/min/ml, and related to 
protein concentration in the sample as nmol/min/mg protein. The activity was also 
expressed as a ratio with citrate synthase activity.
2.7.2.3. Cytochrome oxidase (Complex IV)
This assay is based on the method described by Wharton et al (Wharton and 
Tzagoloff, 1967). It measures the oxidation of reduced cytochrome c at 550nm.
Reduced cytochrome c was prepared from 100ml of a 1% solution of 
cytochrome c from horse heart made up in 10mM K+ phosphate buffer. Cytochrome 
c was reduced by adding an excess of ascorbate (13mg). The solution was mixed 
thoroughly. In order to test whether cytochrome c had been reduced competely 50pl 
of the cytochrome c solution were added to each of two cuvettes containing 10mM 
K+ phosphate buffer in a total volume of 1ml. 10pl of freshly made saturated 
ascorbate solution were added to the test cuvette and the change in absorbance 
was noted. A positive change in absorbance indicated that cytochrome c had not 
been completely reduced and therefore needed further treatment with ascorbate.
66
Next, in order to remove the ascorbate the solution was dialysed against 5L of 
10mM K+ phosphate buffer pH7 at 4°C overnight using size 1 dialysis tubes 
(Medicell International Ltd., London, UK). Oxidised cytochrome c was then added to 
the solution and the absorbance measured. If the ascorbate had been removed 
completely there should be no change in absorbance.
The volume of cytochrome c needed in the reaction mix to give 50pM 
reduced cytochrome c (equivalent to an absorbance of 0.96) was calculated from 
the absorbance with 50jnl of stock reduced cytochrome c in a reaction mix of 10mM 
K+ Phosphate buffer (pH 7) in a total volume of 1ml against a reference cuvette 
containing an additional 10pJ of K+ ferricyanide.
Test and reference cuvettes were loaded with 10mM K+ Phosphate buffer (pH 
7), 50pM reduced cytochrome c and H20. The volume of H20  was adjusted to result 
in a total volume of 1ml. Both cuvettes were placed in the spectrophotometer and 
after autozeroing 10jil of ferricyanide were added to the reference cuvette. A note of 
the initial absorbance was made (should be 0.94 -  0.98), the assay was started and 
then the sample was added and the test cuvette mixed as quickly as possible. The 
reaction rate was visualised as a decrease in absorbance as a result of oxidation of 
reduced cytochrome c.
The absorbance at the start of the reaction (t=0) was extrapolated and the 
change in absorbance determined at several time points. A pseudo-first-order rate 
constant k was calculated in k/ml using the equation {In0.96-ln(0.96-change in 
absorbance at a given time point) X 1000/sample volume in [xl X dilution factor}. In 
this equation 0.96 represents the absorbance of cytochrome c fully reduced at the 
start of the reaction. The k/min/ml was calculated by plotting the k/ml values for 5 
time points (0, 0.5, 1, 1.5 and 2minutes) against time. The gradient was calculated
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using a linear regression analysis. The activity of complex IV was expressed as 
k/min/mg protein and as a ratio with the citrate synthase activity.
2.7.3. Citrate synthase
This assay is based on the method described by Coore et al (Coore et al., 1971). 
Citrate synthase is a mitochondrial matrix enzyme that catalyses the condensation 
of oxaloacetate and acetyl CoA in the citric acid cycle. This produces CoA. In the 
assay, the free thiol group combines with 5-5’-dithiobisnitrobenzoic acid (DTNB) 
thus increasing the absorbance at 412nm.
The test and the reference cuvettes were loaded with 100mM Tris (pH 8), 
100pM acetyl CoA, 100jiM DTNB in a total volume of 1ml. The cuvettes were 
loaded into the spectrophotometer and the assay started at 412nm after 
autozeroing. Then, 10jal of oxaloacetate (final concentration 100pM) were added to 
the test cuvette to start the reaction. The reaction rate was expressed as 
absorbance units per ml of sample, and using the molar extinction coefficient of 
13.6x103 for the DTNB-CoA-SH complex as nmol/min/ml. The activity was related to 
the protein concentration of the sample and expressed in nmol/min/mg protein.
2.7.4. Aconitase
This assay is based on the method described by Gardner et al (Gardner et al.,
1994). Following the condensation of oxaloacetae and acetyl CoA to form citrate, in 
the second step of the citric acid cycle citrate needs to be isomerised in order to 
undergo oxidative decarboxylation later. Citrate is therefore first dehydrated and 
then hydrated with cis-aconitate as an intermediate. Both reactions are catalysed by 
aconitase, an iron-sulfur protein. Since aconitase is very labile sample were assayed 
immediately.
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The test and the reference cuvette contained 50mM Tris/HCI buffer (pH 7.4), 
0.4mM NADPH, 5mM sodium citrate, 0.6mM MgCI2, 0.1% Triton X-100, 1-2 units of 
isocitrate dehydrogenase and H20 2 for a total volume of 1ml.
Both cuvettes were loaded into the spectrophotometer, and after autozeroing 
the assay was started at 340nM and left to run until a linear reaction rate was 
reached. The reaction rate was expressed as absorption units per ml of sample. 
Aconitase activity was calculated using the molar extinction coefficient for NADP 
(e=6.22 x 103) and expressed in nmol/min/mg protein.
2.8. Flow cytometry
2.8.1. Principles
Flow cytometry allows rapid measurements of cells as they pass individually in a 
fluid stream past a sensor. This method enables each cell to be measured 
individually rather than resulting in an average value for the whole cell population in 
a given sample. In addition, more than one parameter can be measured at the same 
time. The combination of light scatter and fluorescence yields information on 
physical properties of cells and allows the use of fluorescent probes to detect 
specific proteins, nucleic acid content, enzyme activity or membrane potential. It is 
now very common to combine the measurement of two light scatter (forward and 
side) and several fluorescent parameters (Ormerod, 2000).
The flow cytometer used in this thesis (FACScalibur, Becton Dickinson, UK) 
uses lasers as the source of illumination. The scattered and fluorescent light 
generated by individual cells travelling through the laser beam is collected by 
photodetectors, which then convert the photon pulses into electronic signals. These 
signals are amplified and filtered, and finally converted digitally into binary numbers 
by a computer system. Data generated in this way can be analysed on-line or 
digitally stored for later, off-line analysis (for details see (Ormerod, 2000).
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In this thesis, forward angle light scatter (FSC) and right angle light scatter (S 
(side) SC) were used to describe cell size and cell surface morphology respectively. 
Fluorescein (FITC-green) and propidium iodide (Pl-red) were used as fluorescence 
colours. The instrument set up consisted of a set of mirrors (placed at 45° to the 
incident laser beam) and orthogonally positioned absorption and interference filters. 
The first mirror was a 500nm long-pass dichroic filter set at right angles to the laser 
beam path. This mirror reflected wavelengths that were shorter than 500nm towards 
the SSC detector. Wavelengths above 500nm passed on to the second mirror, a 
560nm short-pass dichroic filter so that wavelengths longer than 560nm were 
reflected towards the Pl-red detector passing through a filter centred at 578nm with 
a 28nm half-peak bandpass. Wavelengths shorter than 560nm and longer than 
500nm at the second mirror passed on towards the FITC fluorescence detector 
through a 530nm filter with a 30nm half-peak band-pass.
The measurement of light scatter parameters was displayed as a dot plot (an 
example is given in Figure 2.2A). On the grounds of this plot a gate (R1 in Figure 
2.2A) was set to exclude cell clumps (as judged by an increase in size) and debris 
(small size). Next, live and dead cells were distinguished within the cell population in 
gate R1. If a cell is damaged or dead the integrity of the cell membrane cannot be 
maintained. The nuclei of these cells become accessible to propidium iodide and 
fluoresce red when excited at 578nm (FL2 channel). Cells labelled with propidium 
iodide have therefore been damaged or have died. Further, the lipophylic dye 
DiOC6(3) (3,3'-dihexyloacarbocyanine, Molecular Probes) can be used to examine 
the mitochondrial membrane potential. Uptake of this dye depends upon 
mitochondrial membrane potential and hence identifies viable cells. Therefore, dead 
cells and viable cells can be differentiated on a dot plot displaying the cell population 
in gate R1 with red fluorescence indicating propidium iodide uptake in FL2 on the x 
axis and green fluorescence indicating DiOC6(3) uptake in FL1 (488nm laser and
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500nm long-pass filter) on the y axis (Figure 2.2B). Measurements of other 
parameters, e.g. involving fluorescent dyes, can then be focused on the cell 
population of interest that has been selected by setting the appropriate gate. Figure 
2.2C gives an example of the fluorescence intensity of DiOC6(3 ) displayed as a 
histogram from the viable cell population gated in Figure 2.2B (R2).
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Figure 2.2. Flow cytometry of cells stained with PI and DiOC6(3)- A. Exclusion of cell 
clumps and debris on side scatter (SSC) and forward scatter (FSC) dot plot graphs. 
B. Dot plot graph of fluorescence staining for PI red fluorescence (FL2) and DiOC6(3 ) 
green fluorescence (FL1) of the gated population in A (R1). Low red fluorescence 
and high green fluorescence indicated viable cells (R2, green) whereas dead cells 
(R3, blue) stain markedly for the red fluorescent dye PI and have little DiOC6(3) green 
fluorescence. The population of cells between the two regions presumably 
represents dying cells. C. Histogram of DiOC6(3) median green fluorescence intensity 
in the viable cell population indicated by the R2 gate in B.
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2.8.2. Sample preparation for flow cytometry
Cells were plated out on 12 well plates at a density of 62500 cells/ml. Following the 
respective experiment, cells were harvested by trypsinisation, resuspended in PBS 
and transferred to FACS tubes containing 5mM EDTA to avoid cell clumping. The 
cells were incubated with 50nM DiOC6(3) for 20 minutes at 37°C. Propidium iodide 
(1pg/ml) was added for two minutes and FACS analysis performed immediately on a 
FACScalibur (Becton Dickinson) flow cytometer.
2.8.3. Mitochondrial membrane potential
2.8.3.1. DiOC6(3)staining and fluorescence microscopy
Cells were plated in quadruplicate in 12 well plates at a density of 62500 cells/ml. At 
the end of the experiment, cells were harvested by trypsinisation, resuspended in 
PBS and transferred to FACS tubes (Becton Dickinson, France). EDTA was then 
added (5mM final concentration). DiOC6(3) was added for 15 minutes, and propidium 
iodide (1pg/ml) was added for two minutes while samples were kept on ice and 
protected from light; FACS analysis was performed immediately on a FACScalibur 
(Becton Dickinson) flow cytometer using the instrument set up described in section
2.8.1.). 104 events were acquired, and debris and cell clumps excluded on a forward 
scatter and side scatter dot plot as described (see section 2.8.1.). Within the 
included events (R1 in figure A), live cells were defined by propidium iodide 
exclusion (see section 2.8.1.). In viable cells DiOC6(3) fluorescence intensity was 
measured as described in section 2.8.1. The instrument settings were standardized, 
and identical gate settings were used for all experiments performed at the same 
time.
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2.9. Cell viability studies
Cell death can be detected by monitoring plasma membrane lysis either by 
measuring the release of cytosolic lactate dehydrogenase or or detecting the uptake 
of the membrane impermeable dye propidium iodide (PI). Both methods were used 
in this thesis. PI uptake measurements by flow cytometry have the advantage that 
the numbers of vable and dead cells can be quantitated. In addition, cells can be 
stained with PI and another fluorescent dye, e.g. DiOC6(3) to probe mitochondrial 
membrane potential on the respective cellular subpopulations, e.g. viable cells. 
However, all assessments using flow cytometry rely on samples in which there is 
minimal cell clumping. With some toxins, e.g. dopamine it was very difficult to 
prepare samples without some degree of cell clumping. In this case, the LDH 
assays were used.
2.9.1. Lactate Dehydrogenase (LDH) assay
When cells die by necrosis, their membranes leak LDH into the medium. The activity 
of LDH in the medium of a cell culture dish thus represents a measure of cell death 
and can be related to the activity of LDH in the total cell fraction of the same culture. 
The total LDH activity of a given sample is the combined activity of LDH acitivity in 
the “dead" and the “live" fraction. Viable cells (= LDH activity of the “live" fraction) 
were expressed as a percentage of the total LDH activity in a given sample.
Cells were plated out in triplicate at a density of circa 62,500 cells per well of 
a 12 well plate using phenol-red free medium. At the end of the experiment, the 
medium of each well was pipetted into a screw top container. This container was 
centrifuged at 13.000 rpm for 5 minutes at 4°C and the supernatant pipetted into a 
fresh container (dead fraction). The cell pellet was added to the live fraction. Cells 
were washed in PBS, harvested by flushing them off the dish with PBS and 
transferred into another screw top container (live fraction). Pairs of supernatant and
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cells of the same well were stored at -20 C until they were assayed for LDH acitivity. 
The ratio of LDH activity in the supernatant to the total LDH activity was taken as the 
percentage of cell death.
The assay is based on the method of Clark and Nicholas (Clark and Nicklas, 
1970) and measures the activity of LDH, a cytoplasmic enzyme catalysing the 
reduction of pyruvate to lactate and the oxidation of NADH to NAD+. As NADH is 
converted to NAD+ the absorbance at 340nm decreases. The test and the reference 
cuvette were loaded with K+ Phosphate buffer (pH 7.4; final concentration 50mM), 
NADH (final concentration 200pM), Triton X-100 (final concentration 0.5% (v/v)) and 
H2Ofor a total volume of 1ml, depending on the volume of sample added to the test 
cuvette. Cuvettes were loaded into the spectrophotometer, and the assay was 
started at 340nm after autozeroing. The reaction was initiated by adding Na 
pyruvate (final concentration 1mM) to the test cuvette. The reaction rate was 
expressed as absorbance units per ml of sample.
Alternatively, for large numbers of samples a LDH Cytotoxicity Detection Kit 
(TaKaRa Biomedicals, Japan) was used. This is a colorimetric assay where the LDH 
catalysed conversion of lactic acid to pyruvate leads to the reduction of NAD+ to 
NADH/H+. In the second step diaphorase transfers H/H+ from NADH/H* to the 
tetrazolium salt INT (yellow), which is reduced to formazan (red). The formazan dye 
is water-soluble and shows the maximum absorption at 500nm whereas the 
tetrazolium salt INT does not absorb at these wavelengths. The change in colour 
from yellow to red, and the respective change in absorption at 500nm, is 
proportionate to the amount of LDH present in the sample. Assays were set up on 
96-well plates at room temperature and ambient air. Samples and controls were 
assayed in quadruplicate. Controls consisted of phenol-red free medium alone in the 
same dilution in PBS as the samples. Care was taken to ensure that reactions were 
read while the rates were in the linear range. First, the change in absorption
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measured in the controls was subtracted from that of the samples. Then, the change 
in absorption in the respective sample pairs, i.e. dead and live fraction, was 
combined to give the total LDH activity per sample. Finally, the ratio of LDH activity 
in the live fraction and total LDH activity was taken as the percentage of viable cells.
2.9.2. Flow cytometry
Cells were plated in quadruplicate in 12 well plates at a density of 62500 cells/ml. At 
the end of the experiment, cells were harvested by trypsinisation, resuspended in 
PBS and transferred to FACS tubes (Becton Dickinson, France). EDTA was then 
added (5mM final concentration). DiOC6<3 ) was added for 15 minutes, and propidium 
iodide (1 pg/ml) was added for two minutes while samples were kept on ice and 
protected from light; FACS analysis was performed immediately on a FACScalibur 
(Becton Dickinson) flow cytometer using the instrument set up described in section
2.8.1.). 104 events were acquired, and debris and cell clumps excluded on a forward 
scatter and side scatter dot plot as described (see section 2.8.1.). Within the 
included events (R1 in figure A), live cells were defined by propidium iodide 
exclusion (see section 2.8.1.). Viable cells were expressed as a percentage of the 
total number of included events. The instrument settings were standardized, and 
identical gate settings were used for all experiments performed at the same time.
2.10. GSH assays
These experiments were performed in collaboration with C Tomlinson, Department 
of Clinical Neuroscience, Royal Free and University College London Medical 
School. Cells were plated out at a density of 62.500 cells/ml on 10cm Petri dishes.
At the end of the experiment, cells were harvested with Versine and the cell pellet 
resuspended in 500pl 5% metaphosphoric acid, mixed for 3 min and centrifuged at 
10 000 x g for 5 min at 4°C. The supernatant was used to determine glutathione
77
levels using the Calbiochem GSH assay kit according to the manufacturers 
instructions (Calbiochem, La Jolla, USA) using a GSH standard curve. The GSH 
standard was quantitated spectrophotometrically at 412nm following its reaction with 
DTNB.
2.11. Dopamine Uptake
The ability of the HEK293 cells to take up dopamine was examined in collaboration 
with Drs P Korlipara, K Messmer and JM Cooper, Department of Clinical 
Neuroscience, Royal Free and University College London Medical School using 
[2,5,6-3H]-dopamine. HEK293 cells were grown to 80% confluency on 10cm plates. 
Cells were washed in PBS, which was replaced by HEK293 growth medium 
containing 2jiCi/ml [3H]-dopamine (Amersham, UK) and 20(iM pargyline (Sigma). 
The plates were incubated at 37°C in a humidified incubator. At various time points 
(0 - 60 minutes) a plate of cells was removed and washed three times in 10ml of ice- 
cold PBS. The cells were harvested by scraping in 4ml of PBS, pelleted for 10min at 
1000 x g and resuspended in 0.5ml of PBS followed by analysis on a liquid 
scintillation counter (Beckman, UK). The number of cells was determined by cell 
counting and the data corrected for cell number.
2.12. Statistical analysis
Data was analysed first to assess whether it was normally distributed (data display 
in histograms). In case of normal distribution parametric statistics were used. Data 
from two independent groups was compared using a Student’s t-test; data from 
three or more groups of observations was compared using one-way analysis of 
variance (ANOVA) with post-hoc t-test comparing subgroups if a main effect was 
observed. Non-parametric data from two independent groups was assessed using 
the Mann-Whitney U-test. Three or more groups of observations were compared
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using the Kruskal-Wallis test followed by post-hoc Dunn’s Multiple Comparison test 
if the Kruskal-Wallis test was significant.
Different frequencies of variables were analysed using Fisher’s exact test. All data 
was analysed using commercially available software wit statistical significance levels 
set to p<0.05.
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CHAPTER 3.
A HEK293 cell model for a-synuclein Parkinson’s disease
3.1. Introduction
3.1.1. Clinical features of Parkinson’s disease (PD)
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
with an estimated prevalence of 1 to 2% in the population over 65 years of age (de 
Rijk et al., 2000). PD most commonly manifests between the 5th and the 7th decade 
with bradykinesia, tremor, rigidity and abnormal postural reflexes. The diagnosis of 
PD is made on clinical grounds; other clinical signs may indicate other causes of 
parkinsonism, e.g. frequent falls backwards and supranuclear gaze palsy would 
suggest progressive supranuclear palsy. However, post mortem neuropathological 
examination showed that clinical diagnosis is not always able to correctly identify 
sporadic PD (Hughes et al., 1992a; Hughes et al., 1992b). Thus, the 
neuropathological examination remains the gold standard for the diagnosis of 
parkinsonian syndromes.
3.1.2. Pathological features of PD
PD is characterised pathologically by the degeneration of the pars compacta of the 
substantia nigra, the locus coeruleus and substantia innominata. Within the 
substantia nigra, the greatest loss of neurones tends to be observed in the 
ventrolateral tier, followed by the medial ventral tier and dorsal tier (Fearnley and 
Lees, 1991). The pattern of neuronal cell loss within the substantia nigra is relatively 
specific for PD and differs from that observed in other parkinsonian syndromes such 
as striatonigral degeneration or supranuclear palsy. At the time of onset of 
symptoms, a large proportion (50-70%) of dopaminergic neurones in the substantia 
nigra pars compacta have already been lost resulting in reduced dopamine
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synthesis and release from the striatal nerve terminals (Lang and Lozano, 1998a). 
Subsequently, the loss of dopamine in the putamen is most prominent in the dorsal 
and intermediate subdivisions of the putamen, which might underlie some of the 
symptoms of PD, i.e. akinesia and rigidity (Kish et al., 1988).
The formation of Lewy bodies (LBs), and Lewy neurites in surviving 
dopaminergic neurones is the hallmark pathological finding in PD. Lewy neurites are 
degenerating ubiquitin positive neuronal processes found in all affected brainstem 
regions, in particular the dorsal motor nucleus of the vagus nerve (Gai et al., 1995). 
LBs are intracytoplasmic eosinophilic inclusions composed predominantly of 
ubiquitin and a-synuclein (Spillantini et al., 1997); however, a number of other 
proteins have been identified within LBs such as synphilin-1, parkin, neurofilaments, 
UCH-L1, proteasomal components, heat-shock protein and nitrated a-synuclein 
(Giasson et al., 2000; Good et al., 1998; li et al., 1997; Lowe et al., 1990; 
Schlossmacher et al., 2002; Shashidharan et al., 2000; Wakabayashi et al., 2000). 
On electron microscopy, LBs characteristically consist of a dense granular core 
surrounded by a halo of radiating filaments (Duffy and Tennyson, 1965). LBs are 
found in the substantia nigra, locus coeruleus, the dorsal motor nucleus of the vagus 
nerve, as well as the substantia innominata and the intermediolateral cell column of 
the spinal cord. LBs are not specific for PD and can also be found in brains of 
patients with Alzheimer’s disease and a disorder called cortical LB dementia; in 
addition, LBs can be incidental findings in postmortem pathological specimens at a 
greater frequency than PD (Gibb and Lees, 1988).
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Figure 3.1. Lewy body stained with a-synuclein. A section of substantia 
nigra of a patient with PD shows a dopaminergic neurone that contains 
a LB. Immunohistochemistry reveals that the LB stains intensely with an 
antibody to a-synuclein (dark brown, arrow). This image was downloaded 
from www.feany-lab.bwh.harvard.edu/link2/.
3.1.3. Pathogenetic mechanisms in PD
Several recent advances have increased our understanding of the pathogenesis of 
PD. A significant genetic element in the aetiology of PD, in at least a proportion of 
patients, is suggested by results from twin studies, case control studies and the 
identification of mutations in several genes in familial PD. In addition, environmental 
toxins have been associated with parkinsonism including carbon monoxide, 
manganese and, most importantly, 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine 
(MPTP). The clinical and pathological syndromes associated with both the familial 
PD cases and those caused by environmental agents are remarkably similar; they 
all cause parkinsonism and give rise to relative selective loss of dopaminergic 
neurones with, apart from parkin PD, the formation of LBs. This lends support to the 
hypothesis that PD is a heterogenous disease likely to be caused by more than one 
specific aetiological factor. The pharmacological replacement, of dopamine by L- 
Dopa or dopamine agonists, as well as other treatments such as deep brain 
stimulation, can relieve PD symptoms but do not stop disease progression (Lang 
and Lozano, 1998b).
3.1.4. Environmental toxins and PD
Epidemiological evidence suggests that toxins are involved in the pathogenesis of 
PD. Anecdotal reports describe parkinsonism with carbon monoxide (Gordon, 1965; 
Grinker, 1926; Klawans et al., 1982), manganese (Couper, 1837; Huang et al.,
1993; Mena, 1979) and MPTP (Davis etal., 1979; Langston and Ballard, 1983) 
exposure. One study suggested that prolonged occupational exposure to a 
combination of either iron and lead, or iron and copper increased the risk for PD 
(Gorell et al., 1998). Pesticide exposure, e.g. in well water, may be another risk 
factor for PD, in particular with prolonged exposure (Gorell et al., 1998; Liou et al., 
1997; Petrovitch et al., 2002; Seidler et al., 1996; Semchuk et al., 1992). Specific
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pesticides including paraquat, organochlorine and carbamate derivatives were 
identified in some studies (Liou et al., 1997; Seidler et al., 1996; Semchuk et al., 
1992). An interaction between paraquat, or rotenone, and a-synuclein, a major 
component of LBs in PD, has been reported (see section 3.1.8.5.2) possibly linking 
these environmental agents to a possible genetic factor.
Other environmental agents have been shown to have a neuroprotective 
effect and hence reduce the risk of PD. These may include caffeine (Ascherio et al., 
2001; Ross et al., 2000) and cigarette smoking (Hernan et al., 2001). The amount of 
cigarette smoking was recently found to inversely correlate with the age of onset of 
PD in both monozygotic (MZ) and dizygotic (DZ) twins (Tanner et al., 2002). The 
correlation was stronger in MZ twins despite a high concordance for smoking. Thus, 
cigarette smoking might be one of the additional factors that are relevant modulators 
of disease onset in PD.
3.1.5. Evidence for mitochondrial involvement in PD
Research into mitochondrial involvement in the pathogenesis of PD began with the 
discovery that the metabolite of MPTP, MPP+, inhibited complex I of the 
mitochondrial respiratory chain (Mizuno et al., 1987; Nicklas et al., 1985; Ramsay et 
al., 1986). A Parkinsonian syndrome with bradykinesia and rigidity and a good 
response to L-dopa was first described in drug abusers after exposure to MPTP 
(Langston and Ballard, 1983). MPTP was also shown to induce Parkinsonism 
(tremor, rigidity, akinesia and postural instability) in other primates (Langston et al., 
1984). A link to PD pathology was observed in squirrel monkeys where prolonged 
MPTP application in older animals led to loss of dopaminergic neurones and 
eosinophilic inclusions in a very similar distribution to the pathology of PD (Forno et 
al., 1986).
Complex I deficiency was first identified in the substantia nigra of post
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mortem PD brain (Janetzky et al., 1994; Schapira et al., 1990a; Schapira et al., 
1989). The defect appeared to be restricted both to complex I and the substantia 
nigra with other brain areas such as striatum (caudate and putamen), cortex, 
cerebellum, globus pallidum, tegmentum and substantia innominata showing normal 
mitochondrial respiratory chain activity (Cooper et al., 1995; Gu et al., 1998b; 
Janetzky et al., 1994; Mann et al., 1994; Mann et al., 1992; Schapira et al., 1990b). 
In multiple system atrophy, a disorder with parkinsonism and degeneration of 
neurones in substantia nigra, no mitochondrial respiratory chain defect was found 
(Gu et al., 1997) and there was no complex I abnormality in Lewy body rich 
cingulate cortex of diffuse Lewy body brains (Gu et al., 1998b). This suggests that 
the complex I defect is specific to PD and selective for the substantia nigra, but not 
related to the formation of Lewy bodies and not seen merely when the substantia 
nigra degenerates, e.g in multiple system atrophy. However, other reports described 
reduced immunoreactivity for a-ketoglutarate, an enzyme of the citric acid cycle, in 
substantia nigra of PD patients (Mizuno et al., 1994).
Mitochondrial respiratory chain activity has also been assessed in other PD 
tissues (Table 3.1.). In skeletal muscle, both reduced (Bindoff et al., 1989; Blin et al., 
1994; Cardellach et al., 1993; Nakagawa-Hattori et al., 1992; Shoffner et al., 1991) 
and normal complex I activity have been reported (Anderson et al., 1993; DiDonato 
et al., 1993; Mann et al., 1992; Reichmann et al., 1994). Mitochondrial respiratory 
chain analysis in platelets showed more consistent results, in particular, when 
isolated platelet mitochondria are used, with a complex I defect either alone or 
together with a milder defect in other complexes (Benecke et al., 1993; Haas et al., 
1995; Krige et al., 1992). In platelets, the severity of the complex I defect has varied 
between studies from 16-55% deficiency. In lymphoblasts, complex I activity was 
reported to be either reduced (Barroso et al., 1993) or normal (Martin et al., 1996; 
Yoshino et al., 1992). One group studied mitochondrial respiratory chain activities in
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PD fibroblasts and found a significant decrease in the oxidative decarboxylation of 
(1-14C) pyruvate but not (1,4-14C) succinate suggesting a differential impairment of 
complex I but not complex ll/lll (Mytilineou et al., 1994).
It is unclear whether the discrepancy of results reflects methodological 
differences or whether they could be explained by heterogeneity of the PD patients 
in terms of the presence of a mitochondrial defect. Tissue homogenates are most 
commonly used to assess mitochondrial respiratory chain activity in post mortem 
brain because mitochondria cannot easily be isolated. However, assays for 
mitochondrial respiratory chain function are most sensitive in purified mitochondria. 
This was demonstrated in platelets where homogenate analysis was normal (Mann 
et al., 1992) whereas isolated mitochondria were abnormal (Krige et al., 1992). 
Hence, using tissue homogenates may fail to recognise more subtle defects in other 
areas of the PD brain apart from substantia nigra, where the defect may be more 
severe.
Taken together, there seems to be consistent evidence for a complex I 
defect but not for abnormalities in other mitochondrial respiratory chain complexes in 
PD. The defect was found most consistently in substantia nigra and platelets 
whereas the results in other tissues were variable. Why the complex I defect should 
be restricted to platelets and substantia nigra and not affect other brain regions is 
not clear. In addtion, not all PD patients have an identifiable complex I defect. This 
might indicate that a complex I defect is relevant only to a subset of PD patients.
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Tissue Reference MRC defect
Substantia nigra (Schapira etal., 1989) Complex I
(Schapira et al., 1990a) Complex I
(Janetzky et al., 1994) Complex I
(Mann et al., 1992) Complex I
(Mann et al., 1994) Complex I
(Mizuno et al., 1994) Reduced a-ketoglutarate 
immunoreactivity
Striatum (Cooper et al., 1995) No defect
Cortex, cerebellum, globus (Mann et al., 1992) No defect
pallidus, tegmentum,
Substantia innominata, (Gu et al., 1998b) No defect
cingulate cortex
Muscle (Bindoff et al., 1989) Complex I
(Blin et al., 1994) Complex I
(Cardellach et al., 1993) Complex I
(Nakagawa-Hattori et al., 
1992)
Complex I
(Shoffner et al., 1991) Complex I
(Anderson etal., 1993) No defect
(DiDonato etal., 1993) No defect
(Mann et al., 1992) No defect
(Reichmann et al., 1994) No defect
Platelets (Haas et al., 1995) Complex I
(Krige et al., 1992) Complex I
(Benecke et al., 1993) Complex I
Lymphoblasts (Barroso et al., 1993) Complex I
(Martin et al., 1996) No defect
(Yoshino et al., 1992) No defect
Fibroblasts (Mytilineou et al., 1994) Complex I
Table 3.1. Mitochondrial respiratory chain activity in PD tissues. Defects in 
mitochondrial respiratory chain complexes other than complex I have not been 
reported.
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3.1.5.1. Causes of mitochondrial involvement in PD
What causes the complex I defect in at least a subset of patients with PD remains 
unclear. Primary causes might include abnormalities in the genes, both nuclear and 
mitochondrial that encode the subunits of mitochondrial respiratory chain 
complexes. However, a complex I defect may also be secondary, e.g. caused by a 
mitochondrial toxin such as MPTP or rotenone.
3.1.5.1.1. Mitochondrial DNA (mtDNA)
As dicussed in the general introduction, mitochondria contain their own DNA 
(mtDNA), which encodes transfer RNAs, ribosomal RNA and some of the subunits 
of the mitochondrial respiratory chain complexes (see section 1.1.1). The following 
section examines the evidence to support the involvement of mtDNA in PD.
Cvbrid models
In order to examine the role of mtDNA cell cybrid systems were first introduced by 
King and Attardi (King and Attardi, 1989). They combine nuclear DNA from cells 
rendered mtDNA-less (p° cells) by the addition of ethidium bromide or 
dideoxycytosine with mtDNA from enucleated cells, most conveniently platelets, 
which carry no nuclear DNA. The system allows the investigation of the structural 
and functional consequences of mutated mtDNA without the influence of the original 
nucleus. Hence, if mtDNA were important for the phenotype of the original cells, one 
would expect a defect to be transmitted to and persist in the cybrids. Alternatively, 
one would expect that a nuclear abnormality, giving rise to a defect in mitochondrial 
respiratory chain activity, would be corrected by the nucleus of the host cell in the 
cybrids.
Swerdlow and colleagues generated cybrids from platelets of unselected PD 
patients, or controls, and p° neuroblastoma cells. After 5-6 weeks in the PD cybrids
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a 20% decrease of complex I activity was observed, and PD cybrids were more 
sensitive to MPP+ toxicity than controls (Swerdlow et al., 1996). Similar results were 
reported when platelets from PD patients with a platelet complex I defect were fused 
with p° cells (A549 lung-derived) (Gu et al., 1998a). The PD cybrids had a specific 
complex I defect (mean 25% decrease in activity) which, similar to the Swerdlow et 
al study, implied that the PD patient's mtDNA caused this deficiency (Gu et al., 
1998a). In addition, a correlation of platelet complex I activity and cybrid complex I 
activity discriminated even more clearly between the PD patients and controls. This 
suggested that in this group of idiopathic PD patients pre-selected by their low 
platelet complex I activity, the mitochondrial respiratory chain defect was determined 
by the mtDNA derived from their platelets.
In these studies no mtDNA mutations have yet been reported and it remains 
unclear whether mitochondrial changes in PD result from inherited mutations in the 
genes coding for mitochondrial respiratory chain proteins or whether mitochondrial 
function is compromised as a consequence of sporadic somatic mutations.
MtDNA studies
Mitochondria contain 2-10 molecules of their own DNA, mitochondrial DNA (mtDNA, 
see section 1.1.1). Over 100 mtDNA mutations have been associated with human 
diseases (Zeviani and Carelli, 2003)(www.mitomap.org). The exclusive maternal 
inheritance of mtDNA is reflected in a proportion of cases where the disease is 
passed through the maternal line. While maternal inheritance of a disease will 
implicate a mtDNA mutation, the majority of patients with mitochondrial mutations 
may have no such family history (Petty et al., 1986). MtDNA deletions, the most 
common mtDNA mutation, present as sporadic cases; for example, 40% of patients 
with Leber’s hereditary optic neuropathy (LHON) and the A-G 11778 mtDNA 
mutation have no family history.
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Several studies have sequenced mtDNA in unselected PD patients. In many, 
no mutation has been identified, whilst in others sequence changes of uncertain 
significance have been described (Kosel et al., 1998; Mayr-Wohlfart et al., 1997). A 
meta-analysis of candidate genes in PD suggested a significant risk association for 
the A4336G mutation of tRNAGlLJ with PD (Tan et al., 2000). However, this analysis 
was unable to take account of another study published subsequently, which showed 
no association of this mutation with PD (Simon et al., 2000).
How can the apparently selective complex I defect in PD be reconciled with 
these findings? The detection of a heteroplasmic mutation by sequence analysis 
may be dependent upon the mutant load. Hence, with a mutant load of no more than
5-20% it may be impossible to pick up a change in mtDNA. In addition, it is possible 
that the mutant load in the substantia nigra is higher than in blood, which has been 
used in most studies. It is also conceivable that the mitochondrial defect observed in 
PD tissue is associated with abnormalities of nuclear encoded mitochondrial 
proteins or is the result of exposure to environmental toxins (see next sections). 
However, as discussed in the previous section the cybrid data indicated that at least 
in a proportion of PD patients the mitochondrial defect was mediated through 
mtDNA. Thus maybe subgroups of PD patients differ in the primary cause (mtDNA, 
nuclear DNA, toxin) but not in the downstream consequence, i.e. mitochondrial 
dysfunction.
3.1.5.1.2. Nuclear genes
As dicussed in the general introduction (see section 1.1.1) the majority of the 
subunits of the complexes of the mitochondrial respiratory chain are encoded by 
nuclear DNA. Patients with neurodegenerative diseases have been described with 
mutations in nuclear genes encoding mitochondrial respiratory chain subunits. A 
single base change in the flavoprotein of succinate dehydrogenase (complex II)
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(Bourgeron et al., 1995) and in nuclear-encoded complex I genes (Loeffen et al., 
1998; Triepels et al., 1999) gave rise to Leigh’s syndrome and another mutation in 
the 18kD subunit of complex I was associated with encephalomyopathy (van den 
Heuvel et al., 1998). In three siblings leukodystrophy and myoclonic epilepsy 
developed with a mutation in the NADH binding site encoding nuclear complex I 
gene (Schuelke et al., 1999). Inheritance was autosomal recessive in all these 
patients and they were found to be either homozygous or compound heterozygous 
for the respective gene defect. Recently, the first nuclear-encoded mitochondrial 
protein, PTEN induced kinase (PINK1, see section 3.1.8.4.) was implicated in PD 
(Valente et al., 2004). While PINK1 is not part of complex I of the mitochondrial 
respiratory chain the discovery of PINK1 mutations in families with PD provided the 
first link between a nuclear encoded mitochondrial protein and PD.
3.1.5.1.3. Mitochondrial toxins
Epidemiological evidence suggested that environmental toxins, such as rotenone 
(Liou et al., 1997), could be a risk factor for PD (see section 3.1.4). Two of the 
toxins, MPTP and rotenone, are known to inhibit complex I of the mitochondrial 
respiratory chain. In fact, as discussed above, it was the discovery of the association 
of MPTP exposure and the development of parkinsonism, and the subsequent 
identification of MPP+, the active metabolite of MPTP, as a mitochondrial toxin that 
led to research into the involvement of mitochondria in PD. While there is no 
evidence to suggest widespread MPTP exposure rotenone is used as an insecticide 
and fish poison. It is therefore possible that for example rural populations are 
exposed to rotenone and could thus be at greater risk to toxin-mediated complex I 
inhibition and subsequent damage to the substantia nigra. However, the half-life of 
rotenone in solution is short so that in lakes rotenone may only be present for a few 
days (Hisata, 2002). Recently, in Guadaloupe atypical parkinsonism (sharing clinical
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and pathological similarities with progressive supranuclear palsy) was linked to the 
consumption of medicinal preparations made from the tropical plant family 
Annonacea (Caparros-Lefebvre and Elbaz, 1999). These plants contain 
Annonaceae acetogenins, which are lipophilic inhibitors of complex I of the 
mitochondrial respiratory chain (Cave et al., 1997). MPTP, rotenone and other toxins 
have been used to generate models of PD (see next section).
3.1.6. Toxin models of PD
The main neurotoxins used to generate toxin models of PD include 6- 
hydroxydopamine (6-OHDA), MPTP, rotenone and paraquat. It seems that all these 
toxins generate reactive oxygen species. Only MPTP has been associated with 
parkinsonism in humans; the MPTP model is therefore the most widely studied toxin 
model of PD.
6-OHDA toxin models
Models using 6-OHDA have been the first to investigate substantia nigra 
dopaminergic cell death (Ungerstedt, 1968). 6-OHDA cannot cross the blood brain 
barrier and therefore needs to be injected stereotactically into the midbrain of 
animals. 6-OHDA induces relatively selective loss of dopaminergic neurones 
because it is taken up preferentially by dopamine and monoamine transporters 
(Luthman et al., 1989). In the cytosol of these neurones 6-OHDA then accumulates 
and generates oxidative stress and quinones that can damage other molecules. 
Dopaminergic neurone loss accompanied by an increase in protein bound dopamine 
oxidation products was ameliorated by concomitant injection of antioxidants 
(glutathione and ascorbic acid) supporting the hypothesis that 6-OHDA caused 
neuronal cell death by generating oxidative stress (Hastings et al., 1996). Animals 
injected with 6-OHDA have a quantifiable motor deficit, but characteristic LBs have
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not been observed. This model has been particularly useful for pharmacological 
screening but does not replicate many key features of PD.
MPTP models
Parkinsonism was induced in a group of drug addicts that used drugs contaminated 
with MPTP (Langston and Ballard, 1983). MPTP is converted to N-methyl-4- 
phenylpyridinium (MPP+) within glial cells by monoamine oxidase (preferentially 
MAO-B (Singer et al., 1986), which is actively taken up by monoamine transporters 
in the membranes of dopaminergic neurones. Within cells MPP+ enters 
mitochondria and selectively binds to and inhibits NADH C0 Q 10 reductase (complex 
I), which leads to an inhibition of ATP synthesis and the generation of free radicals 
(Krueger et al., 1990; Ramsay and Singer, 1986). MPTP has been used for the 
development of mouse and primate models of PD (Bloem et al., 1990). In non­
human primates, MPTP caused tremor, rigidity, akinesia and postural instability, 
which were all successfully treated with L-Dopa and dopamine agonists. In the non­
human primate brains dopaminergic neurones were selectively lost in brain areas 
similar to idiopathic PD, including the substantia nigra. However, MPTP-induced 
subacute or acute onset parkinsonism lacked the typical EM features of LBs (Forno 
et al., 1988). The MPTP model represents the best-characterised model of PD and 
fulfils many of the criteria for a good model of the disease with the exception of LB 
formation. However, it remains unknown whether chronic administration of MPTP 
may induce the formation of LBs. An in depth discussion of the MPTP model, has 
been published elsewhere (Beal, 2001).
Rotenone
Rotenone belongs to the family of the rotenoids, which are natural cytotoxic 
compounds extracted from tropical plants. Rotenone is the most potent member and
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is used widely as an insecticide and fish poison. Rotenone is a highly lipophilic 
molecule (Talpade et al., 2000) that therefore readily enters all cells where it binds 
to mitochondrial respiratory chain complex I.
As discussed above (section 3.1.4.) epidemiological evidence suggests that 
the exposure to pesticides may be a risk factor for PD. Rats chronically infused 
intravenously with rotenone developed hypokinesia, postural instability, gait 
unsteadiness and paw tremor, and this correlated with the degree of degeneration of 
dopaminergic nigro-striatal neurones (Betarbet et al., 2000). On light microscopy 
these neurones exhibited cytoplasmic inclusions im mu noreactive for a-synuclein 
and ubiquitin, which ultrastructurally contained fibrils similar to those in LBs.
However, there was a somewhat variable response of the animals to rotenone with 
only 12 out of 25 rats developing lesions in the dopaminergic neurones of the 
substantia nigra.
Since rotenone enters all cells the selective loss of dopaminergic neurones 
in the rat model by Betarbet and colleagues suggested that dopaminergic neurones 
were particularly sensitive to complex I inhibition. However, acute rotenone 
intoxication was reported to spare dopaminergic neurones (Ferrante et al., 1997), 
and in rats chronically infused with rotenone significant reductions in the numbers of 
DARPP-32-positive, cholinergic and NADPH diaphorase-positive neurones was 
described (Hoglinger et al., 2003). These findings indicate a more widespread 
toxicity of rotenone and query the concept of selective toxicity of rotenone to 
dopaminergic neurones.
Paraquat
As discussed above (section 3.1.4.) exposure to the herbicide paraquat (N,N’- 
dimethyl-4-4’biperidinium) may increase the risk for PD (Liou et al., 1997). Paraquat 
has a structure similar to MPP+; paraquat does not easily cross the blood brain
94
barrier (Shimizu et al., 2001) and it is not known what determines its distribution in 
the brain (Widdowson et al., 1996a; Widdowson et al., 1996b). Paraquat is a known 
intracellular generator of superoxide, which is promoted by the mitochondrial 
NAD(P)H -quinone oxidoreductase (Shimada et al., 1998) and can lead to damage 
to the cell and in particular to mitochondria (Hirai et al., 1992). Systemic 
administration of paraquat to mice led to degeneration of dopaminergic neurones in 
the substantia nigra and the formation of a-synuclein containing inclusions 
(Manning-Bog et al., 2002). This suggests that models using paraquat may be 
useful tools with which to explore the interaction of an environmental risk factor for 
PD and a-synuclein.
3.1.7. Secondary features of PD
The following section covers the evidence for oxidative stress, excitotoxicity and 
proteolytic stress in PD. These features of PD may be secondary to the primary 
underlying pathology and might contribute to or be influenced by mitochondrial 
respiratory chain defects as discussed in the previous section. However, this is only 
one example of the links that exist between each of these features. Ultimately, they 
all seem to contribute to the pathological events that result in the death of 
dopaminergic neurones in the substantia nigra (Figure 3.2). It is not clear what 
initiates the pathological cascade leading on to dopaminergic neurone loss in the 
substantia nigra and hence can be regarded as a primary event with subsequent 
involvement of other pathways. For example while it is clear that oxidative stress 
plays a role in these events it remains unclear whether oxidative stress is the result 
or the cause of mitochondrial dysfunction, or might be linked to dopamine 
metabolism. Further, the cell type specific contribution to these processes in the 
substantia nigra remains a matter of debate. Evidence is emerging to suggest 
involvement of glial cells (astrocytes, oligodendrocytes, microglia) in the
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pathophysiology of PD. Several studies reported that there was a substantial degree 
of gliosis, and in particular microglia activation, in PD brains (Banati et al., 1998; 
Forno et al., 1992; McGeer et al., 1988; Mirza et al., 2000). Astrocytes contribute to 
dopamine metabolism in that they contain monoamine oxidases A and B as well as 
catechol-O-methyl transferase; in addition they contain glutathione peroxidase and 
in both ways might protect dopaminergic neurones from ROS (Hirsch et al., 1999).
In addition, microglia, but not dopaminergic neurones, in PD were shown to have 
iNOS (Hunot et al., 1996) and could therefore be an important source of reactive 
nitrogen species, in particular the membrane permeable NO*, resulting in nitration 
within dopaminergic neurones. However, it remains unclear whether the involvement 
of glial cells is a primary event, or a contributing but not causally related feature.
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Figure 3.2. Possible common pathomechanisms in PD I. There is good evidence for 
mitochondrial dysfunction, oxidative stress, protein misfolding, and the involvement 
of the UPS with proteolytic stress in PD. All these pathways seem to be 
interconnected. It remains unknown which is the first step in the pathogenetic 
cascade that leads to cell death (presumably by programmed cell death) and 
whether events taking place in glial cells are as important as those within 
dopaminergic neurones in the substantia nigra. DA: dopamine. ATP: adenosin 
triphosphate. UPS: ubiquitin-proteasome system. ROS: reactive oxygen species. 
RNS: reactive nitrogen species. NOS: nitric oxide synthase. LB: Lewy body.
3.1.7.1. Evidence for oxidative stress in PD
The basic mechanisms underlying oxidative stress are discussed in detail in chapter 
1 (section 1.1.3.). Compromised anti-oxidant defences or increased free radical 
generation may tip the balance towards increased oxidative stress (Figure 3.2.). 
Postmortem homogenate analysis of PD substantia nigra consistently revealed 
increased iron levels (Dexter et al., 1989; Earle, 1968; Hirsch et al.( 1991; Olanow, 
1992; Sofic et al., 1988) and decreased levels of reduced glutathione (Perry et al., 
1982; Sian et al., 1994; Sofic et al., 1992). Iron is known to function as a chelator for 
H20 2 in the Fenton reaction giving hydroxyl radicals; it also interacts with 
superoxide, which can reduce Fe(lll) and oxidise Fe2+, and can accelerate the 
Fenton reaction (Halliwell and Gutteridge, 1999). Thus increased iron levels can 
indicate increased free radical production. Others have reported less consistent 
results regarding GSH, glutathione peroxidase, catalase, increased mitochondrial 
GSSG levels (Ambani et al., 1975; Damieretal., 1993; Johannsen et al., 1991; Kish 
et al., 1985; Marttila et al., 1988b; Radunovic et al., 1997; Saggu et al., 1989; Sian 
et al., 1994; Yoritaka et al., 1997; Yoshida et al., 1994), or abnormalities of ferritin 
(Cabrera-Valdivia et al., 1994; Connor et al., 1995; Dexter et al., 1990; Jellinger et 
al., 1990; Kuiper et al., 1994; Logroscino et al., 1997; Mann et al., 1994; Riederer et 
al., 1989). In PD substantia nigra increased oxidative damage has been reported to 
lipids (lipid peroxidation) (Dexter et al., 1994), increased levels of 4-hydroxynonenal 
(also in cerebrospinal fluid) (Picklo et al., 1999; Yoritaka et al., 1996), DNA (rise in 8- 
OHdG in mitochondria and total DNA) (Alam et al., 1997b; Sanchez-Ramos et al., 
1994; Shimura-Miura et al., 1999) and protein carbonyl production (Alam et al., 
1997a; Floor and Wetzel, 1998). In addition, increased immunoreactivity has been 
reported for nitrotyrosine in Lewy bodies in PD substantia nigra (Giasson et al.,
2000; Good et al., 1998).
Taken together, these studies provide evidence for oxidative stress in PD
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substantia nigra, which has led to oxidative damage to lipids, DNA and proteins. 
Since these studies were performed on post-mortem tissue of patients with long­
standing PD, and in all likelihood including patients who had been on L-dopa 
therapy, they likely represent a snapshot of end-stage PD substantia nigra. Thus the 
time course and interrelationship to other processes in PD pathophysiology remain 
unclear (Figure 3.2.).
However, dispite the evidence in support of oxidative stress treatment of 
patients with MOA B inhibitors, e.g. deprenyl, or with antioxidants, e.g. tocopherol 
(vitamin E), has not demonstrated neuroprotection or an effect on the progression of 
disability in early Parkinson’s disease (The Parkinson's Disease Study Group,
1993), although deprenyl can delay the requirement of additional symptomatic 
therapy by 9-12 months. Since it is not entirely clear whether antioxidants reach the 
target cells these negative results do not necessarily mean that antioxidants per se 
are not suitable forms of treatment.
3.1.7.2. Dopamine
The relatively selective loss of dopaminergic neurones in the substantia nigra 
suggests that dopamine itself might be relevant in the pathogenesis of PD. 
Substantia nigra neurones, but also cells in other organs such as the adrenal gland, 
synthesise DA using tyrosine hydroxylase (TH). Vesicular monoamine transporters 
(VMAT) then actively transport dopamine into specialised monoaminergic storage 
vesicles within dopaminergic cells. Neuronal cells predominantly express VMAT-2 
whereas non-neuronal cells predominantly express VMAT-1. Substantia nigra 
neurones are known to be TH positive, synthesizing dopamine, and express 
dopamine uptake transporter (DAT) in pre-synaptic terminals to facilitate re-uptake 
of extracellular dopamine (Reith et al., 1997). Dopaminergic substantia nigra 
neurones have their cell bodies in the substantia nigra and their neu rites extend
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mainly into the striatum where dopamine is released from the nerve terminals. 
Dopaminergic neurones are not the only cells in the brain that can take up and 
metabolise dopamine. Glial cells, particularly astrocytes, contain DAT and 
monoamine oxidases.
Dopamine metabolism includes the enzymatic deamination by monoamine 
oxidases (MAO-A and MAO-B) to 3,4-dihydroxyphenylacetaldehyde (DOPAL). This 
can generate H20 2 (Sandri et al., 1990) and oxidised glutathione (Werner and 
Cohen, 1991). DOPAL can be oxidised to 3,4-dihydroxyphenylacetic acid (DOPAC) 
by DOPAL dehydrogenase or reduced to 3,4-dihydroxyphenylethanol (DOPET) by 
DOPAL reductase (Figure 3.3). In addition, dopamine can spontaneously undergo 
auto-oxidation to form catechol-quinones, which themselves can act as oxidants by 
forming toxic hydroxyl radicals, or they can react as electrophiles and bind to and 
inhibit sulfhydryl groups within the cell (Graham, 1978; Shen et al., 1997; Terland et 
al., 1997).
In PD brain, dopamine turnover was found to be increased (Hornykiewicz 
and Kish, 1987), and 6-OHDA was shown to be toxic after injection into rat striatum 
(Hastings et al., 1996, see section 3.1.6.). In rat striatal primary cell culture 
(McLaughlin et al., 1998) and rat foetal mesencephalic cells (Michel and Hefti, 1990; 
Tanaka et al., 1991) dopamine also led to cell death. Astrocytes were also found to 
take up and metabolise dopamine (Langeveld et al., 1995; Liesi et al., 1981); in SH- 
SY5Y cells, co-culturing with astrocytes protected against the toxic effects of 6- 
OHDA (Yu and Zuo, 1997) suggesting that astrocytes may be able to protect 
dopaminergic neurones from oxidative stress generated via dopamine metabolism. 
Evidence to support the hypothesis of oxidative damage from dopamine metabolism 
comes from the attenuation of dopamine toxicity by antioxidants and free radical 
scavengers (ascorbic acid, N-acetyl cysteine, cysteine glutathione, harmalol, 
harmaline) in PC-12 cells (Lee et al., 2000) and primary striatal cell culture
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(McLaughlin et al., 1998; Soto-Otero et al., 2000). In addition, exposure of isolated 
intact mitochondria to dopamine and its metabolites, e.g. dopamine-quinone, led to 
impaired mitochondrial respiratory chain function and mitochondrial swelling 
suggestive of opening of the mitochondrial transition pore (MTP) (Berman and 
Hastings, 1999; Cohen et al., 1997; Kim et al., 1999) thus providing a possible link 
between dopamine toxicity and mechanisms involved in apoptosis (see section 
1.1.2.2). This was attenuated by inhibition of MAO-A and MAO-B, or the addition of 
catalase suggesting the involvement of free radical generation, and cyclosporin A 
that can stabilise the MTP (Berman and Hastings, 1999; Cohen et al., 1997). A link 
of dopamine to mitochondrial respiratory function is not consistent. While one study 
reported that in mitochondria isolated from rat brain dopamine inhibited complex I 
activity (Ben-Shachar et al., 1995) others have not established a direct influence of 
dopamine on mitochondrial function (Morikawa et al., 1996).
An unresolved question is whether L-dopa given as a treatment to PD 
patients may contribute to the processes leading to neuronal cell death. In healthy 
humans (Quinn et al., 1986; Rajput et al., 1997), rodents (Perry et al., 1984) or 
primates (Lyras et al., 2002) chronic administration of L-dopa does not seem to give 
rise to increased levels of oxidative stress or damage the substantia nigra. However, 
the effects of L-dopa within substantia nigra in PD patients may be different, and the 
magnitude of the effect could in fact depend on how many dopaminergic neurones 
have already been lost. This hypothesis could be addressed using functional 
imaging studies, such as those that have been used in twin studies (Piccini et al.,
1999).
3.1.7.3. Proteolytic stress
Impairment of UPS function may be an important contributor to the pathogenesis of 
PD (McNaught et al., 2001) (Figure 3.2.). In dopaminergic neurones in the
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substantia nigra in PD a-subunits of the 20S proteasome were reported to be 
differentially lost compared with p-subunits, (McNaught et al., 2002a); this may have 
consequences for proteasomal function since the proteolytic activity was decreased 
by about 40% (McNaught and Jenner, 2001). The specific absence in substantia 
nigra, compared with relatively unaffected areas in PD, of aggresomes, sites of high 
proteolytic activity that safeguard the nucleus and other cell organelles form toxic 
proteins (Kopito, 2000) may provide indirect evidence for impaired proteasomal 
function in dopaminergic neurones in the substantia nigra (Johnston et al., 1998; 
McNaught and Jenner, 2001; Wigley et al., 1999). As a consequence this could 
mean that dopaminergic neurones are selectively exposed to increased levels of 
toxic proteins while areas able to form aggresomes are relatively spared. The 
observation that the most abundant proteinaceous components of LBs, a-synuclein 
and oxidised proteins such as nitrotyrosine, do not seem to require ubiquitination for 
their degradation within the 20S proteasome (Bennett et al., 1999; Davies, 2001; 
Spillantini et al., 1998; Stefanis et al., 2001; Tofaris et al., 2001) suggests that it is 
not a failure of ubiquitination but of the 20S proteasome that leads to their 
accumulation. This hypothesis would be consistent with a report indicating a marked 
increase in polyubiquitinated proteins within the substantia nigra of patients with 
sporadic PD (McNaught et al., 2002b).
What causes abnormal 20S proteasomal function in sporadic PD remains 
unknown. Environmental proteasomal inhibitors (e.g. polyphenols) have been 
described (Nam et al., 2001), and protesomal function may also be sensitive to 
oxidative stress (Bulteau et al., 2001). Finally, since a number of the processes of 
the UPS require ATP a compromise of mitochondrial function might have secondary 
effects on proteasomal function. Indeed, in rats rotenone mediated complex I 
inhibition was associated with the formation of LB-like inclusion (Betarbet et al., 
2000), and in COS-7 cells normal mitochondrial function was necessary to prevent
102
and remove a-synuclein aggregates (Lee et al., 2002a). Thus it is likely that in PD 
proteosomal pathology has to be viewed as one of many other factors that interact 
in the pathophysiology of PD (Figure 3.2).
3.1.7.4. Evidence for programmed cell death in PD
As discussed in the previous sections, there is good evidence for mitochondrial 
respiratory chain dysfunction, oxidative stress and free radical mediated damage to 
lipids, DNA and proteins in PD substantia nigra. These processes may ultimately 
lead to the initiation of programmed cell death (Figure 3.2, and section 1.1.2.2). 
Signs of apoptosis have been detected in dopaminergic neurones of the substantia 
nigra in normal aging (Anglade et al., 1997). In PD, postmortem brain analysis 
revealed nuclear condensation, chromatin fragmentation and the formation of 
apoptotic bodies, which indicate programmed cell death (Mochizuki et al., 1996; 
Tatton et al., 1998; Tompkins et al., 1997). However, concerns have been raised 
towards some of the techniques used to detect apoptosis, in particular terminal 
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labelling 
(TUNEL), which was shown to be susceptible to artefacts in the examination of 
postmortem brain tissue (Tatton et al., 1998). Using this technique conflicting results 
were reported with evidence showing apoptosis in some studies (Tatton et al., 1998; 
Anglade et al., 1997; Mochizuki et al., 1996) while other studies reported data that 
did not support the concept of apoptosis specifically in PD dopaminergic neurones 
(Banati et al., 1998; Kingsbury et al., 1998; Kosel et al., 1997). In support of 
apoptois, other studies have reported a rise of BAX, an apoptosis inducing protein 
(see section 1.1.2.2), in substantia nigra neurones (Hartmann et al., 2001a; Tatton, 
2000). In addition, Fas, FADD (Ferrer et al., 2000; Hartmann et al., 2002; Mogi et 
al., 1996) and caspase 8 (Hartmann et al., 2001b) were also implicated in neuronal 
cell death in PD substantia nigra. This raises the issue that cell death signals in PD
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dopaminergic neurones may not only originate from within the cell (oxidative stress, 
mitochondrial dysfunction) but that extracellular death signals (?originating from glial 
cells) could also contribute to triggering programmed cell death in dopaminergic 
neurones (see section 1.1.2.2).
Data from experimental models supports the involvement of programmed 
cell death in PD. The substantia nigra of MPTP treated mice showed evidence of 
apoptotic nuclear changes (Tatton and Kish, 1997); in liver and brain mitochondria, 
MPP+ opened the MTP and led to cytochrome c release (Cassarino et al., 1999). In 
neuronal cell culture, MPP+ was shown to up-regulate NF-kB (Cassarino et al.,
2000). NF-kB is known, when activated, to translocate from its cytoplasmic location 
to the nucleus where it binds to DNA and can induced apoptosis (Thanos and 
Maniatis, 1995). Evidence for activated NF-kB was found in dopaminergic neurones 
of PD patients (Hunot et al., 1997), and activated NF-kB also protected neuronal 
cells in culture from apoptosis induced by FeS04 or amyloid beta peptide mediated 
oxidative stress (Mattson et al., 1997). Interestingly, pramipexole, a dopamine 
agonist, inhibited MTP opening in response to MPP+ and attenuated the levels of 
free radicals in neuronal cells, rats and isolated mitochondria (Cassarino et al.,
1998). Caspase inhibitors improved survival of dopaminergic neurones transplanted 
into the substantia nigra of lesioned animals, and levels of prostate apoptosis 
response-4 protein (Par-4), an important proapoptotic protein in neurones, are 
elevated in midbrain dopaminergic neurones of MPTP treated monkeys and mice 
(Duan et al., 1999a; Duan et al., 1999b). These authors demonstrated that inhibition 
of Par-4 synthesis by antisense oligonucleotide treatment prevents apoptosis in 
cultured dopaminergic cells. Furthermore, dopamine induced apoptosis in PC-12 
cells and cyanide enhanced DA toxicity (Jones et al., 2000). Thus, it is likely that the 
pathogenetic factors involved in PD nigral cell death may cause cell dysfunction as 
well as lower the neurones’ threshold to apoptosis.
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Taken together the available evidence supports a role of apoptotic cell death 
in PD neuronal loss. It seems that some of the controversies that arose may have 
been caused by the susceptibility to artefact in postmortem brain tissue of one 
particular technique to detect apoptosis, the TUNEL technique (Tatton et al., 2003).
3.1.8. The genetics of PD
Evidence for a genetic contribution to the pathogenesis comes from epidemiological 
and twin studies. PD was found to be more common among relatives of index cases 
compared to matched controls in several case control studies (De Michele et al., 
1996; Marderetal., 1996; Payamietal., 1994; Sveinbjornsdottir et al., 2000; 
Vieregge and Heberlein, 1995). It appears that the risk of a given relative to have 
PD increases depending upon how many members of the family are already 
affected. From all studies combined it was estimated that the relative risk in first- 
degree relatives of individuals with PD is in the range of 2-3 times that of the general 
population (Gasser, 1998). This is in keeping with a multifactorial aetiology of PD 
that entails an inheritable component in a subset of families (Lazzarini et al., 1994).
In addition, mutations in four different genes - a-synuclein on chromosome 
4q21/PARK1 (Polymeropoulos et al., 1997), and 4q/PARK4 (Kruger et al., 1998), 
parkin on 6q25-27/PARK2 (Kitada et al., 1998), DJ-1 on 1p36/PARK7 (Bonifati et 
al., 2002; van Duijn et al., 2001), and PINK1/PARK6 on 1p35-p36 (Valente et al., 
2004) have been described in familial PD (HUGO, for a review see Foltynie et al., 
2002 and Gwinn-Hardy and Farrer, 2002) (Table 3.2.). There is also evidence 
implicating mutations in ubiquitin carboxyhydrolase -L1 (UCH-L1) in the 
pathogenesis of PD (4p14/PARK5, (Leroy et al., 1998). In addition, PD-related 
genes have been linked to five further loci, 2p13/PARK3 (Gasser et al., 1998), 
4p15/PARK4 (Farrer et al., 1999), 12p11/PARK8 (Funayama et al., 2002), 
1p36/PARK9 (Kufor-Rakeb syndrome; Hampshire et al., 2001), and 1p32/PARK10
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(Hicks et al., 2002). Other genes associated with parkinsonism include tau (fronto- 
temporal dementia with parkinsonism, FTDP17) (Clark et al., 1998), and the X- 
linked recessive syndrome of parkinsonism and dystonia (Lubag)(Xp13)(Wilhelmsen 
et al., 1991).
The discoveries of mutations in genes that are associated with PD have 
offered the chance to gain new insight into the pathogenesis of this disease. As the 
function of the proteins encoded by these genes is unravelled (see next section) 
their relevance to the pathological cascade in PD becomes clearer (Figure 3.4). 
However, this has added another level of complexity to the various inter 
relationships between the pathological processes involved in PD (Figure 3.4).
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Gene Mode of 
inheritance
Locus Chromoso­
mal location
Reference
a-synuclein Autosomal dominant Park 1 4q21-q23 (Polymeropoulos et al., 
1997)
Parkin Autosomal recessive Park 2 6q21.2-27 (Kitada et al., 1998)
Unknown Autosomal dominant Park 3 2p13 (Gasser et al., 1998)
a-synuclein Autosomal dominant Park 4 4q (Kruger et al., 1998)
UCH-L1 Autosomal dominant Park 5 4p14 (Leroy et al., 1998)
PINK 1 Autosomal recessive Park 6 1p35- (Valente et al., 2004)
DJ-1 Autosomal recessive Park 7 1p36 (Bonifati et al., 2002)
Unknown Autosomal dominant Park 8 12p11 q13.1 (Funayama et al., 
2002)
Unknown Autosomal recessive Park 9 1p36 (Hampshire et al., 
2001)
Unknown Late onset 
susceptibility gene
Park 10 1p32 (Hicks et al., 2002)
NR4A2 Susceptibility gene NA 2q22-23 (Le et al., 2003)
Synphilin 1 Susceptibility gene NA 5q23.1 -23.3 (Marx et al., 2003)
Tau Susceptibility gene NA 17q21 (Martin et al., 2001)
Unknown X-linked recessive 
(Lubag)
NA Xp13 (Wilhelmsen et al., 
1991)
Table 3.2. Genes and chromosomal loci linked to familial PD or implicated in the 
pathogenesis of PD. NA: not assigned.
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3.1.8.1. Twin studies
Since monozygotic twins (MZ) have identical DNA whereas dizygotic twins (DZ) only 
have 50% DNA in common, an increased concordance rate of a disease in MZ twins 
as opposed to DZ twins argues for a genetic aetiology of that disease given that 
environment is either random or more controlled for in twins. In PD, five studies 
compared the concordance rate in MZ pairs with that in DZ pairs (Marsden, 1987; 
Marttila et al., 1988a; Tanner et al., 1999; Vieregge et al., 1992; Ward et al., 1983). 
Taking the results of these studies together, 21 of 162 MZ pairs (13%) showed 
concordance compared with 16 of 147 DZ pairs (16%). These results would suggest 
that there is no significant difference in the MZ/DZ concordance ratio (1.2/1.0) and 
hence they do not support the notion of a genetic contribution in PD. However, it 
needs to be born in mind that the diagnosis of PD rests on clinical assessment 
alone. This is not always accurate and cannot predict the onset of PD in a given 
individual. The onset of PD differed substantially between the MZ co-twins (Golbe, 
1999) and it is therefore conceivable that individuals that were to develop PD later in 
life were missed. A large study on 161 twin pairs that on clinical grounds alone were 
diagnosed with PD found increased concordance in monozygotic twins in those who 
developed the disease before the age of 50 years, but no increase in those who 
manifested at a later age (Tanner et al., 1999). In another twin study employing both 
clinical assessment and a sensitive and specific marker to identify surviving 
nigrostriatal dopaminergic neurones, 18fluoro-dopa positron emission tomography, 
also demonstrated increased concordance amongst identical twins (Piccini et al.,
1999). In that study, 18 twin pairs, 10 MZ and 8 DZ, where 1 twin was affected with 
PD and the other healthy, were scanned twice with an interval of 4 years. In all 10 
MZ pairs, but only 2 DZ pairs, 18fluoro-dopa uptake declined substantially between 
scans indicating a concordance of 72% in MZ pairs and 18% in DZ pairs. This 
concordance provides evidence to support the notion that genetic factors play a role
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in PD; however, since the concordance was not 100% it seems that these genetic 
factors did not exclusively determine whether an individual developed PD. Thus 
other non-genetic factors, e.g. environmental toxins, might also have a substantial 
role in the pathogenesis of PD.
3.1.8.2. Identification of Parkin mutations in autosomal recessive PD
Loss of function mutations (deletions and point mutations) in the parkin gene are 
associated with autosomal recessive juvenile PD (ARJPD) (Kitada et al., 1998; 
Shimura et al., 1999). Recently, a case control study revealed an association of a 
single nucleotide polymorphism (258 T/G) in the parkin promoter with late-onset 
idiopathic PD (West et al., 2002) suggesting that the parkin gene may also be 
important in the pathogenesis of idiopathic PD. Clinically, parkin-associated ARJPD 
resembles idiopathic PD but can also be associated with dystonia and marked L- 
Dopa induced dyskinesias. While there is a severe loss of dopaminergic neurones in 
the substantia nigra pars compacta and the locus coeruleus reminiscent of 
idiopathic PD, with the exception of one reported case (Farrer et al., 2001), LBs 
have not been observed. However, the true incidence of LB pathology in ARJPD 
may only be revealed after more parkin-positive patients have undergone post­
mortem analysis.
Parkin itself is a 465 amino acid ubiquitin protein ligase (E3) that plays a role 
in the transfer of ubiquitin to proteins destined for degradation in the ubiquitin- 
proteasome-system (UPS) (Shimura et al., 2000). E3-ligases specifically target 
those proteins by facilitating ubiquitination (see section 1.1.6). Thus a loss of parkin 
function could result in the loss of the specificity of this process; however, it is not 
understood if alternative mechanisms can compensate for the loss of parkin.
Recently, two parkin knock-out mouse models have been published 
(Goldberg et al., 2003; Itier et al., 2003). In both models mice were viable, fertile and
109
had only subtle behavioural abnormalities. Gross pathology was normal and in 
particular there was no loss of dopaminergic neurones. However, extracellular DA 
levels in the striatum were increased and medium sized striatal spiny neurones were 
less excitable with electrical stimulation than controls in the study by Goldberg and 
colleagues, and Itier and colleagues reported that their parkin deficient animals 
showed increased dopamine metabolism. Greene and colleagues reported on a 
parkin knock-out model in drosophila (Greene et al., 2003). Parkin knock-out did not 
affect viability of flies and brain morphology was normal including tyrosine 
hydroxylase staining. This is in accord with the findings in the mouse knock-out 
models. In contrast to the mouse models parkin deficient flies exhibited pathology in 
muscle and male germ line associated with mitochondrial structural abnormalities 
(swelling and disintegration of cristae).
Data from the studies of Goldberg and colleagues and Itier and colleagues 
suggest that parkin may have a role in the functional regulation of dopamine release 
from the substantia nigra into the striatum whereas a loss of parkin does not seem 
to be associated with a loss of dopaminergic neurones. The role of parkin in other 
tissues remains to be elucidated. Constitutive over-expression of mutant parkin in 
NT2 and SK-N-MC neuronal cells was associated with increased levels of oxidative 
stress when compared to over-expression of wild-type parkin (Hyun et al., 2002). 
This was independent of whether or not the mutant parkin retained enzyme activity.
It needs to be shown if this is due to specific interference of the mutant parkin 
protein with UPS function, e.g. abnormal ubiquitin protein ligase activity with 
subsequent accumulation of mutated or damaged proteins that cannot be 
ubiquitinated, or a non-specific consequence of abundant expression of a mutant 
protein in these cells.
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3.1.8.3. Ubiquitin carboxyhydrolase -L1 (UCH-L1)
Two siblings from a German pedigree with autosomal dominantly inherited PD with 
incomplete penetrance carried mutations (I93M) in the ubiquitin carboxyhydrolase - 
L1 (UCH-L1, PARK 5) gene (Leroy et al., 1998). This resulted in reduced but not 
completely absent activity of the hydrolase. A polymorphism (S18Y) of the UCH-L1 
gene has been described to protect against PD (Levecque et al., 2001; Maraganore 
et al., 1999; Satoh and Kuroda, 2001). The neuropathological changes caused by 
the UCH-L1 mutation in humans remain unknown. UCH-L1 belongs to the protein 
family of ubiquitin C-terminal hydrolases, which hydrolyses the bond between 
ubiquitin and its substrate in order to recycle ubiquitin. Interestingly though, a 
second enzymatic function, dimerisation dependent ubiquitin ligase activity, has 
been described (Liu et al., 2002). The mutation of UCH-L1 seems to confer a loss of 
ligase activity and may thus promote parkinsonism whereas the polymorphism 
increases ligase activity and could therefore protect against parkinsonism (Liu et al., 
2002). Neurodegeneration associated with the loss of UCH-L1 and UCH-L3 in the 
gracile axonal dystrophy mice further suggests that these proteins may be 
particularly important for neuronal function. However, these mice did not develop 
parkinsonism (Kurihara et al., 2001).
3.1.8.4. Other genes
Mutations in the DJ-1 gene (PARK 7) were recently identified in families with 
autosomal recessive, early onset PD (Bonifati et al., 2002). The function of DJ-1 is 
unknown. However, there is evidence to suggest that DJ-1 may be important for the 
regulation and monitoring of oxidative stress response since it was shown that the 
intracellular generation of free radicals led to an increase in and oxidation of DJ-1 
(Mitsumoto and Nakagawa, 2001; Mitsumoto et al., 2001).
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Parkinsonism is a feature of patients with autosomal dominant 
frontotemporal dementia-parkinsonism (FTDP) associated with tau mutations on 
chromosome 17 (Hutton et al., 1998). This suggests that tau might also play a role 
in the pathogenesis of PD. This is consistent with tau immunoreactivity observed in 
a subset of LBs, i.e. those in the brainstem, of patients with PD (Arima et al., 1999), 
and also genetic linkage to the tau gene with clinically diagnosed idiopathic PD 
(Farrer et al., 2002; Gilman et al., 1998; Marks et al., 2001) and an association of 3 
out of 5 examined single nucleotide polymorphisms in the tau gene (SNP 3, SNP 9i, 
SNP 11) with idiopathic PD in 1056 subjects (426 affected) from 235 families (Martin 
et al., 2001). Tau and a-synuclein were both found within inclusions in the brain of 
two members of the Contoursi kindred with the G209A a-synuclein mutation and 
parkinsonism (Duda et al., 2002; Giasson et al., 2003) and may interact in the 
events leading to aggregation (Giasson et al., 2003). This may be linked to the role 
of tau in microtubule-based transport of aggregates (Kopito, 2000). However, no 
association between the tau locus and 157 pathologically confirmed sporadic PD 
cases has been reported in another study (de Silva et al., 2002), which suggests 
that any association may be weak, or that the clinical diagnosis of PD may not have 
been correct in all the original association studies.
Recently, two mutations (G to A transition in exon 4 nucleotide 11185, and G 
to A transition in nucleotide 15600, in NT_004610) in a gene encoding a putative 
mitochondrial protein called PTEN-induced kinase (PINK 1, PARK 6) have been 
identified in three consanguineous families with rare autosomal recessive early 
onset PD from Italy and Spain (Valente et al., 2004). Immunocytochemically, PINK 1 
localised to mitochondria in transfected COS-7 cells and Western blot of 
mitochondrial enriched fractions confirmed mitochondrial localisation. Expression of 
wild-type or G309D mutant PINK 1 in SH-SY5Y cells had no effect on mitochondrial 
membrane potential but cells overexpressing the wild-type form were protected from
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the effects of the proteosomal inhibitor MG-132 on mitochondrial membrane 
potential and apoptosis (Valente et al., 2004). This is the first nuclear-encoded 
mitochondrial protein that has firmly been associated with PD.
3.1.8.5. Identification of a-synuclein mutations in autosomal dominant PD
In a large Italian-Greek-American PD pedigree (the Contursi kindred, a pedigree 
with 592 members of which 60 were affected), PD was observed with highly 
penetrant autosomal dominant inheritance (Polymeropoulos et al., 1997). The 
clinical picture was very similar to PD apart from tremor being infrequent; patients 
had on average an earlier onset (46±13 years) of the disease and a more rapid 
progression to death with a mean survival of about 10 years (Golbe et al., 1990; 
Polymeropoulos et al., 1996) and pathological features similar to those of typical PD. 
In this kindred, Polymeropoulos and collegues identified a G209A substitution in the 
a-synuclein gene, leading to the substitution of alanine to threonine at position 53 
(A53T) in the a-synuclein protein (Polymeropoulos et al., 1997). A second mutation 
in the a-synuclein gene (G88C; causing an alanine to proline (A30P) substitution in 
the a-synuclein protein) was identified in a German pedigree with early-onset PD 
(Kruger et al., 1998). Recently, genetic analysis in another family with young onset 
autosomal dominant PD revealed a triplication of the a-synuclein locus. This 
suggests that not only can mutations in the a-synuclein gene cause PD but also that 
the over-expression of the wild-type form alone may by associated with PD 
(Singleton et al., 2003). However, the number of PD patients in whom such genetic 
abnormalities in the a-synuclein gene underlie their disease is small (<10%). The 
analysis of the a-synuclein gene in two case series of patients with sporadic PD 
(Vaughan etal., 1998a; Warner and Schapira, 1998) or familial PD (Vaughan et al.,
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1998b) did not reveal any abnormalities suggesting that for the vast majority of PD 
patients mutations in the a-synuclein are not relevant.
3.1.8.5.1. a-synuclein
The 19kD (140 amino acid) protein a-synuclein belongs to the synuclein family of 
proteins (Lavedan, 1998). Synucleins are abundant in the brain; a-synuclein, p- 
synuclein and y-synuclein are similar in amino acid length (127-140), share 55-62% 
of amino acid sequences and have a similar domain organisation (Lavedan, 1998). 
a-synuclein was first sequenced in the electric ray (Torpedo californica) (Maroteaux 
et al., 1988). The function of a-synuclein is incompletely understood. The protein 
contains 11 imperfect amino acid repeats with the consensus sequence of KTKEGV. 
A hydrophobic amino acid sequence in the centre of a-synuclein is essential for 
filament assembly (Giasson et al., 2001), while it can bind to lipid membranes 
through its the amino-terminal repeats (Eliezer et al., 2001; Jensen et al., 1998; Jo 
et al., 2000; McLean et al., 2000; Perrin et al., 2000).
3.1.8.5.2. a-synuclein and fibrillogenesis
Synucleins in their native state are unfolded proteins with minimal secondary 
structure (Jakes et al., 1994; Weinreb et al., 1996). When a-synuclein binds to lipid 
membranes it changes its structure to assume a a-helix conformation (Davidson et 
al., 1998; Eliezer et al., 2001; Jo et al., 2000; Perrin et al., 2000). In vitro, both the 
full-length and the carboxy-terminated form of a-synuclein can assemble into 
filaments resembling those seen in humans; the PD associated G209A mutation 
was consistently shown to facilitate fibril formation possibly leading to the generation 
of seeds that enhance further fibril formation in a nucleation-dependent process 
(Biere et al., 2000; Conway et al., 1998; Conway et al., 2000a; Conway et al.,
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2000b; Crowther et al., 1998; El-Agnaf et al., 1998; Giasson et al., 2001; Giasson et 
al., 1999; Narhi et al., 1999; Serpell et al., 2000; Wood et al., 1999). However, 
results regarding the effects of the G88C a-synuclein mutation are not consistent; 
promotion of fibrillogenesis (Narhi et al., 1999), no change (Serpell et al., 2000) or 
inhibition of fibril formation (Conway et al., 2000b) has been reported. Fibillogenesis 
may not only be facilitated by a-synuclein mutations. In vitro work showed that 
paraquat and rotenone, an inhibitor of complex I of the mitochondrial respiratory 
chain, promoted a-synuclein fibrillogenesis (Uversky et al., 2001). Interestingly, the 
same group also found that metals and pesticides had a synergistic effect on a- 
synuclein fibril formation (Uversky et al., 2002).
3.1.8.5.3. Tissue and subcellular distribution of a-synuclein
By immunohistochemistry and ultrastructural anlysis a-synuclein was found in nerve 
terminals close to synaptic vesicles (Clayton and George, 1999). a-synuclein has 
been shown to bind to lipid membranes through its amino-terminal repeats (Eliezer 
et al., 2001; Jensen et al., 1998; Jo et al., 2000; McLean et al., 2000; Perrin et al.,
2000). Subcellular fractionation analysis in human temporal cortex and 
immunostaining in neocortical and limbic regions confirmed that a-synuclein is 
expressed in synaptic vesicles (Irizarry et al., 1996). a-synuclein was shown to 
inhibit phospholipase D2, which localises to the plasma membrane where it could be 
involved in signal-induced cytoskeletal regulation and exocytosis; this might indicate 
that a-synuclein contributes to the regulation of vesicular transport (Jenco et al., 
1998) within axons (Jensen et al., 1998) or regulation of the size of the vesicular 
pool (Murphy et al., 2000). Recently, transient transfection of wild-type, G88C or 
G209A mutant a-synuclein into primary cortical rat neurones revealed that axonal
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transport was slower with both mutant a-synuclein forms when compared to cells 
transfected with the wild-type form (Saha et al., 2004).
a-synuclein expression was also described in rat substantia nigra pars 
compacta (Kholodilov et al., 1999) suggesting an association with dopaminergic 
structures, and, as discussed in the next section there is evidence to suggest that 
the absence of a-synuclein has a bearing on the regulation of dopamine release 
(Masliah et al., 2000) further linking a-synuclein with the vesicular catecholamine- 
storing compartment (Figure 3.3).
3.1.8.5.4. Role of a-synuclein in dopamine metabolism
The mechanisms of dopamine synthesis, storage, release and re-uptake have been 
described in section 3.1.7.2. a-synuclein may be important for dopamine 
homoeostasis because there is evidence to suggest it is involved in the regulation of 
dopamine synthesis, dopamine uptake and vesicular storage of dopamine (Figure 
3.3). Immunoprecipitation and immunoelectronmicroscopy in brain homogenates 
and dopaminergic cells revealed an association of a-synuclein with tyrosine 
hydroxylase (Perez et al., 2002). In a cell free system recombinant a-synuclein 
inhibited tyrosine hydroxylase activity, which may indicate a regulatory role for a- 
synuclein in dopamine synthesis (Perez et al., 2002). There are also suggestions 
that there may be an interaction between a-synuclein and the dopamine uptake 
transporter (DAT); however, the data are not consistent since they either showed an 
increase in DAT activity with a-synuclein expression (Lee et al., 2001a), an inhibition 
of DAT function (Wersinger and Sidhu, 2003) or no change of DAT acitivity in a a- 
synuclein knock-out mouse model indicating that a-synuclein may not be essential 
for DAT function (Dauer et al., 2002).
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3.1.8.5.5. Consequences of altered dopamine metabolism
As discussed above the metabolism of dopamine can contribute to oxidative stress 
(see section 3.1.7.2.). Increased levels of oxidative stress generated from dopamine 
oxidation may be relevant to the formation of a-synuclein aggregates (Figures 3.2 
and 3.3). It has been reported that mutated (G209A) a-synuclein expression 
promoted the formation of a-synuclein oligomers or protofibrils, a non-fibrillar 
precursor of the fibrils found in LBs (Conway et al., 2001). The same group revealed 
that dopamine-quinones derived from oxidation of dopamine and L-Dopa stabilised 
the protofibrils whereas antioxidants enhanced fibril formation. This could indicate 
that enhanced dopamine oxidation or diminished cellular antioxidant defences 
or/and increased a-synuclein expression may lead to the formation of presumably 
toxic protofibrils.
Taken together there is evidence for a close link of a-synuclein and 
dopamine (Figure 3.3). This seems to be an important factor that might contribute to 
the relative selective loss of dopaminergic neurones in PD. The co-occurrence of a- 
synuclein and dopamine might not only promote aggregate formation but also may 
contribute to the generation of oxidative stress with respect to the potentially 
important role of a-synuclein for dopamine compartmentalisation within and release 
from catecholamine-storing vesicles (Figure 3.3). In addition, the regulation of 
dopamine synthesis may involve a-synuclein (Figure 3.3.).
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Figure 3.3. Interaction of a-synuclein and dopamine (DA), a-synuclein down-regulates 
tyrosine hydroxylase (TH) expression and could interact with the dopamine uptake 
transporter (DAT) regulating DA uptake, a-synuclein may contribute to the regulation 
of vesicular dopamine handling. Mutations in a-synuclein could decrease vesicular 
dopamine uptake through the vesicular monoamine transporter (VMAT) leading to 
increased cytoplasmic DA concentrations. DA undergoes enzymatic deamination 
by monoamine oxidases (MAO, in astrocytes) to form3,4-dihydroxyphenylacetal- 
Dehyde (DOPAL), which can be oxidised to 3,4-dihydroxyphenylacetic acid (DOPAC) 
by DOPAL dehydrogenase or reduced to 3,4-dihydroxyphenylethanol (DOPET) by 
DOPAL reductase. DA can also auto-oxidise resulting in catechol-quinones, which 
may stabilise potentially toxic a-synuclein proto-fibrils. Antioxidants enhance the 
transformation of protofibrils into inert fibrils found in Lewy bodies.
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3.1.8.5.6. a-synuclein knock-out models
The study of a-synuclein knock-out models can contribute to the understanding of a- 
synuclein function (for the principles of knock-out models see chapter 1, section), a- 
synuclein knock-out mice did not exhibit any obvious pathological features when 
compared to wild-type mice, their development was normal and they were fertile 
(Abeliovich et al., 2000). Histological examination revealed a normal complement of 
tyrosine hydroxylase positive dopaminergic neurones in the substantia nigra without 
any morphological differences when compared to wild-type dopaminergic neurones. 
The distribution of vesicular proteins was indistinguishable from wild-type mice, and 
there was no difference in dopamine release and re-uptake. Knock-out mice differed 
from wild-type mice with respect to their dopamine content in the striatum (18% 
reduction), an attenuated locomotor response to amphetamine-induced dopamine 
release, and increased dopamine release in response to two consecutive electrical 
stimuli in striatal brain slices.
In a different a-synuclein knock-out mouse model animals were also viable 
and fertile (Dauer et al., 2002). The absence of a-synuclein was shown to protect 
animals from MPTP and MPP+ induced degeneration and loss of dopaminergic 
neurones (Dauer et al., 2002). Similar results were obtained in the knock-out mice 
by Schliiter and colleagues. Again, mice were viable and fertile, and were resistant 
to the toxic effects of MPTP (Schluter et al., 2003). Cabin and colleagues reported 
that in their a-synuclein knockout mice the population of vesicles that form the 
reserve pool (those vesicles that have not docked to the cell membranes) was 
diminished compared to control mice (Cabin et al., 2002). In electrical stimulation 
experiments in hippocampal slices of these mice, both the depletion of reserve pool 
vesicles and the substitution of docked vesicles by reserve pool vesicles observed in 
normal control mice were impaired in the a-synuclein knockout mice (Cabin et al., 
2002).
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These data suggest that a-synuclein is not essential for either mouse brain 
development or intact dopaminergic neuronal function. However a-synuclein may 
play a role in the generation of certain vesicular subpopulations (reserve pool) in the 
synapse and the regulation of dopamine release from the vesicular pre-synaptic 
population where it may exert activity-dependent inhibitory control over dopamine 
neurotransmission (Abeliovich et al., 2000). In addition, data from these models 
indicated the possibility of a link between a-synuclein expression and the ability of 
MPP+ to cause cell death via inhibition of complex I of the mitochondrial respiratory 
chain.
3.1.8.5.7. Transgenic mouse models of wild-type a-synuclein over-expression
Five different transgenic models of wild-type a-synuclein over-expression have been 
published. These models used different promoters, and showed variable 
phenotypes and pathological changes. However, none of the models were able to 
demonstrate selective toxicity of a-synuclein to dopaminergic neurones. This limits 
the power of the models considerably.
Transgenic mice expressed wild-type human a-synuclein driven by the 
platelet derived growth factor-fi (Masliah et al., 2000). Clinical assessement showed 
deficits in the rotarod performance of one-year-old animals with high a-synuclein 
expression. Pathologically, animals developed nuclear and cytoplasmic 
intraneuronal inclusions in the neocortex, the hippocampus, the olfactory bulb and 
the substantia nigra (Masliah et al., 2000). These inclusions were immunoreactive to 
human a-synuclein and ubiquitin, and EM revealed electron dense deposits 
associated with endoplasmic reticulum and the nucleus. In older mice with more 
prolonged a-synuclein expression, cytoplasmic inclusions contained fine granular 
material which was ultrastructurally immuno-positive for a-synuclein, but lacked
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fibrillar aggregates typical of LBs. Tyrosine hydroxylase expression was reduced in 
the substantia nigra of transgenic animals, and the number of tyrosine hydroxylase- 
positive nerve terminals in the striatum was reduced in animals with high a- 
synuclein expression. However, there was no loss of tyrosine hydroxylase-positive 
dopaminergic neurones in the substantia nigra. In this model, some features of PD 
were reproduced (a-synuclein and ubiquitin positive inclusions, and locomotor 
impairment) whereas others were lacking (including no loss of substantia nigra 
dopaminergic neurones, no formation of fibrils, as described in section 3.1.8.5.2, 
which are one of the key morphological features of LBs and atypical nuclear 
localisation of some of the inclusions).
Transgenic mice expressing wild-type a-synuclein under the control of Thy-1 
promoter exhibited prominent locomotor abnormalities as assessed by the rotarod 
test as early as 3 weeks of age (van der Putten et al., 2000). The Thy-1 promoter is 
expressed in spinal cord, brainstem, cerebellum and telencephalon but not in 
dopaminergic neurones of the substantia nigra. Thus, there was no pathology in 
dopaminergic neurones of the substantia nigra. In contrast, corresponding to the 
expression of the Thy-1 promoter pathological changes were observed in motor 
neurones in the spinal cord, brainstem, cerebellum and telencephalon. Some of 
these neurones showed cytoplasmic a-synuclein and ubiquitin immunoreactivity 
similar to LBs, however, no filaments were observed on EM. Hence, this model does 
not reproduce the selective loss of dopaminergic substantia nigra neurones, but 
mimics the extra-nigral pathology of dementia with Lewy bodies and Lewy neurites. 
In addition, as the pathological changes involved motor neurones in the spinal cord - 
a feature which is not seen in PD - this may have contributed to the abnormal motor 
performance of these transgenic mice.
In two models the prion promoter was used to regulate a-synuclein 
expression (Giasson et al., 2002; Lee et al., 2002b). This promoter is expressed in
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most neurones including those in the substantia nigra. In both models wild-type 
overexpression did not cause any overt behavioural or pathological changes; 
Giasson and co-workers describe that all mice with the wild-type a-synuclein 
transgene were healthy up to 28 months of age. Matsuoka and colleagues used the 
tyrosine hydroxylase promoter to drive the a-synuclein transgene (Matsuoka et al., 
2001). This led to accumulation of a-synuclein within dopaminergic cell bodies but, 
in mice up to one year of age, not to the formation of inclusions or any quantitative 
differences in dopaminergic neurone numbers or dopamine content between 
transgenic animals and controls, and there were no histopathological abnormalities 
(Matsuoka et al., 2001).
Taken together the over-expression of human wild-type a-synuclein in mice 
did not give consistent results. Only two models (those by Abeliovich and colleagues 
and by van der Putten and colleagues) had a phenotype with deficits in motor 
performance; animals in the other three transgenic mouse models did not show any 
phenotype. While the model reported by Abeliovich and colleagues demonstrated 
the formation of a-synuclein and ubiquitin positive inclusions in the substantia nigra 
and a possible role of a-synuclein in dopamine homoeostasis the other models did 
not show any abnormalities of dopaminergic neurones in the substantia nigra. The 
reasons for the discrepant results in these models remain unclear. One possible 
explanation may be the type of promotor chosen, which differed in the models. This 
determines the site and level of expression of the transgene and may explain why 
for example in the model by van der Putten and colleagues a-synuclein may not 
have been expressed in dopaminergic neurones in the substantia nigra.
3.1.8.5.8. Transgenic mouse models of mutant a-synuclein over-expression
Mice overexpressing G209A a-synuclein under the control of the prion promoter 
remained healthy until 7 months of age (Giasson et al., 2002). At 8 months, mice
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started to neglect their grooming behaviour, lost weight and exhibited decreased 
ambulation. Resistance to passive movement of the limbs and ’’freezing" of the hind 
limbs was noted, and these mice developed weakness. The mice rapidly 
deteriorated and had to be sacrificed within 10-21 days after onset of symptoms. 
Histologically, no changes were observed before 6 months of age. Between 8 and 
16 months, mutant G209A transgenic mice showed inclusions immunoreactive for 
the native and the nitrated form of a-synuclein in the spinal cord, brainstem, 
cerebellum and the thalamus while tyrosine hydroxylase-positive substantia nigra 
neurones were not involved, a-synuclein immunoreactive cytoplasmic inclusions in 
the spinal cord contained 10-16nm fibrils ultrastructurally (ubiquitin immunostaining 
was present in only 10-25%). Mutant G209A transgenic mice also showed evidence 
of axonal degeneration in the spinal cord and an axonal neuropathy. However, no 
pathological changes were observed in the dopaminergic neurones of the substantia 
nigra and the phenotype may at least to some degree be caused by the pronounced 
pathological involvement of the spinal cord and peripheral nerves. It is currently not 
known whether these animals will develop a neurological phenotype at a greater 
age.
In another transgenic mouse model mutant a-synuclein was over-expressed 
under the control of the prion promoter (Lee et al., 2002b). G209A but not G88C 
mutant a-synuclein was associated with a rapidly progressive phenotype including 
reduced posturing and movement, leading to paralysis and death. Pathological 
accumulations of a-synuclein and ubiquitin were shown in neuronal cell bodies in 
brainstem, midbrain, cerebellum and spinal cord before clinical symptoms 
developed. However, there was no loss of striatal dopamine, and no qualitative 
changes of tyrosine hydroxylase or dopamine-uptake transporter expression were 
observed.
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In conclusion, in some of these transgenic mouse models, whether over­
expressing the wild-type or mutant form of the protein, a-synuclein expression led to 
neurodegeneration that involved the dopaminergic system. However, selective loss 
of dopaminergic neurones has not been observed. Hence, these transgenic mice 
may actually model synucleinopathies, a group of neurodegenerative disorders 
where a-synuclein pathology is a common theme, rather than PD (Goedert, 2001). 
Reasons for the variability of the phenotype of these transgenic a-synuclein mice 
include the type of promoter chosen, which directly influences where the transgene 
is expressed. In one model at least, pathology was observed in the substantia nigra, 
although the promoter was not expressed in dopaminergic neurones in the 
substantia nigra (van der Putten et al., 2000), whereas in another model with a 
tyrosine hydroxylase promoter the animals remained healthy and no pathological 
changes were noted (Matsuoka et al., 2001). Variable expression of the transgene, 
different mouse genetic backgrounds and the integration site may also contribute to 
the differences observed between the models.
3.1.8.5.9. Other animal models of a-synuclein PD
Transgenic Drosophila models of PD expressing human wild-type, G209A or G88C 
mutant a-synuclein were generated using a bipartite expression system where the 
transcriptional activation of the transgene depends on the yeast protein GAL-4 
(Feany and Bender, 2000). Flies with a transgene downstream of a GAL-4 
responsive element were crossbred with flies expressing the yeast activator in a 
tissue- and cell-type specific pattern. Overall, the nervous system developed 
normally in the transgenic flies with central nervous system transgene activation. 
However, there was clear age-dependant loss of specific tyrosine hydroxylase 
positive dorso-medial dopaminergic neurones in flies over-expressing either wild- 
type or the mutant forms of a-synuclein. Other dopaminergic neuronal subsets,
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cortical and serotoninergic neurones were spared. Thus, the anatomical specificity 
of dopaminergic neurodegeneration in this model resembled idiopathic PD. a- 
synuclein immunostaining revealed cytoplasmic aggregates similar to LBs 
ultrastructurally. However, a-synuclein aggregates and degenerative changes also 
developed in the flies with retinal activation only of a-synuclein expression 
suggesting that the effect of a-synuclein overexpression was not specific to 
dopaminergic neurones. While the locomotor behaviour of young transgenic flies did 
not differ from control flies, their climbing ability was lost prematurely. Thus, this 
model captured all the essential features of PD with age-dependant selective 
dopaminergic loss, development of LBs and a neurological phenotype with motor 
impairment (for a more detailed review of transgenic Drosophila models of 
neurodegenerative diseases see Muqit and Feany, 2002).
Over-expression of a-synuclein has been selectively induced unilaterally in 
the substantia nigra of adult rats by targeted injection of an adenovirus vector 
containing either wild-type, G209A (Kirik et al., 2002) or G88C (Klein et al., 2002) 
mutant a-synuclein under the control of the chicken fi-actin promoter. Both wild- 
type and G209A mutant a-synuclein expressing rats developed dystrophic neurites; 
and cytoplasmic a-synuclein, but not ubiquitin, immunoreactive inclusions (Kirik et 
al., 2002) or accumulation (Klein et al., 2002) were observed histologically. These 
changes were accompanied by a loss of 30-80% (Kirik et al., 2002) or 53% (Klein et 
al., 2002) of the nigral dopaminergic neurones with an associated reduction in 
striatal dopamine and tyrosine hydroxylase levels. However, despite substantial 
dopamine loss, motor behaviour was only marginally affected (Kirik et al., 2002) or 
not affected at all (Klein et al., 2002) in all the treated animals at all time points.
In summary, targeted a-synuclein over-expression in the nigro-striatal 
system using viral vectors reproduced some of the features of PD. However, these 
models did not reliably develop a movement disorder, and whilst selective
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histological changes within the substantia nigra dopaminergic neurones were 
observed, unlike in human PD the a-synuclein immunoreactive inclusions were 
ubiquitin negative, and no EM data was presented to assess whether or not they 
contained fibrils.
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Figure 3.4. Possible common pathomechanisms in PD II. Mutations in five genes 
are known to cause familial PD. These genes encode a-synuclein, DJ-1, parkin, 
ubiquitin carboxyhydrolase L1 (UCH-L1) and PINK-1. Mutations in these genes, or 
altered expression, but also environmental toxins, are likely to contribute to the 
pathogenesis of PD. Common pathways include mitochondrial dysfunction, oxidative 
stress, protein misfolding and the UPS. a-synuclein is present in the cytosol and is 
also associated with vesicles. It interacts with dopamine compartmentalisation and 
forms adducts with dopamine which can promote its aggregation and can cause 
oxidative stress. Parkin UCH-L1 contribute to the function of the ubiquitin- 
proteasome system (UPS). Abnormal UPS function may increase the levels of toxic 
proteins increasing oxidative stress and aggregate formation including Lewy bodies 
(LB). This may enhance cell death or cell survival. DJ-1 protects against oxidative 
stress. PINK-1 encodes for a mitochondrial protein kinase. Environmental toxins 
such as rotenone or paraquat can interfere with mitochondrial function leading to 
oxidative stress which can promote e.g. a-synuclein aggregation. Cytosolic 
dopamine can be oxidised causing oxidative stress and potentially compromising 
mitochondrial function. Black arrows indicate primary causative genetic links, blue 
arrows indicated presumably secondary consequences of either genetic or 
environmental primary effects. MRC: mitochondrial respiratory chain.
3.2. Rationale to study inducible wild-type and G209A mutant a-synuclein 
expression in HEK293 cells
The generation of a stable, inducible cell culture model of wild-type and G209A 
mutant a-synuclein PD will allow the study of the structural, biochemical and 
functional consequences of increased wild-type and G209A mutant a-synuclein 
expression as a model of sporadic and autosomal dominant PD. a-synuclein 
appears to play a central role in PD; it is the main component of LBs, the 
histopathological hallmark of sporadic PD, and two different a-synuclein gene 
mutations give rise to autosomal dominant PD with a clinical and pathological 
phenotype similar to that of sporadic PD. The precise role of a-synuclein is not 
clear, nor is the effect of the various mutations on a-synuclein function or the 
significance of a-synuclein in LBs. In PD caused by a-synuclein mutations it remains 
unclear whether the pathomechanisms are similar to those of sporadic PD and may 
include oxidative stress, mitochondrial respiratory chain defects or the formation of 
LBs.
It was the purpose of this thesis to generate cell models with wild-type or 
G209A mutant a-synuclein expression under the control of ponasterone A in 
HEK293 cells. These models were used to study the subcellular localisation of wild- 
type or G209A mutant a-synuclein to examine whether expression of either protein 
was associated with particular organelles such as mitochondria or the Golgi 
network, or the formation of aggregates. The models were further used to examine 
the effect of wild-type or G209A mutant a-synuclein expression on mitochondrial 
respiratory function and the sensitivity to the complex I inhibitor rotenone given the 
evidence that suggests an involvement of a complex I defect in sporadic PD. Finally, 
the models were used to test whether the expression of wild-type or G209A mutant 
a-synuclein was associated with the generation of oxidative stress or increased the
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vulnerability to toxins that generate oxidative stress such as paraquat and dopamine 
because of the evidence suggesting that increased levels of oxidative stress may 
contribute to cell death in sporadic PD.
3.3. Results
3.3.1. Characterisation of dopaminergic properties in HEK293, SH-SY5Y 
neuroblastoma and hNT2 teratocarcinoma cells
HEK293, SH-SY5Y neuroblastoma (undifferentiated and differentiated for 14 days) 
and hNT2 teratocarcinoma (undifferentiated) cells were characterised regarding 
their dopaminergic properties using immunocytochemistry (see section 2.5.2) and 
Western blotting (see section 2.6.5.) with antibodies against tyrosine hydroxylase 
(TH), VMAT 1 and 2, dopamine uptake transporter (DAT).
Immunocytochemistry revealed that all cell lines had cytoplasmic 
immunoreactivity with the tyrosine hydroxylase (TH) antibody (Figure 3.5A, D, G, J). 
However, after SH-SY5Y differentiation for 14 days not all cells expressed 
neurofilament so that not all cells were differentiated (Figure 3.5J), and not all cells 
expressing neurofilament were immunoreactive for TH (Figure 3.5J). Staining with 
the VMAT-1 antibody was positive in the cytoplasm of all cell lines and in cell 
processes of both non-differentiated and differentiated SH-SY5Y cells (Figure 3.5B, 
E, H, K). Staining with the VMAT-2 antibody showed some cytoplasmic 
immunoreactivity in hNT2 (Figure 3.5F) and SH-SY5Y cells (Figure 3.5I) with 
enhancement of staining intensity in differentiated SH-SY5Y cells (Figure 3.5L). 
HEK293 cells exhibited no VMAT-2 staining (Figure 3.5C). All the cell lines were 
negative for staining with an antibody to the dopamine uptake transporter (DAT, 
data not shown). Controls for each antibody and cell line (omission of the primary 
antibody) showed no immunostaining. Western blot analysis failed to reveal any 
specific band of the predicted size (data not shown).
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Figure 3.5: Immunocytochemistry. All cell lines stained positive for tyrosine hydroxylase 
(A,D,G,J). Expression was cytoplasmic, in particular in differentiated SHSY5Y (arrow 
heads indicate co-localisation with neurofilament antibody, yellow in J). Staining 
with the VMAT-1 antibody was positive in the cytoplasm of all cell lines (B,E,H,K, arrow 
head in B) and in cell processes of both non-differentiated and differentiated SHSY5Y 
cells (arrow heads in H). Staining with the VMAT-2 antibody showed some 
cytoplasmic staining in hNT2 (F) and SHSY5Y cells with enhancement in differentiated 
SHSY5Y cells (I and L). There was no VMAT-2 staining in the HEK293 cells (C). Scale 
bar=20fim.
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3.3.2. Generation of vectors
This work was performed in collaboration with Dr. Sarah Tabrizi (Department of 
Clinical Neurosciences, Royal Free and University College London Medical School). 
RNA was extracted from lymphoblasts of an affected male patient of the Contoursi 
kindred with the G209A a-synuclein mutation and controls lymphoblasts containing 
wild-type a-synuclein. Using RT-PCR, cDNA was generated from the isolated RNA. 
The resultant cDNA was immediately used to amplify total a-synuclein cDNA by 
PCR using the nested primers. This total a-synuclein cDNA PCR product served as 
the template for PCR amplification of the a-synuclein open reading frame using the 
forward and revers primers as described (see section 2.4.2.). A haemagglutinine 
(HA) epitope was cloned in at the 3’ end to serve as a reporter gene. This allowed 
tagging of the expressed protein.
Both G209A mutant and wild-type a-synuclein-HA amplified fragments were 
restricted with Kpn-\ and Bc/-I and cloned into the Kpn-1 and BamH I sites of the 
pIND vector. The ligation products were then propagated through E.coli and then 
individual clones screened by PCR amplification for the presence of a-synuclein 
insert. Colonies containing the a-synuclein insert were picked off, and the pIND 
plasmid was isolated from the E.coli and sequenced. Eight a-synuclein constructs of 
each wild-type and G209A mutant a-synuclein were sequenced and found to have 
the correct orientation and sequences.
This yielded two vectors for transfection: pIND containing wild-type a- 
synuclein with a haemagglutinine tag (pIND. a-syn-HA) and pIND containing G209A 
mutant a-synuclein with a haemagglutinine tag (pIND. a-syn/G209A-HA).
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3.3.3. Analysis of the Ecdysone Mammalian system in neuronal cell lines
SH-SY5Y cells and hNT2 cells were transfected with the pVgRxR plasmid and cells 
selected with Zeocin (for methods see section 2.4.3.). Resistant lines were cloned 
and transfected with either the pIND plasmid alone, the pIND.a-synuclein-HA 
plasmid or the plND.G209Aa-synuclein-HA plasmid, which confers resistance to 
G418. G418 resistant SH-SY5Y and hNT2 cultures were cloned (see section 2.4.4.) 
indicating the successful transfection with both plasmids. In each cell line, a mixed 
pINDO cell line, 10 wild-type a-synuclein and 10 G209A mutant a-synuclein clones 
were then screened by immunocytochemistry for expression of a-synuclein or 
haemagglutinin. There was low-level immunostaining of a-synuclein without 
ponasterone A induction (Figure 3.6A). None of the clones showed any a-synuclein 
(Figure 3.6B) or haemagglutinin (Figure 3.6D) expression upon induction with 
ponasterone A while positive controls (transfected ECR293 cell lines, see next 
section) showed clear a-synuclein or haemagglutinine immunostaining (Figure 3.7).
In order to test whether the cell cultures contained the pIND.a-synuclein 
construct DNA was extracted (see section 2.4.5.) from a clone resistant to Zeocin 
and G418 transfected with the empty pIND plasmid (hNT2.pINDO) and a clone 
resistant to Zeocin and G418 transfected with pIND containing G209A mutant a- 
synuclein cDNA (hNT2. plND.a-syn/G209A). Using PCR (see section 2.4.8.), the 
multiple cloning site of the pINDO plasmid was amplified and separated on an 
agarose gel. This revealed that there was no insert in the pINDO culture (Figure 
3.6C). In contrast, a band at about 700bp was found in the hNT2 culture with the 
plND.a-syn/G209A insert (Figure 3.6C). This indicated that neuronal cell lines had 
successfully been transfected with the pIND. a-synuclein-HA plasmid and thus 
acquired resistance to both Zeocin and G418 antibiotics. However, ponasterone A 
failed to induce the Ecdysone system to express a-synuclein/HA. This suggests that
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in the neuronal lines one of the two plasmids was non-functional or, alternatively, 
that there might have been an alteration within the cDNA containing multiple cloning 
site within pINDO, e.g. a shift of the open reading frame or a change in the position 
of the ATG stop codon. Since identical plasmid and cDNA stocks were successfully 
used to transfect HEK293 cells (see next section) a problem inherent to the cell lines 
may be more likely. This would be consistent with the failure of other researchers 
within the Department of Clinical Neurosciences to induce expression after transient 
transfections of many other lines (Dr M Cleeter, Dr JM Cooper, personal 
communication).
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Figure 3.6. Assessment of hNT2 cells after transfection with pVgRxR and pIND. 
Endogenous a-synuclein expression is shown in A. Upon induction with pon­
asterone A (5|llM for 48 hours) there was no change in a-synuclein staining (B), 
and staining for haemagglutinine (HA) was negative (D). PCR amplification of 
the multiple cloning site of pIND revealed a band of about 700bp (C) in cells 
transfected with a-synuclein cDNA (hNT2 MUT) indicating that these cells 
contained the pIND.a-syn/HA plasmid.
3.3.4. Expression of a-synuclein cDNA in EcR293 cells 
Immunocytochemistry
The EcR293 cell line that contained a functional pVgRxR plasmid (Invitrogen) was 
transfected with pINDO, pIND.a-synuclein-HA or plND.G209Aa-synuclein-HA, as 
described (see section 2.4.3.). Cells were selected for resistance to G418. A dose 
was chosen that killed all untransfected cells within 10 days. This dose was 
established in collaboration with Dr S Tabrizi, Department of Clinical Neurosciences, 
RFH+UCL Medical School. Resistant colonies from each transfection were selected 
after 2-3 weeks and individual clones isolated through ring cloning (see section
2.4.4.). A total of three clonal cultures transfected with wild-type a-synuclein (WTsyn 
1-3), 3 clonal cultures transfected with G209A mutant a-synuclein (MUTsyn 1-3) 
with >70% of cells expressing a-synuclein/HA after ponasterone A induction, and a 
mixed culture transfected with pIND without insert (pINDO) were isolated (section
2.4.4.).
These cells were immunostained with antibodies to HA (for detection of the 
HA tag) or a-synuclein (see section 2.5.1.). In the absence of ponasterone A, there 
was very weak, if any, staining with the a-synuclein antibody, and no staining with 
the HA antibody (data not shown), in the pINDO (Figure 3.7A), WTsyn (Figure 3.7C) 
or MUTsyn (Figure 3.7E) transfected cells. This suggests that the background 
expression of WTsyn and plND.a-syn/G209A cells is the result of endogenous a- 
synuclein and not due to leakage of the introduced gene constructs. Induction with 
5pM ponasterone A for 48 hours did not result in a-synuclein or HA immunostaining 
in the pINDO cell culture (Figure 3.7B); in WTsyn (Figure 3.7D) or MUTsyn cell lines 
(Figure 3.7F) ponasterone A led to the expression of extranuclear a-synuclein. 
Staining was diffuse (Figure 3.7D and F) but in a subset of cells aggregate-like 
staining of WTsyn (Figure 3.7G) or MUTsyn (Figure 3.7H) was observed.
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Figure 3.7. Expression of a-synuclein cDNA in in EcR293 cells. Staining after 
induction with 5pM ponasterone A for 48 hours in cells transfected with pINDO 
(A and B), pIND.a-syn/HA (WTsyn C and D) or plND.a-synG209A/HA 
(MUTsyn E and F). There was no immunostaining without induction (A, C and E), 
or with ponasterone A induction in pINDO (B). In pIND.a-syn/HA cells (D), or 
plND.a-synG209A/HA cells (F) ponasterone A induced expression of a-synuclein 
outside the nucleus (red staining). Staining was diffuse (D and F) but in a subset of 
cells aggregate-like staining was observed for both wild-type (G) and G209A mutant 
a-synclein (H). Scale bar = 10pm, except E (=20pm).
In ponasterone A induced WTsyn (Figure 3.8A, C and E) and MUTsyn cell lines 
(Figure 3.8B, D and F) a-synuclein immunostaining co-localised with HA 
immunoreactivity (Figure 3.8E for WTsyn, F for MUTsyn) indicating expression of 
the transfected cDNA.
Induction of a-synuclein/HA expression with different concentrations of 
ponasterone A revealed that the number of cells expressing a-synuclein, but not the 
intensity of a-synuclein staining, increased from with increasing concentrations of 
ponasterone A (data not shown). Assessment of a-synuclein expression over time 
(24, 48, 72, 96 hours) revealed no difference in the staining intensity or the number 
of expressing cells (data not shown). Because cells grew over-confluent after 96 
hours in culture longer expression of a-synuclein was not possible without 
harvesting and splitting cells.
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Figure 3.8. Immunocytochemical localisation of a-synuclein and HA in HEK 293 
derived cell lines after induction with 5|jM pon A for 48 hours. Double labelling 
showes that wild-type a-synuclein (red in A) or G209A mutant a-synuclein (red 
in B) co-localised with HA (green in C and D) as indicated on merged images 
(yellow in E and F). G. Phase contrast to B, D and F. Scale bar = 10pm.
Western blots
Levels of protein expression were assessed by Western blot using a mouse 
monoclonal antibody against a-synuclein or rat monoclonal antibody against 
haemagglutinin (for methods see section 2.6.5.). In the absence of ponasterone A 
induction, with either antibody there was no significant staining at 20kD, the size of 
the band expected from the molecular weight of a-synuclein, in either the pINDO or 
any of the WTsyn or MUTsyn clones (Figure 3.9A and B). Following ponasterone A 
(5pM for 48h) induction, a band of about 20kD was stained in the three WTsyn and 
the three MUTsyn clones with both the a-synuclein antibody (Figure 3.9A) or the HA 
antibody (Figure 3.9B) while there was no band in the ponasterone A induced pINDO 
cells. Levels of a-synuclein/HA expression in all cell cultures containing the a- 
synuclein pIND constructs were similar at 5pM ponasterone A. The level of a- 
synuclein expression (wild-type or mutant) was proportional to the concentration of 
ponasterone A used with the inducible cell lines (Figure 3.9C). Thus the production 
of a-synuclein protein by these cell lines was tightly controlled by ponasterone A.
3.3.5. DNA sequencing
The a-synuclein cDNA was sequenced in the three WTsyn and MUTsyn clones. The 
inserted a-synuclein cDNA was amplified by PCR using primers to the plasmid 
multiple cloning site and separated on agarose gels to confirm the size of the 
product (for methods see sections 2.4.5., 2.4.8. and 2.4.11.). The sequence was 
determined commercially at MWG (MWG, Germany). This documented that the 
three WTsyn EcR 293 clones contained the wild-type a-synuclein insert (Figure 
3.10), and the MUTsyn EcR293 cell lines contained the mutant G209A a-synuclein 
insert (Figure 3.10, and appendix).
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Figure 3.9. Western blot showing a-synuclein and HA expression following 
ponasterone A induction. A. pIND.a-synuclein-HA expression induced by 
pon A in three cell lines each of wild-type a -syn  and mut a-syn and pIND.O 
is tested with a a-synuclein antibody. B. pIND. a-synuclein-HA expression 
induced by pon A in three cell lines each of wild-type a-syn and mut a-syn 
and pIND.O tested with a HA antibody. C. Increasing concentrations of 
ponasterone A (0.1, 0.5, 1.0, 3.0 and 5pm) resulted in greater expression 
of the mutant protein. Similar results were obtained with the wild-type 
piND.a-syn cell lines (data not shown).
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Figure 3.10. Sequence section of the a-synuclein gene. A sequence section is 
shown that contains the G209A a-synuclein mutation in 3 MUTsyn clones and wild- 
type genotype in the 3 WTsyn cell lines. For the complete sequences see appendix
3.
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3.3.6. Subcellular localisation of a-synuclein expression
WTsyn and MUTsyn cell lines were stained with an antibody to a-synuclein and 
propidium iodide to label the nucleus (Figure 3.7B and D, respectively). WTsyn 
(Figure 3.11A, C, E, G, I, K, M) and MUTsyn (Figure 3.11B, D, F, H, J, L, N) cell 
cultures were stained with an antibody to a-synuclein and MitoTracker® (Figure 
3.11A, B), COI cytochrome c oxidase subunit (Figure 3.11C, D), Golgi zone (Figure 
3.11E, F), lysosomal associated membrane protein-1 (Figure 3.11G, H), ubiquitin 
(Figure 3.111, J), vesicle associated membrane protein (VAMP, Figure 3.11K, L) or 
vesicular monoamine transporter-1 (VMAT-1, Figure 3.11M, N).
There was no co-localisation of a-synuclein with markers for the cell 
nucleus (Figure 3.7B for WTsyn, Figure 3.7D for MUTsyn), mitochondria using 
MitoTracker® (Figure 3.11A for WTsyn, Figure 3.11B for MUTsyn) or COI subunit of 
cytochrome c oxidase (Figure 3.11C for WTsyn, Figure 3.11D for MUTsyn), Golgi 
zone (Figure 3.11E for WTsyn, Figure 3.11F for MUTsyn), or lysosomes (Figure 
3.11G for WTsyn, Figure 3.11H for MUTsyn). Neither the wild-type (Figure 3.111) nor 
mutant a-synuclein deposits stained for ubiquitin (Figure 3.11J). However, co­
localisation of both wild-type (Figure 3.11K) and mutant a-synuclein (Figure 3.11L) 
was observed with vesicle associated membrane protein (VAMP), indicating that a- 
synuclein was associated with intracellular vesicles. Staining for vesicular 
monoamine transporter (VMAT 1) showed that a proportion of vesicles were positive 
for both this protein and wild-type (Figure 3.11M) or mutant a-synuclein (Figure 
3.11N).
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Figure 3.11. Subcellular localisation of a-synuclein in HEK 293 derived cell lines. 
Immunocytochemistry of cells expressing wild-type or mutant G209A a-synuclein. 
Co-staining of a-synuclein (green fluorescence) with MitoTracker (red fluorescence) 
showed that wild-type or mutant a-synuclein were not localised in mitochondria 
(A and B). This was confirmed with COI subunit stain of cytochrome oxidase 
(C and D, COX 1, green; a-synuclein in red). Dual staining with green fluorescence 
for the Golgi network (E and F) and lysosomes (G and H) showed separate I 
ocalisation for wild-type (E and G) and mutant (F and H) a-synuclein (red fluorescence). 
Scale bar equals 10pm.
Wild-type G209A mutant
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Figure 3.11, continued. Dual labeling studies indicated that wild-type a-synuclein (I) 
mutant a-synuclein (J) (red fluorescence) did not stain for ubiquitin (green in I and J). 
Both wild-type (red in K) and mutant a-synuclein (red in L) co-localised with VAMP 
(green) as shown by the merged fluorescence (yellow in K and L), they also stained 
with VMAT-1 (wild-type in M and mutant in N, arrow) although this was not exclusive 
to the distribution of either of the vesicle stains (arrow heads in N). VAMP: vesicular 
associated membrane protein; VMAT: vesicular monoamine transporter.
Scale bar equals 10pm.
3.3.7. Cell v iab ility
Cell viability experiments addressed the questions whether wild-type a-synuclein or 
G209A mutant a-synuclein alone lead to increased cell death or whether their 
expression enhanced the vulnerability to dopamine or rotenone.
Cell viability was not significantly affected by ponasterone A induction of wild- 
type or G209A mutant a-synuclein expression for 48 hours as shown both by LDH 
assay (Figure 3.12A; for methods see section 2.9.1.) or flow cytometry (Figure 
3.12B; for methods see section 2.9.2.) (Kruskal-Wallis test, see section 2.12.).
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Figure 3.12. Cell viability with a-synuclein expression after 48 hours 5pM 
ponasterone alone. A. LDH assays revealed that less than 10% of cells died with a- 
synuclein expression (wild-type or G209A mutant) or ponasterone A treatment 
alone. B. Propidium iodide staining followed by flow cytometry confirmed that there 
was very little cell death with or without ponasterone A induction.
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3.3.8. Mitochondrial function
3.3.8.1. Mitochondrial Respiratory Chain activities
Mitochondrial citrate synthase activities and the complex I, ll/lll and IV citrate 
synthase ratios were measured in pINDO, WTsyn and MUTsyn cells in the absence 
of ponasterone A and compared to those activities after induction with ponasterone 
A (5pM) for 48h (for methods see section 2.7.2.). Ponasterone A caused a slight, 
but not significant, decrease in the CS activity and complex I, ll/lll and IV CS ratios 
in the pINDO cells (Table 3.3.). Ponasterone A induction of WTsyn or MUTsyn had 
no significant effect upon the CS activities or CS ratios for mitochondrial complexes 
I, ll-lll and IV (Table 3.3.).
Cell line Citrate synthase (CS) Complex l/CS Complex ll-lll/CS Complex IV/CS
pon A - + - + - + - +
PINDO 0.486 0.437 0.135 0.125 0.19 0.18 0.011 0.010
(0.092) (0.043) (0.034) (0.037) (0.03) (0.03) (0.003) (0.003)
WTsyn 0.619 0.636 0.124 0.123 0.19 0.19 0.011 0.011
(0.102) (0.128) (0.028) (0.029) (0.04) (0.04) (0.001) (0.001)
MUTsyn 0.850 0.860 0.080 0.074 0.16 0.16 0.010 0.009
(0.150) (0.227) (0.015) (0.014) (0.03) (0.04) (0.001) (0.001)
Table 3.3. Effect of ponasterone A induction on (mitochondrial respiratory 
chain/citrate synthase) ratios. Ponasterone A induction of wild-type or mutant a- 
synuclein expression or ponasterone A treatment alone had no significant effect on 
mitochondrial respiratory chain/citrate synthase ratios when compared to non­
induced cells (Kruskal-Wallis test, see section 2.12.). Values are expressed as 
mean (± SEM), n=4, (except n=3 for WTsyn and MUTsyn Complex IV). Citrate 
synthase (CS) is expressed as the specific activity, nmol/min/mg protein.
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3.3.8.2. Mitochondrial membrane potential
To optimise the selectivity of the lipophylic dye DiOC6(3) (3,3'-dihexyloacarbocyanine, 
Molecular Probes) for mitochondrial localisation HEK293 pINDO cells, grown on 
coverslips, were incubated with either 5, 25 or 50nM DiOC6(3) for 20 minutes, 
washed and mounted in PBS. To confirm mitochondrial co-localisation of DiOC6(3) , 
cells on coverslips were stained first with the mitochondrial dye MitoTracker® (3 pM 
CMXRos-H2, Molecular Probes) and thereafter with DiOC6(3), washed and mounted 
in PBS (for methods see section 2.8.3.1.).
Using fluorescence microscopy DiOC6(3) staining of HEK293 cells was not 
detectable at 5nM (Figure 3.13A) and was weak at 25nM (Figure 3.13B). Clear 
mitochondrial networks could be seen with 50nM DiOC6(3 ) (Figure 3.13C). Co- 
staining with the mitochondrial marker MitoTracker® revealed DiOC6(3 ) staining that 
co-localised with the mitochondria on con focal microscopy (Figure 3.13D). To test 
the specificity of the DiOC6(3) stain for mitochondrial membrane depolarisation, cells 
were treated with the ionophore CCCP (100pM, m-chlorophenylhydrazone) for 30 
minutes. On microscopy, DiOC6(3 ) staining was abolished from the majority of cells 
after treatment with CCCP (100pM) to depolarise mitochondria (Figure 3.13G), 
which correlated with approximately 75% decrease in the median DiOC6(3) 
fluorescence signal when analysed by flow cytometry (Figure 3.14).
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Figure 3.13. DiOC6(3) staining. No or minimal staining with 5 (A) or 25nM (B) DiOC6(3). 
Mitochondrial networks are clearly visible with 50nM DiOC6(3) (C,D) and co-staining with 
3pM mitotracker (E) reveals co-localisation with DiOC6(3) (F). DiOC6(3) staining is abolished 
when cells are pre-treated with 100pM CCCP (G). Scale bar = 20jim.
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Figure 3.14. The effect of CCCP on mitochondrial membrane potential using flow 
cytometry and staining with 50nM DiOC6(3) Increasing concentrations of CCCP 
caused a reduction of 50nM DiOC6(3) median fluorescence intensity of HEK293 
pINDO cells. Values are expressed as mean ±SEM, n=3.
To determine the effect of a-synuclein expression on mitochondrial 
membrane potential, cells were grown in the presence and absence of 5pM 
ponasterone A, stained for DiOC6(3) (50nM) and analysed by flow cytometry (for 
methods see section 2.8.3.). The median fluorescence for DiOC6(3) was not 
significantly affected by ponasterone A in pINDO, WTsyn cells or MUTsyn cells 
(Figure 3.15).
ponA - + - + - +
pIND WTsyn MUTsyn
Figure 3.15. Effect of wild-type and mutant a-synuclein expression upon 
mitochondrial membrane potential. Ponasterone A (48 hours, 5pM) induction of wild-
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type or mutant a-synuclein expression did not significantly affect DiOC6(3) median 
fluorescence intensity. Statistical analyses compared open versus solid bars, 
Kruskal-Wallis test (see section 2.12.). Values are expressed as mean ±SEM; 
pINDO, n=6; WTsyn, n=6 for each WT1-3 culture, total n=18; and MUTsyn, n=6 for 
each MUT1-3 culture, total n=18.
3.3.9. Effect of rotenone on cell viability
To analyse the effect of a-synuclein expression on rotenone toxicity the pINDO, 
WTsyn and MUTsyn cell lines were exposed to 50nM rotenone for 36 hours 
following 48h incubation with 5pM ponasterone A or DMSO. In PC12 cells, this 
concentration of rotenone inhibits about 50% of complex I activity after 3 hours of 
exposure (Hartley et al., 1994). Rotenone caused a significant increase in cell death 
compared with no rotenone treatment; however, a-synuclein expression, either wild- 
type or G209A mutant, did not significantly affect levels of cell death (Figure 3.16).
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Figure 3.16. Effect of rotenone on cell viability using flow cytometry and propidium 
iodide staining. Ponasterone A induction did not influence the percentage of viable 
cells in pIND, WTsyn or MUTsyn cell lines. Statistical analysis compared open 
versus solid bars, Kruskal-Wallis test (see section 2.12). Values are expressed as 
means ±SEM; pINDO, n=6; WTsyn, n=6 for each WT1-3 culture, total n=18; and 
MUTsyn, n=6 for each MUT1-3 culture, total n=18.
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3.3.10. Effect o f rotenone on mitochondrial membrane potential
The effect of a-synuclein on mitochondrial membrane potential was analysed after 
pINDO, WTsyn and MUTsyn cell lines were incubated for 48h with 5pM ponasterone 
A or DMSO followed by exposure to 50nM rotenone for 36 hours (for methods see 
section 2.8.3.1.). DiOC6(3) staining intensity after rotenone exposure was compared 
to and expressed as a proportion of DiOC6(3) staining intensity in untreated cells of 
the respective cell line. In pINDO cells rotenone caused a 52.2± 9.5% decrease in 
DiOC6(3) staining, which was very similar after ponasterone A induction (50+ 8%, 
Figure 3.17). However, WTsyn expression enhanced the rotenone induced 
mitochondrial depolarisation from 41+2.6% decrease in the absence to 54± 3.8% in 
the presence of ponasterone A respectively (p=0.001, Figure 3.17), A similar but 
smaller change was observed with G209A mutant a-synuclein expression (49±
3.9% decrease in fluorescence enhanced to 54± 5.7% decrease in the presence of 
ponasterone A, p=0.05, Figure 3.17).
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Figure 3.17. Effect of wild-type or mutant a-synuclein expression upon 
mitochondrial membrane potential and rotenone toxicity. Ponasterone A (48 hours, 
5pM) induction of wild-type or mutant a-synuclein expression exacerbated the 
reduction of DiOC6(3) median fluorescence intensity in response to 50nM rotenone. 
Statistical analyses (see section 2.12.) compared open versus solid bars, Kruskal- 
Wallis test, p=0.006. Post-hoc Dunn’s Multiple Comparison Test revealed a
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significant difference in WTsyn comparing before and after ponA *: p= 0.001; in 
MUTsyn this comparison almost reached statistical significance **: p=0.05. Values 
are expressed as mean ±SEM, pINDO, n=6; WTsyn, n=6 for each WT1-3 culture, 
total n=18; and MUTsyn, n=6 for each MUT1-3 culture, total n=18.
3.3.11. Oxidative stress
3.3.11.1. Effect o f a-synuclein expression alone on levels o f oxidative stress
Aconitase is an enzyme present in the mitochondrial matrix and also in the 
cytoplasm. Aconitase activity decreased following incubation with increasing 
concentrations of H202 whereas there was little change in citrate synthase activity 
(Figure 3.18). This confirmed that aconitase activity was a sensitive marker of 
oxidative stress (for methods see section 2.7.4.).
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Figure 3.18. Effect of H202on aconitase and citrate synthase activity in HEK293 
cells. Activity of aconitase, or citrate synthase respectively, was assayed before the 
addition of H202 (10, 25, 50 and 100|iM) in each sample (baseline). H202 was then 
added, the sample incubated for 5 minutes and the assay continued for a further 45 
minutes. In each sample, the enzyme activity after H202 incubation was expressed in 
% of the respective baseline enzyme activity. There was little effect of H202 on 
citrate synthase activity whereas aconitase activity decreased with increasing 
concentrations of H202. Data is expressed as means of n=3, error bars are SDs.
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Ponasterone A induction (5pM for 48 hours) had no significant effect upon aconitase 
activity in pINDO cells (Figure 3.19). The results were similar in cells expressing 
wild-type a-synuclein or G209A mutant a-synuclein (Figure 3.19) implying that a- 
synuclein expression alone in these cells did not cause increased oxidative stress.
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Figure 3.19. Influence of a-synuclein expression upon aconitase activity. All cell 
lines were incubated with ponasterone A (5pM, solid bars) or DMSO (open bars) for 
48h and assessed for aconitase activity. Wild-type and mutant a-synuclein 
expression did not significantly affect aconitase activity. Statistical analysis 
compared open versus solid bars, Kruskal-Wallis test (see section 2.12.). Values are 
expressed as mean ± SEM; pINDO n = 7, WTsyn and MUTsyn n=12.
Ponasterone A induction (5|iM for 48 hours) had no significant effect on GSH levels 
in pINDO cells (Figure 3.20; for methods see section 2.10.). In cells expressing wild- 
type or G209A mutant a-synuclein the results were similar to those in the pINDO 
cells. This is consistent with the results obtained in the aconitase assays and 
suggests that the expression of either form of a-synuclein did not cause oxidative 
stress in these cells.
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Figure 3.20. Influence of wild-type or G209A mutant a-synuclein expression upon 
GSH levels. All cell lines were incubated with ponasterone A (5pM, solid bars) or 
DMSO (open bars) for 48h and assessed for GSH levels. Wild-type and mutant a- 
synuclein expression did not significantly affect GSH levels. Statistical analysis 
compared open versus solid bars, Kruskal-Wallis test (see section 2.12.). Values are 
expressed as mean ± SEM; n=4.
3.3.11.2. Effect of a-synuclein upon vulnerability to oxidative stress
HEK293 cell cultures were exposed to the free radical generator paraquat.
Incubation of HEK293 pINDO cells with increasing concentrations of paraquat (0- 
500pM) over 24 hours had no discernible effect upon cell death or cell proliferation 
on microscopical evaluation. Consistent with increasing free radical generation it 
caused a dose dependent decrease in aconitase activity (Figure 3.21 A). At a 
paraquat concentration of 75pM, aconitase activity was decreased by approximately 
60%, and this was the concentration chosen for further experiments.
Incubation of pINDO cells with ponasterone A (5pM) had no significant effect 
upon the paraquat-induced inhibition of aconitase activity (Figure 3.21B). However, 
in both WTsyn and the MUTsyn cell lines, ponasterone A induced a-synuclein 
expression partially protected the aconitase activity from paraquat (75pM) induced 
inactivation. The protection was greater in the WTsyn (40% increase in activity, p=
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0.0001), than the MUTsyn expressing cell lines (25% increase in activity, p<0.05) 
(Figure 3.21 B).
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Figure 3.21. Effect of paraquat exposure on aconitase activity. A. Effect of exposure 
to increasing concentrations of paraquat for 24 h upon aconitase activity in pINDO 
cells. Values are expressed as mean ± SEM (n=3). B. Effect of 5pM ponasterone A 
induction for 48h upon paraquat (0.075mM for 24h) induced aconitase inactivation in 
pINDO, WTsyn and MUTsyn cell lines. Wild-type and mutant a-synuclein expression 
partially protected aconitase activity from inactivation by paraquat (statistical 
analyses (see section 2.12.) compared open versus solid bars, Kruskal-Wallis test
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p< 0.0001; post-hoc Dunn’s Multiple Comparisons test *p=0.001; **p<0.05). Values 
are expressed as mean ±SEM, pINDO (n=4), WTsyn and MUTsyn (n=9).
3.3.12. Effect of dopamine on cell viability
The effect of wild-type or mutant a-synuclein expression on dopamine toxicity was 
studied. Following treatment with ponasterone A (5pM) for 48 hours the addition of 
dopamine for a further 48 hours resulted in a dose dependent increase in cell death 
(for methods see section 2.9.1.) in all three cell lines, pINDO, WTsyn and MUTsyn 
(Figure 3.22). At 0.5mM dopamine both wild-type and G209A mutant a-synuclein 
expression caused increased cell death compared to pIND-zero lines (p=0.05 and 
p=0.007 respectively) but there was no significant difference in susceptibility 
between the two a-synuclein lines. At higher concentrations of dopamine, however, 
G209A mutant a-synuclein expression caused significantly greater cell death than 
wild-type (p=0.0003 and p=0.02 for 0.75mM and 1mM dopamine respectively). 
There was no significant difference in cell toxicity between pIND-zero and wild-type 
a-synuclein lines at these concentrations.
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Figure 3.22. Effect of dopamine at increasing concentrations on cell death 
(determined using LDH assays, for methods see section 2.9.1.). Cell lines were
* * *
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induced with 5pM ponasterone A for 48 hours and then treated with dopamine at the 
stated doses for a further 48 hours. Increasing concentrations of dopamine caused 
cell death in all cell lines (Kruskal-Wallis test, p<0.001, see section 2.12.). Dunn’s 
post-hoc Multiple Comparison test revealed that at 0.5mM dopamine there was 
significantly more cell death in wild-type a-synuclein expressing cells (hatched bars, 
*p=0.05) and G209 mutant a-synuclein expressing cells (filled bars, $p=0.007) 
compared with pINDO cells (open bars). At 0.75 and 1 .OmM dopamine there was 
significantly more cell death in the MUTsyn cell line than in either the pINDO or 
WTsyn lines (**p=0.0003 and ***p=0.02 respectively). Values are means ± SEM, 
n=5.
3.3.13. Effect of alpha-synuclein on oxidative stress caused by dopamine
Aconitase activity was determined to identify whether oxidative stress contributed to 
these increased levels of cell death due to dopamine. Without ponasterone A 
induction, exposure to dopamine (0.5mM) for 24h caused a significant decrease in 
aconitase activity in pINDO, WTsyn and MUTsyn (20.4%, 29.3% and 21.5% 
decrease respectively, p<0.0001, Kruskal-Wallis test, Figure 3.23A), consistent with 
oxidative damage. Ponasterone A (5pM for 48h) induction of pINDO and WTsyn 
cells mildly protected the cells from the decrease in aconitase activity induced by 
dopamine (not statistically significant). However, ponasterone A induction of 
MUTsyn cells significantly enhanced the dopamine induced decrease in aconitase 
activity (Figure 3.23A, p=0.0001, post-hoc Dunn’s Multiple Comparison test). The 
relative change in the response to dopamine by the different cell lines after induction 
with ponasterone A can be seen more clearly in figure 3.23B.
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Figure 3.23. Influence of dopamine upon oxidative damage. A. In pINDO, WTsyn 
and MUTsyn HEK293 cell lines, aconitase activity was determined under normal 
growth conditions (open bars), and following exposure to dopamine alone (0.5mM, 
hatched bars) or dopamine exposure after ponasterone A (5pM) induction (solid 
bars). Dopamine caused significant aconitase inactivation (open bars versus 
hatched bars, * p<0.0001, Kruskal-Wallis test, see section 2.12.). Mutant <x- 
synuclein expression enhanced dopamine induced aconitase inactivation (solid bar 
versus hatched bar, **p=0.0001, post-hoc Dunn’s Multiple Comparison test). Values 
are expressed as mean ± SEM, n=6, 12 and 12 for pINDO, WTsyn and MUTsyn. B. 
From the data in A, in pINDO, WTsyn and MUTsyn cells, aconitase activities in the 
presence of dopamine (0.5mM) were subtracted from aconitase activities 
determined in the presence of dopamine (0.5mM) following ponasterone A (5pM for
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48h) induction showing the change in aconitase activity more clearly.
3.3.14. Effect of dopamine compartmentalisation on dopamine induced 
oxidative stress
Preincubation with the vesicular monoamine transporter inhibitor reserpine (500nM) 
was used to investigate whether the increased oxidative damage was consistent 
with an abnormality of the vesicular uptake of dopamine in MUTsyn cells exposed to 
dopamine. Reserpine had no effect upon aconitase activity on its own (data not 
shown); however, the dopamine-induced inactivation of aconitase activity was 
significantly enhanced in the pINDO (52.3% greater inhibition, p<0.001) cells 
following reserpine pre-treatment (Figure 3.24). This is consistent with reserpine 
inducing increased cytoplasmic dopamine concentrations resulting in increased free 
radical damage in pINDO. However, in the MUTsyn expressing cells the inhibition in 
aconitase activity was only enhanced by 20.6% (p<0.05) relative to the inhibition 
seen in the absence of reserpine (Figure 3.24). This diminished effect of reserpine in 
MUTsyn expressing cells is consistent with the suggestion that MUTsyn is acting in 
a similar way to reserpine.
Figure 3.24. Dopamine compartmentalisation and aconitase activity. Influence of 
reserpine pre-treatment upon dopamine (0.5mM) induced aconitase inactivation in 
ponasterone A induced cells (open versus solid bars, p<0.0001, Kruskal-Wallis test,
reserpine - +
pIND
* * *
 -  +  -  +
 WTsyn MUTsyn
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see section 2.12.). Post-hoc analysis (Dunn’s Multiple Comparison Test) shows that 
reserpine lead to significant aconitase inactivation in pINDO cells (*p<0.001), and 
WTsyn cells (**p<0.01) while in MUTsyn cells the difference was less significant 
(**p<0.05). Values are expressed as means ± SD (n=4 for pINDO, n=12 for WTsyn 
and MUTsyn cells respectively).
3.3.15. Effect of a-synuclein on dopamine uptake
Catecholamine fluorescence (for methods see section 2.5.5.) revealed punctate 
cytoplasmic staining (Figure 3.25A) which increased in intensity following exposure 
to 0.5mM dopamine for 24 hours (Figure 3.25B).
Figure 3.25. Catecholamine stain in HEK293 cells. Glyoxylic acid catecholamine 
fluorescence in normal HEK293 cells (A) and cells exposed to 0.5mM dopamine for 
24 hours (B).
The uptake of radioactively labelled dopamine was investigated in collaboration with 
Dr K Messmer and Dr P Korlipara, Department of Clinical Neurosciences, RFH and 
University College London School of Medicine (for methods see section 2.11.). This 
showed that there was a time dependant uptake of 3H-dopamine in HEK293 cells 
(Figure 3.26).
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Figure 3.26.3H dopamine uptake in HEK293 cells. Uptake analysis of 3H dopamine 
demonstrated a time dependent increase in cellular accumulation of 3H dopamine.
The effect of wild-type or G209A mutant a-synuclein expression on 3H dopamine 
uptake was examined in collaboration with Dr JM Cooper, Department of Clinical 
Neurosciences, RFH+UCL Medical School. Following induction with 5pM 
ponasterone A for 48 hours the mean 3H dopamine uptake in wild-type or G209A 
mutant a-synuclein expressing cells was not statistically different compared with the 
respective values in the absence of ponasterone A (Figure 3.27). Ponasterone A 
had no influence on 3H dopamine uptake in pINDO cells (Figure 3.27).
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Figure 3.27. Expression of a-synuclein on 3H dopamine uptake in HEK293 cells. 
The influence of ponasterone A induction upon 3H dopamine uptake in pINDO, 
WTsyn and MUTsyn cells after 30 minutes. There was no significant effect of either
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wild-type or G209A mutant a-synuclein on 3H dopamine uptake (open versus solid 
bars, Kruskal-Wallis test, see section 2.12.). Values are expressed as mean ±SEM, 
n=4.
3.4. Discussion
3.4.1. Dopaminergic properties of neuronal (SH-SY5Y and hNT2) and EcR293 
cells
Parkinson’s disease (PD) is characterised by the selective loss of neurones of the 
nigro-striatal dopaminergic system, which suggests that pathogenetic events relating 
to the dopamine (DA) system are relevant for PD pathogenesis. Thus, the cell line 
used for the establishment of the cell culture model should ideally have properties 
similar to those of the substantia nigra.
Substantia nigra neurones, but also cells in other organs such as the adrenal 
gland, synthesise DA using tyrosine hydroxylase (TH). Vesicular monoamine 
transporters (VMAT) then actively transport dopamine into specialised 
monoaminergic storage vesicles. Neuronal cells predominantly express VMAT-2 
whereas non-neuronal cells predominantly express VMAT-1. Substantia nigra 
neurones are known to be TH positive, synthesizing dopamine, and express DAT in 
pre-synaptic terminals to facilitate re-uptake of extracellular dopamine (Reith et al.,
1997). PD was found to coincide with a loss of DAT and VMAT-2 positive cells in the 
substantia nigra indicating the presence of VMAT-2 positive storage vesicles 
(Harrington et al., 1996; Hirsch et al., 1988; Lehericy et al., 1994). Thus, key 
features of substantia nigra neurones are the facility to synthesise, store and release 
dopamine using TH and VMAT-2 positive vesicles, respectively, as well as the 
capacity for re-uptake of released dopamine through DAT.
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In the first part of this work, the dopaminergic properties of the neuronal cell 
lines NT2 and SH-SY5Y (differentiated and undifferentiated), and human embryonic 
kidney cells (HEK293), were characterised using immunocytochemistry and 
Western blot. In light of the key features of substantia nigra neurones cell lines were 
characterised using antibodies against TH, VMAT-1 and 2, and DAT. Although the 
antibodies used for Western blot analysis did not give bands of the expected sizes, 
the antibodies were suitable for immunocytochemistry.
HNT2 neuroblastoma cells immunoreacted with antibodies against tyrosine 
hydroxylase and VMAT-1 and 2 suggesting they can synthesise and store 
catecholamines. However, no immunostaining was observed with the DAT antibody. 
This is consistent with a previous report showing tyrosine hydroxylase expression in 
hNT2 cells immunocytochemically (Zigova et al., 1999); interestingly, in that study 
tyrosine hydroxylase expression was upregulated in hNT2 cells following treatment 
with lithium. A mixture of VMAT-1 and 2 expression in hNT2 cells may indicate that 
these cells had a mixed peripheral (VMAT-1) and central nervous system (VMAT-2) 
phenotype. HNT2 cells were only assessed in the undifferentiated state. It is 
possible that following full differentiation into post-mitotic neurones they might adopt 
a more central nervous system phenotype with respect to VMAT expression.
SH-SH5Y neuroblastoma cells in the undifferentiated state also 
immunostained for tyrosine hydroxylase, VMAT-1 and VMAT-2 suggesting that, 
similar to hNT2 cells, they were capable of catecholamine synthesis and storage. 
These results are consistent with TH enzyme activity measurements in SH-SY5Y 
cells (Ross et al., 1983), immonoblotting in SH-SY5Y cells (Chen et al., 1998), as 
well as immunocytochemical evidence for tyrosine hydroxylase expression in SH- 
SY5Y (Presgraves et al., 2004). Similar to hNT2 cells, in SH-SY5Y cells a mixture of 
VMAT-1 and VMAT-2 expression could indicate that these cells had properties of 
both peripheral neurones and central nervous system neurones. However, SH-
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SY5Y cells did not have immunostaining with the DAT antibody. This is in accord 
with absent DAT gene expression reported in a previous study in SH-SY5Y cells 
(Lode et al., 1995).
Differentiated SH-SY5Y cells resembled undifferentiated SH-SY5Y cells. 
Tyrosine hydroxylase staining was observed in both differentiated (neurofilament 
positive) and undifferentiated cells. This may indicate that qualitatively the 
expression of tyrosine hydroxylase expression did not depend on cell differentiation 
so that the staining pattern was similar in differentiated and undifferentiated cells. 
With immunocytochemistry it was not possible to assess whether quantitatively 
tyrosine hydroxylase expression changes depending on the state of differentiation. 
Differentiated SH-SY5Y cells did not express DAT. However, SH-SY5Y cells were 
shown to take up 3H-dopamine suggesting that dopamine enters these cells by 
different mechanisms (P Korlipara, personal communication). This is in agreement 
with the presence of the noradrenaline-uptake transporter, which also transports 
dopamine (Pacholczyk et al., 1991).
Immunocytochemically, HEK293 cells expressed TH indicating they are able 
to synthesise dopamine, and VMAT-1 indicating that they can store catecholamines. 
In addition, HEK293 cells were able to take up 3H-dopamine but did not have 
immunostaining for DAT. These results are consistent with reports showing that 
proximal tubules in the kidney can synthesize dopamine (Goldstein et al., 1972), and 
it is well-established hat dopamine has a substantial influence on renal function, e.g. 
sodium excretion (Hussain and Lokhandwala, 1998). HEK293 cells were described 
to synthesise and store dopamine (Eshleman et al., 1997). Previous studies have 
also shown that HEK293 cells accumulated dopamine and MPP+ (Grundemann et 
al., 1998; Okada et al., 1998), and were sensitive to dopamine (Luo and Roth,
2000). While HEK293 cells do not express the dopamine or noradrenalin 
transporters (DAT or NAT, Burton et al., 1998), it has been shown that other
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transporters transport dopamine including the organic cation transporter 
(Grundemann et al., 1998). This is in accord with reports that relatively high 
concentrations of DA were needed to have a toxic effect on HEK293 cells (Okada et 
al., 1998) as well as relative resistance to MPP+ in HEK293 cells (Storch et al.,
1999) with enhancement of DA or MPP+ toxicity after transfection of DAT 
(Wersinger and Sidhu, 2003).
Taken together these results indicate that HEK293, SH-SY5Y and hNT2 
cells had dopaminergic features. While HEK293 cells expressed the phenotype of 
peripheral dopaminergic cells, SH-SY5Y and hNT2 cells exhibited a mixture of 
peripheral/central nervous system characteristics. This mirrored the properties of 
substantia nigra neurons apart from the expression of DAT. Thus, SH-SY5Y cells 
are possibly superior to the other cell lines as they are neuronal, can be 
differentiated easily and have been shown to express the noradrenaline-uptake 
transporter, which also transports dopamine (Pacholczyk et al., 1991). Since hNT2 
cells are also neuronal and can be differentiated, hNT2 and SH-SY5Y cell lines 
might be the most suitable cell lines of these three cell lines for the generation of cell 
culture models for Parkinson’s disease.
However, while HEK293 cells are not dopaminergic neurones, they 
expressed tyrosine hydroxylase, VMAT1 positive vesicles and catecholamines, and 
showed dopamine uptake. There is evidence to suggest that HEK293 cells may 
have originated form a neuronal lineage within kidney epithelium (Graham et al., 
1977; Shaw et al., 2002). HEK293 cells were derived originally by transformation 
with adenovirus DNA, a virus that is highly neurotropic. There is evidence showing 
that HEK293 cells have neuronal properties
(http://www.mbi.ufl.edu/~shaw/293.html); e.g., immunohistochemistry and 
immunoblotting revealed positive staining for neurofilaments, an intermediate
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filament of neurones (Shaw et al., 2002). This indicates that HEK293 cells are a 
suitable model for a-synuclein over expression.
3.4.2. The stable and inducible HEK293 cell model for a-synuclein PD
The model described in this thesis chapter is a stable and inducible model for wild- 
type or G209A mutant a-synuclein expression in HEK293 cells. It utilised the 
Ecdysone-lnducible Mammalian Expression System, which has been described in 
detail in section 2.4.1.. Mammalian cells are not normally responsive to the inducing 
agent ponasterone A, an analogue of the insect hormone ecdysone, and do not 
contain the ecdysone receptor. Therefore, basal levels of transcription are very low 
or absent altogether. Disadvantages of this system include the amount of time 
needed to generate a cell model de novo since it requires the successive 
transfection of two plasmids (pVgRxR and pIND) and screening and isolation of 
clones that are expressing as has been the case in the neuronal cell lines described 
in this thesis chapter. Furthermore, while the SH-SY5Y or hNT-2 cell lines would 
have been suitable cell lines to establish a a-synuclein cell culture model using the 
Ecdysone-lnducible Mammalian Expression System was not successful in these 
cells. This problem was overcome to some degree in that Invitrogen offers a cell line 
(EcR293) of HEK293 cells successfully transfected with pVgRxR plasmid.
a-synuclein immunocytochemistry and Western blot documented that there 
were only very low endogenous levels of a-synuclein in the pIND.a-syn or pIND.a- 
syn/G209A transfected cells in the absence of ponasterone A (Fig. 1A) and likewise 
no or only weak expression in the pIND.zero cells. The detection of the HA tag 
distinguished between endogenous a-synuclein and ponasterone A induced 
expression of the a-synuclein constructs. In the absence of ponasterone A there 
was no HA signal indicating that the background expression of pIND.a-syn and
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plND.a-syn/G209A cells reflected endogenous a-synuclein expression and was not 
due to leakage of the introduced gene constructs.
The level of a-synuclein expression (wild-type or G209A mutant) was 
proportional to the concentration of ponasterone A used with the inducible cell lines. 
Thus the production of a-synuclein protein by these cell lines was tightly controlled 
by ponasterone A. Levels of a-synuclein expression from the constructs were higher 
at all concentrations of ponasterone A compared with expression levels of 
endogenous a-synuclein. This indicated that any effects of a-synuclein expression 
from following ponasterone A induction were most likely due to construct expression 
alone and less likely caused by an interaction between endogenous and 
ponasterone A induced a-synuclein. Immunocytochemical analysis suggested that 
the increase in a-synuclein/HA levels on Western blot may be due to a greater 
number of cells expressing with increasing concentrations of ponasterone A while 
the intensity of staining in individual expressing cells was similar irrespective of 
ponasterone A concentration. This could indicate that there was a threshold for 
expression in each individual cell and that variation of the ponasterone A 
concentration above this threshold, once the cell had been ‘switched on’, resulted in 
similar levels of expression.
Taken together, the HEK293 a-synuclein model described in this thesis 
chapter has a number of advantages. Expression of wild-type or G209A mutant a- 
synuclein was stable and inducible with good control over the levels of protein 
expressed and no expression in the absence of the inducing agent ponasterone A.
In addition, in contrast to constitutive cell models this inducible model made it 
possible to assess the effect of a-synuclein expression against the same cellular 
background in the absence of expression. This helped to remove the inherent cell- 
to-cell variability, which can make interpretation difficult in constitutive models. In
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addition, models with constitutive expression can lead to a selection of cell 
populations that have adapted to the expressed protein, a problem that does not 
occur with this inducible model. A weakness of the model is the cell line HEK293 in 
that it is not a neuronal dopaminergic cell line. However, the cell line exhibited 
features similar to those of dopaminergic neurones in the substantia nigra; the cells 
were able to express tyrosine hydroxylase indicating catecholamine production, they 
expressed VMAT-1 as evidence for the presence of catecholamine storage vesicles, 
and there was clear evidence of dopamine uptake. Hence HEK293 cells are a 
suitable cell line with which to investigate PD, a disease that relatively selectively 
affects dopaminergic neurones. A drawback of the cell line is that HEK293 cells 
cannot be differentiated into post-mitotic neurones. Thus aspects of PD that pertain 
to e.g. neurites cannot be easily addressed with this model. In addition, experiments 
addressing long-term consequences of a-synuclein expression are difficult because 
the cells continue to divide so that one cannot assess the consequences of 
prolonged exposure to the expressed protein in individual cells.
3.4.3. Subcellular localisation of wild-type and G209A mutant a-synuclein
There is evidence to suggest that a-synuclein is localised in nerve terminals near 
synaptic vesicles (see section 3.1.9.5.3.). Immunocytochemistry in HEK293 cells 
expressing either wild-type or G209A mutant a-synuclein showed co-localisation of 
a-synuclein with vesicle associated membrane protein (VAMP). This indicated that 
the localisation of a-synuclein in these cell models was similar to that observed in 
human cortex (Irizarry et al., 1996) and in primary rat hippocampal neurones 
(Murphy et al., 2000). Staining with an antibody to vesicle associated membrane 
transporter (VMAT) a marker for catecholaminergic vesicles revealed partial co­
localisation with wild-type or G209A mutant a-synuclein in the HEK293 cells. This 
suggested that at least some of the a-synuclein might be associated with these
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vesicles, and it also indicates that in the HEK293 model there was no difference 
between wild-type and G209A mutant a-synuclein.
The role of a-synuclein for synaptic vesicles in nerve terminals is not clear. 
Studies in a-synuclein knock-out mice indicated that a-synuclein is not essential for 
neuronal function but that its function might be more subtle, e.g. in regulating vesicle 
function and transmitter release including dopamine (Abeliovich et al., 2000; 
Lotharius and Brundin, 2002), the regulation of vesicular transport (Jenco et al.,
1998) within axons (Jensen et al., 1998; Saha et al., 2004) or the size of the 
vesicular pool (Murphy et al., 2000).
There was no association of a-synuclein with other organelles such as 
mitochondria, lysosomes, Golgi-network or the nucleus. This was in accord with the 
association of a-synuclein with vesicles as discussed above and did not indicate 
that a-synuclein was involved directly with other organelles. Immunocytochemistry 
revealed two different types (aggregate-Iike and diffuse) of staining for both wild- 
type or G209A mutant a-synuclein and neither form of a-synuclein co-localised with 
ubiquitin. Why there were different a-synuclein staining patterns was not clear. It is 
possible that the aggregate-like staining reflected the presence of a-synuclein in the 
vesicular population rather than true Lewy-body like aggregates. This would be in 
keeping with the absence of ubiquitination. In other cell culture models (non­
differentiated SH-SY5Y (Lee et al., 2004), HEK293 (Tanaka et al., 2004), or PC-12 
cells (Stefanis et al., 2001) wild-type a-synuclein over-expression did not always 
lead to aggregate formation or impairment of the UPS (for a summary of different 
cell culture models and results see appendix 2). However, ‘aggregate-like’ 
immunostaining was found in mouse hypothalamic GT1-7 cells (Hsu et al., 2000) 
and wild-type a-synuclein over-expression promoted inclusion formation in BE-M17 
neuroblastoma cells (Ostrerova-Golts et al., 2000), COS-7 (monkey kidney) cells
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and differentiated SH-SY5Y cells (Lee et al., 2004). Over-expression of either 
mutant form of a-synuclein enhanced inclusion formation in In SH-SY5Y 
neuroblastoma cells (Ostrerova-Golts et al., 2000), or was associated with impaired 
function of the UPS and apoptosis in PC-12 cells (Stefanis et al., 2001; Tanaka et 
al., 2001). The differences between the cell culture models could be due to the 
different cell lines used, or the expression systems (see appendix 2). In particular 
the level of protein expression may be much higher with constitutive expression 
compared with the inducible Ecdysone System. This may be relevant to the 
functional capacity of the UPS, so that some UPS impairment could be non-specific.
3.4.4. a-synuclein expression in HEK-293 cells had no effect on mitochondrial 
function
The data presented in this thesis chapter and in other in vitro models examined the 
relationship of wild-type or mutant a-synuclein over-expression. Over-expression of 
wild-type a-synuclein was associated with PD in a family with a-synuclein gene 
triplication (Singleton et al., 2003). However, in sporadic PD mitochondrial 
dysfunction, in particular complex I, may precede a-synuclein accumulation and 
aggregation (Kowall et al., 2000; Manning-Bog et al., 2002; Sherer et al., 2002; 
Sherer et al., 2003)(see appendix 2). It is not known if in patients with a-synuclein 
mutations mitochondrial respiratory chain function is affected.
There was no evidence that wild-type or G209A mutant a-synuclein 
expression affected mitochondrial function as measured by either respiratory chain 
enzyme activities in isolated mitochondria or mitochondrial membrane potential in 
live cells. This is in agreement with the observations in PC-12 cells where 
mitochondrial membrane potential was unaffected by the expression of either wild- 
type or G88C mutant a-synuclein (Tanaka et al., 2001). It conflicts with a report of 
decreased MTT activity in murine hypothalamic cells constitutively over-expressing
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wild-type a-synuclein (Hsu et al., 2000)(see appendix 2). However, MTT activity has 
been reported to be relatively non-specific, and in the absence of confirmatory data, 
a less reliable marker of respiratory chain activity (Berridge and Tan, 1993). The 
data suggest that expression of either wild-type or mutant a-synuclein does not 
interfere directly with mitochondrial function. This is in accord with the 
immunocytochemical data showing no direct association between a-synuclein and 
mitochondria at the cellular level (Tabrizi et al., 2000a). However, it is not possible to 
exclude mitochondrial dysfunction induced by a-synuclein over prolonged periods of 
time, or as a secondary or cell specific effect. The HEK293 cells did exhibit 
dopaminergic characteristics, but the analysis of post-mitotic cells, which resemble 
dopaminergic neurones more closely, would help address these questions.
There is strong evidence for a role of a complex I defect in PD (see section
3.1.5.). This is supported by the observation that a-synuclein knock-out mice were 
resistant to the selective complex I inhibitor MPTP (Dauer et al., 2002), and by the 
recent identification of a mutation in a putative mitochondrial protein called PTEN- 
induced kinase (PINK 1) in a family with PD (Valente et al., 2004). Thus it is 
conceivable that a complex I defect is responsible for the generation of oxidative 
stress, which subsequently leads to a-synuclein aggregation and the loss of 
dopaminergic neurones. However, it is not likely that wild-type or mutant a-synuclein 
cause a defect of the mitochondrial respiratory chain.
3.4.5. a-synuclein expression in HEK-293 cells enhanced the mitochondrial 
sensitivity to Rotenone
Rotenone, a selective inhibitor of complex I of the mitochondrial respiratory chain, 
has been implicated as an environmental toxin that could be relevant to the 
pathogenesis of PD (see section 3.1.5.3.), and it has been used to generate animal 
models of PD (see section 3.1.6.). Short-term rotenone exposure induced a
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decrease in mitochondrial membrane potential, as predicted for a respiratory chain 
inhibitor. This was potentiated by wild-type a-synuclein expression and, to a lesser 
degree by mutant a-synuclein expression suggesting that both enhance the 
sensitivity of the mitochondrial membrane potential to inhibition of the respiratory 
chain. While this did not significantly induce cell death over the short term, it might 
lead to decreased viability with prolonged exposure as previously reported 
(Lehmensiek et al., 2002)(see appendix 2). Although the data obtained with cell 
models can only be extrapolated with caution to the situation in the natural disease 
state, these data emphasise the power of inducible models in that this model 
revealed relatively small differences in sensitivity to rotenone of a-synuclein 
expressing cells.
The results suggest that increased wild type or mutant a-synuclein 
expression promoted the sensitisation of dopaminergic neurones to exogenous 
mitochondrial toxins such as rotenone which may have led to cell damage and 
death. This raises the question of how a-synuclein enhanced the rotenone 
dependent decrease in mitochondrial membrane potential and why expression of 
the wild-type protein rendered these cells more vulnerable than the mutant protein. 
Immunocytochemical analysis did not provide evidence that a-synuclein is 
associated with complex I, and therefore the influence of a-synuclein upon the 
rotenone induced decrease in mitochondrial membrane potential is likely to be 
indirect. Rotenone is known to increase oxidative stress, a-synuclein aggregation 
and apoptosis (Sherer et al., 2002)(see appendix 2). Therefore it is possible that the 
increased expression of wild type and to a lesser degree mutant a-synuclein 
potentiated these effects leading to a greater fall in mitochondrial membrane 
potential. In support of this suggestion the absence of a-synuclein in knockout mice 
resulted in a decrease in MPP+ induced cell death (Dauer et al., 2002). This
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suggests that expression of a-synuclein was necessary so that this selective 
complex I inhibitor could become toxic indicating an interaction of a-synuclein and 
MPP+.
These findings lend support to the hypothesis that mitochondrial dysfunction 
and a-synuclein toxicity are reciprocal. Previous observations suggested that 
respiratory chain dysfunction leads to a-synuclein accumulation and aggregation 
(Kowall et al., 2000; Manning-Bog et al., 2002; Sherer et al., 2002; Sherer et al., 
2003), and we have demonstrated that a-synuclein expression, both wild-type and 
G209A mutant, potentiated the toxicity of respiratory chain inhibitors. This latter 
effect was more pronounced with wild type a-synuclein expression and may be a 
contributory factor in sporadic PD, whereas abnormal dopamine handling may be 
more important for mutant a-synuclein pathology.
3.4.6. Effect of a-synuclein expression alone on oxidative stress
Considerable evidence suggests the involvement of free radicals in the 
pathogenesis of PD (Olanow and Tatton, 1999). Oxidative stress may promote a- 
synuclein aggregation and oxidative damage to a-synuclein (Giasson et al., 2000; 
Ischiropoulos and Beckman, 2003). It remains unknown, however, how exactly free 
radicals are involved and whether free radical generation is a feature of the familial 
forms of the disease. In the inducible cell models used in this thesis chapter, wild- 
type or mutant G209A a-synuclein expression did not affect GSH levels or aconitase 
activity, two reliable markers of oxidative stress (Gardner et al., 1994; Hausladen 
and Fridovich, 1994; Patel et al., 1996). This is in accord with over-expression of 
wild-type a-synuclein in stably transfected SH-SY5Y neuroblastoma cells, which had 
no effect on aconitase activity (Kalivendi et al., 2004) or the exposure to H202 
(Kanda et al., 2000), and it protected SK-NM-C neuronal cells against the effects of
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serum deprivation or H20 2 (Lee et al., 2001c). The results differ from those in mouse 
hypothalamic GT1-7 cells constitutively over-expressing wild-type a-synuclein where 
increased oxidative stress was indicated by qualitatively enhanced oxidation of 2\7'- 
dichlorofluorescein and increased glutathione levels (Hsu et al., 2000)(see appendix 
2). It is not known whether these differences reflect cell specific differences or 
indeed differences in protein expression levels. With constitutive expression protein 
expression levels tend to be generally higher, and cells are exposed to the 
expressed protein for longer periods than in the inducible model reported in this 
thesis chapter.
If using increased wild-type or mutant a-synuclein expression as a model of 
idiopathic PD then the lack of oxidative stress contrasts with what is found in 
patients with idiopathic PD (see section 3.1.7.1.). This therefore suggests that 
increased a-synuclein expression alone did not cause oxidative stress. The data 
from the a-synuclein HEK293 cell culture model presented in this thesis chapter 
would therefore predict that in the family with a-synuclein over-expression as a 
result of genomic triplication of the a-synuclein gene (Singleton et al., 2003) 
oxidative stress is not a primary event in the pathogenesis.
3.4.7. a-synuclein expression protected against paraquat toxicity
a-synuclein expression did not increase oxidative stress. However, a-synuclein 
could increase the susceptibility to free radicals. Evidence from epidemiological 
studies suggests that environmental toxins such as pesticides could be involved in 
the pathogenesis of PD (see section 3.1.4.). Paraquat (1,1’-dimethyl-4,4’-5 
bipyridinium) is a common herbicide and rotenone is a widely used insecticide and 
fish poison. The systemic administration of rotenone or paraquat to rodents was 
associated with the development of a-synuclein aggregation (Betarbet et al., 2000; 
Manning-Bog et al., 2002).
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In normal HEK293 cells paraquat incubation caused a dose dependant 
decrease in aconitase activity. This was consistent with paraquat induced oxidative 
stress within cells where it generates superoxide promoted by the mitochondrial 
NAD(P)H -quinone oxidoreductase (Shimada et al., 1998). This can lead to damage 
to the cell and in particular the mitochondria (Hirai et al., 1992). In the a-synuclein 
HEK293 cell model expression of wild-type a-synuclein partially protected the 
aconitase activity from inhibition by paraquat generated superoxide production. This 
indicates that this increase of antioxidant protection may be a consequence of wild- 
type a-synuclein expression. It is possible that a-synuclein itself has antioxidant 
properties; alternatively it may have induced the cell to increase its own antioxidant 
defences. This is in accord with elevated GSH levels reported with wild-type a- 
synuclein expression (Hsu et al., 2000)(see appendix 2). Elevated GSH levels were 
not seen in the HEK293 a-synuclein model. However, this does not exclude 
changes in other antioxidants. The protective effect of a-synuclein expression 
against paraquat induced oxidative stress was also observed with mutant a- 
synuclein expression. However, compared to wild-type a-synuclein it was less 
pronounced. This implies that G209A mutant a-synuclein either had an impaired 
antioxidant role or did not induce the cellular defences as much as the wild-type 
form. A loss of anti-oxidant action of a-synuclein conferred by the G209A mutation is 
in agreement with other studies using SH-SY5Y neuroblastoma cells; cells 
constitutively over-expressing mutant a-synuclein were more vulnerable to free 
radical damage induced by H202 (Kanda et al., 2000) or menadione (Ko et al., 
2000)(see appendix 2).
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3.4.8. a-synuclein expression in HEK-293 cells increased dopamine mediated 
toxicity
In HEK293 cells dopamine clearly caused cell death at concentrations above 
0.25mM. At concentrations of >0.5mM the expression of G209A mutant a-synuclein 
enhanced dopamine mediated cell death compared to no expression or the 
expression of wild-type a-synuclein. Dopamine induced cell death has been 
confirmed in a number of systems (Alexander et al., 1997; Lai and Yu, 1997; Ziv et 
al., 1994), and increased susceptibility of a-synuclein, both wild-type and G88C or 
G209A mutant, expressing SH-SY5Y cells has also been reported (Junn and 
Mouradian, 2002). The concentrations of dopamine used in these experiments are 
similar to those reported in the cell bodies of dopaminergic neurones (Jonsson, 
1971). At present the mechanisms by which G209A mutant a-synuclein increases 
dopamine toxicity are not known, a-synuclein is highly expressed in human brain 
presynaptic terminals (Irizarry et al., 1996), in rat substantia nigra pars compacta 
(Kholodilov et al., 1999) and is also a major component in the Lewy bodies of 
dopamine containing neurones in PD brains (Spillantini et al., 1997). Thus a- 
synuclein is expressed at sites of high dopamine content and it may function to 
modulate dopamine release (Abeliovich et al., 2000).
It was also clear that dopamine caused oxidative stress in HEK293 cells, and 
this was exacerbated by the expression of G209A mutant a-synuclein but 
unchanged by wild-type a-synuclein expression. Consequently the increase in cell 
death following dopamine exposure in mutant a-synuclein expressing cells may be 
explained by an increase in free radical damage presumably via dopamine 
metabolism. Dopamine is unstable and is readily oxidised to the dopamine quinone 
and generates superoxide and hydrogen peroxide. Dopamine can also co-valently 
modify free cysteine, cysteine in glutathione and cysteinyl residues in protein
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(LaVoie and Hastings, 1999). Sulphydryl groups on cysteines are often associated 
with active sites on proteins and thus their modification could alter function 
irreversibly. Interestingly, the formation of S-cysteinyl dopamine is associated with 
the loss of monoaminergic striatal terminals in dopamine-induced toxicity (Hastings 
et al., 1996). Thus dopamine toxicity may be mediated via increased reactive 
oxygen species generation and by direct protein modification. It is not likely that the 
enhanced sensitivity is due to a greater vulnerability of G209A mutant a-synuclein 
expressing cells to the free radicals per se because G209A mutant a-synuclein 
partially protected the cells from the oxidative stress induced by paraquat. Hence, it 
is possible that mutant a-synuclein expression itself may cause the cells to generate 
more free radicals in the presence of dopamine.
a-synuclein may influence the uptake of dopamine. If a mutation of a- 
synuclein increased the uptake of dopamine this could elevate the cytoplasmic 
concentration of dopamine. However, no change in uptake of 3H-dopamine was 
observed in the HEK293 a-synuclein cell model irrespective of whether the cells 
expressed wild-type of G209A mutant a-synuclein. Hence, any effect of the G209A 
mutation on dopamine uptake is not a likely explanation for the increased levels of 
dopamine induced oxidative stress that was observed in this model.
Mutant a-synuclein may lead to a decrease in dopaminergic vesicles as 
reported in a model of a-synuclein down regulation (Murphy et al., 2000). 
Alternatively mutant a-synuclein may prevent the normal compartmentalisation of 
dopamine into vesicles, thus elevating cytoplasmic dopamine concentrations. In the 
HEK293 a-synuclein cell model immunocytochemical analysis revealed co­
localisation of a-synuclein, both wild-type and G209A mutant, with a marker for 
vesicles, and at least partial co-localisation with VMAT-1, a marker for 
catecholaminergic vesicles. This provides evidence for a spatial relationship of a-
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synuclein with the catecholaminergic vesicular compartment. The toxicity of 
dopamine may be increased by failure of dopamine compartmentalisation within 
vesicles (Figure 3.3). The damaging effects of dopamine would therefore be 
enhanced if mutant a-synuclein interfered with the function of the vesicular 
monoamine transporter, thereby increasing intra-cytoplasmic dopamine 
concentrations and the potential for cell damage sufficient to cause cell death. The 
use of reserpine mimicked a situation in which the vesicular uptake of dopamine 
was inhibited (Parti et al., 1987). Consistent with the dopamine-induced changes in 
the mutant a-synuclein expressing cells, reserpine enhanced the dopamine induced 
decrease in aconitase activity. Consistent with a report in human mesencephalic 
cells (Lotharius and Brundin, 2002) this data lend further support to the hypothesis 
that a-synuclein is involved in the regulation of vesicular dopamine handling. A 
defect of dopamine compartmentalisation may increase cytoplasmic dopamine 
concentrations resulting in the gradual accumulation of superoxide radicals and 
auto-oxidation products (Lotharius and Brundin, 2002). This may promote a- 
synuclein aggregation and Lewy body formation leading to a slow but progressive 
loss of striatal terminals and nigral neurones. The over-expression of wild-type a- 
synuclein might lead to a similar effect, but over a longer period — such as seen in 
the human wild-type a-synuclein transgenic mice described above (Masliah et al.,
2000).
Free radicals generated from dopamine metabolism in dopaminergic 
neurones may specifically contribute to a-synuclein aggregation and Lewy body 
formation and help to explain their relative selective loss in PD (Giasson et al., 2000; 
Paxinou et al., 2001). Indeed there is recent evidence that dopamine may influence 
a-synuclein toxicity by forming oxidative adducts with a-synuclein preventing the 
conversion of the toxic protofibrils to inert fibrils which are found in Lewy bodies 
(Conway et al., 2001). In addition, accumulation of soluble a-synuclein protein
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complexes has been shown to result in apoptosis mediated by free radicals 
selectively in cultured human dopaminergic neurones (Xu et al., 2002). Further 
evidence linking a-synuclein and dopamine was revealed by the interaction of a- 
synuclein expression and tyrosine hydroxylase activity which may indicate a 
regulatory role of a-synuclein in dopamine synthesis (Perez et al., 2002). The data 
in the HEK293 a-synuclein models add to the accumulating evidence for an 
interaction between a-synuclein and dopamine, which may be important in the 
pathophysiology underlying the relatively selective neuronal death seen in 
Parkinson’s disease.
3.5. Conclusion
Models were established in human embryonic kidney cells with inducible expression 
of increased wild-type a-synuclein expression (to model sporadic PD) and increased 
mutant G209A a-synuclein to model a familial form of Parkinson’s disease. Both 
wild-type and mutant a-synuclein were localised to vesicles, some of which were 
catecholaminergic. Over-expression of wild-type or mutant (G209A) a-synuclein 
alone did not reduce cell viability, cause oxidative stress or impair mitochondrial 
function. However, mutant a-synuclein expression enhanced the susceptibility to 
dopamine toxicity causing increased oxidative stress and cell death. This effect was 
similar to that of reserpine, an inhibitor of vesicular monoamine uptake, in controls. 
These results suggest that in these cell models a-synuclein did not directly cause 
oxidative stress or mitochondrial respiratory chain dysfunction. However, the data 
indicated that a-synuclein may increase the susceptibility of HEK293 cells to 
rotenone induced mitochondrial complex I inhibition (wild-type a-synuclein) and may 
play a role in dopamine compartmentalisation. Loss of function conferred by the 
G209A mutation could therefore increase cytoplasmic dopamine concentrations with
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subsequent cell damage or death. These models might be useful to investigate the 
mechanisms underlying these effects in more detail, and they may also be suitable 
to study the effect of treatment aimed at protecting against rotenone or dopamine 
mediated toxicity.
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CHAPTER 4.
Myoblast and myotube cell culture model for Huntington’s disease
4.1. Introduction
In 1872, George Huntington first described in detail the disease that bears his name. 
He recognised the most important clinical features of Huntington’s disease, namely 
behavioural abnormalities, cognitive decline and movement disorder. In addition, he 
recognised that the disease was transmitted in a dominant pattern within affected 
families. The disease has an estimated prevalence in North America and Europe of 
4-10 in 100,000 (Folstein, 1989).
4.1.1. Clinical features of Huntingtons's disease
Huntington’s disease (HD) is clinically characterised by chorea, ataxia, psychiatric 
abnormalities and dementia. The disease usually manifests during the forth or fifth 
decade of life. The mean survival is 15 to 20 years; HD is inevitably fatal and there 
is no effective treatment.
Patients may present first with behavioural changes, most commonly 
alterations of character, before they develop a movement disorder and cognitive 
function deteriorates. However, they may also develop primarily a movement 
disorder that precedes the psychiatric/cognitive disorder. Symptoms can appear as 
early as 4 years of age (Farrer and Conneally, 1987; van Dijk et al., 1986) or as late 
as 60 or 70 years of age (Folstein, 1989). The movement disorder characteristically 
consists of choreoathetosis, but ataxia, tics and akinetic rigid syndromes are well 
recognised, in particularly in young onset cases (e.g. Westphal variant). Death often 
results from dysphagia; patients may subsequently develop aspiration pneumonia, 
they may suffocate, and suicide is also not infrequent (Harper, 1991).
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In addition to the many signs and symptoms indicative of a brain disorder the 
vast majority of HD patients suffers from marked muscle wasting and weight loss in 
the course of the disease despite adequate dietary intake (Farrer and Conneally, 
1985; Morales et al., 1989; Sanberg et al., 1981). While dysphagia may contribute to 
weight loss a catabolic state as a consequence of increased energy expenditure 
could also be a contributing factor (Pratley et al., 2000). However, in the same study 
total free-living energy expenditure was not different to controls; patients with HD 
may engage in less voluntary physical activity thus balancing the increase in energy 
expenditure because of the movement disorder (Pratley et al., 2000).
4.1.2. Pathology of Huntington's disease
Macroscopically, the characteristic neuropathological findings in HD comprise 
atrophy of the head of the caudate nucleus and the putamen bilaterally. Cell loss of 
deeper layers can be observed in additional brain areas including frontal and 
temporal cortex, thalamus, globus pallidus and cerebellum (de la Monte etal., 1988; 
Hedreen et al., 1991; Vonsattel et al., 1985). Microscopically, the striatal medium 
spiny neurones are most affected (Reiner et al., 1988). These cells make up the 
vast majority of striatal cells and receive inputs from cortex and thalamus, and 
substantia nigra (Albin et al., 1989). All striatal medium spiny neurones employ the 
inhibitory transmitter GAB A but two different populations can be differentiated by 
their receptor status. One population projecting to globus pallidus predominantly has 
substance P, dynorphin and dopamine Di receptors while the other projects to the 
substantia nigra and mainly has enkephalin and dopamine D2 receptors (Albin et al., 
1989). Nuclear and cytoplasmic aggregates are also a typical pathological feature of 
HD (DiFiglia et al., 1997) (see section 4.1.8.2.1.).
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4.1.3. Huntingtin expression and localisation
Huntingtin is a large protein with 3144 amino acids. The polyQ domain begins at 
amino acid 18 and is followed by a 2 prolin repeat domain. The normal function of 
huntingtin remains unclear. Huntingtin does not show any major homology with 
other known proteins, which might have provided some insight into its function. The 
study of huntingtin gene homologues in mouse, rat and pufferfish indicate that this 
gene is highly conserved through evolution (Sharp and Ross, 1996) suggesting that 
it has an important cellular function. Huntingtin contains HEAT (huntingtin elongation 
factor 3) repeats, which consist of multipe repeats of sequences of about 40 amino 
acids (Takano and Gusella, 2002). HEATs are found in proteins that are relevant for 
intracellular transport and chromosomal segregation (Neuwald and Hirano, 2000).
Northern blot analysis of gene expression and in situ hybridisation revealed 
that huntingtin is widely expressed throughout the brain and non-neuronal tissues 
with particularly high levels of expression in testes, ovaries, and lung (The 
Huntington's Disease Collaborative Research Group, 1993; Strong et al., 1993). 
There is evidence from immunohistochemical studies that huntingtin predominantly 
localises to the cytoplasm of both neuronal and non-neuronal tissue (Hoogeveen et 
al., 1993; Trottier et al., 1995a). In HD patients, expression was observed primarily 
in nerve fibres and their varicosities but also in some cell bodies (Trottier et al., 
1995a). In normal brain, huntingtin was immunolocalised to the cytoplasm of 
neuronal somata, dendrites and axons (DiFiglia et al., 1995) whereas mutant 
huntingtin was found in neuronal perikarya and proximal nerve processes but not 
nerve endings (Gourfinkel-An et al., 1997). More specifically, huntingtin was 
described in vesicle enriched fractions (DiFiglia et al., 1995) with an association to 
cytoplasmic granules, which resembled multivesicular bodies that were thought to 
be involved in protein transport and degradation in HD cortical and striatal neurones 
(Sapp et al., 1997). It was further noted that huntingtin could be associated with
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microtubules, which may indicate that huntingtin plays a role in vesicle trafficking 
(Aronin et al., 1999). In support of this notion mutant and normal huntingtin were 
found to be associated with clathrin-coated vesicles in the Golgi network, the 
cytoplasm and the plasma membrane (Velier et al., 1998), and N-terminal fragments 
of mutant huntingtin interfered with synaptic vesicle glutamate uptake in synaptic 
vesicles isolated from a full-length mutant huntingtin mouse model (Li et al., 2000a). 
Thus huntingtin is a widely distributed protein, which may serve a variety of 
functions (Figure 4.1.).
4.1.4. Huntingtin-interacting proteins
In order to understand the normal function of huntingtin several studies have used 
the yeast two-hybrid technique or other biochemical techniques to identifiy proteins 
that interact with HD. This revealed multiple proteins involved in gene transcription, 
intracellular trafficking and vesicle function (for a review see Li and Li, 2004). Many 
of these proteins bind to the N-terminal region of huntingtin, and the length of the 
polyQ repeat can modify the affinity of huntingtin to the interacting proteins. This 
indicates that the N-terminal section of huntingtin might be particularly relevant in 
this process, and abnormal polyQ expansions could thus alter cell function (Figure
4.1.).
The interaction of huntingtin with other proteins has been documented in the 
nucleus and in the cytoplasm (Figure 4.1.). In the nucleus, the formation of nuclear 
huntingtin aggregates or aggregation foci may impair the function of, or interfere in 
another way with, nuclear proteins. These proteins include a number of nuclear 
transcription factors that might be sequestered into aggregates (for a review see 
Sugars and Rubinsztein, 2003). The most extensively studied pathways are those 
involving cAMP response element (CRE) and specificity protein-1 (Sp1). The CRE 
pathway has been found to be involved in neuronal survival (Lonze et al., 2002) and
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is therefore of particular interest. For a more extensive discussion of transcriptional 
abnormalities and references see Sugars and Rubinsztein (Sugars and Rubinsztein,
2003). Problems inherent to microarray analysis, the technique employed to identify 
changes in gene transcription need to be considered, including reproducibility limited 
by cost, and importantly, the correlation of altered gene expression to the disease 
process. In other words, the question is whether altered expression of a gene is 
important in the pathology of HD, and if so, if it is a primary event or secondary to 
something else.
In addition to the interaction of huntingtin with nuclear transcription factors an 
interaction with cytoplasmic proteins has been described, e.g. HAP1 (huntingtin- 
associated protein 1) and HIP1 (huntingtin-interacting protein 1). Both proteins are 
highly expressed in neurones and have been associated with microtubule- 
dependent trans port (Engelender et al., 1997; Li et al., 1998b), endocytosis (Li etal., 
2002) and neuronal survival (Marcora et al., 2003) (Figure 4.1.).
4.1.5. Huntingtin processing
In vitro evidence indicates that full-length huntingtin contains several protease 
cleavage sites within the first 550 amino acids including caspase 3, calpain and an 
aspartatic protease (Gafni and Ellerby, 2002; Kim et al., 2001; Wellington et al„ 
1998). How full-length huntingtin is cleaved into fragments in humans is not fully 
understood. Caspase cleaving sites have been identified in huntingtin, atrophin, and 
the androgen receptor, and mutant huntingtin was found to be cleaved most 
effectively at amino acid 513 resulting in truncated N-terminal fragments that contain 
the polyQ expansion (Wellington et al., 1998). Beause of its small size the N- 
terminal huntingtin fragements are thought to diffuse passively into the nucleus 
(Figure 4.1.).
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4.1.6. Genetics of HD and other CAG repeat disorders
HD is an autosomal dominant disorder caused by an expanded CAG repeat of the 
huntingtin gene on the short arm of chromosome 4 (The Huntington's Disease 
Collaborative Research Group, 1993; Strong etal., 1993); 35 or fewer CAG repeats 
do not cause the disease whereas patients with 40 or more repeats will always 
develop HD. Individuals with 35-39 repeats are at increased risk of developing HD.
In HD, instability of the CAG repeat and an increase in repeat length is more 
likely when the HD gene is inherited from an affected father (MacDonald et al.,
1993). This is often associated with earlier age of onset in these children, a 
phenomenon called “anticipation1, which is most marked with paternal inheritance of 
the HD gene (Harper and Newcombe, 1992). CAG repeat number has been used as 
an approximate measure for disease severity (Becher et al., 1998). In addition, 
longer CAG repeat length often is associated with earlier onset (Gusella et al.,
1997). However, this association is not reliable enough to allow prediction of the age 
of onset from genetic testing in a clinically unaffected individual. This indicates that, 
while there is a substantial contribution of CAG size to age of onset and phenotype, 
other factors, either genetic or environmental, might also be relevant.
HD is one of 9 inherited neurodegenerative diseases caused by an increased 
CAG repeat length (Table 4.1). These diseases include dentatorubral pallidolysian 
atrophy (DRPLA) (Koide et al., 1994; Nagafuchi et al., 1994), spinal and bulbar 
muscular atrophy (SBMA, Kennedy’s disease) (La Spada et al., 1991) and the 
spinocerebellar ataxias (SCA) 1 (Banfi et al., 1994; Orr et al., 1993), 2 (Imbert et al., 
1996; Pulst et al., 1996), 3 (Kawaguchi et al., 1994), 6 (Zhuchenko et al., 1997), 7 
(David et al., 1997) and 17 (Nakamura et al., 2001). CAG repeat disorders share a 
number of features; except for SBMA they all are autosomal dominant, onset of 
symptoms is in midlife, all progress towards a fatal outcome, all disorders cause 
degeneration and neuronal cell death in both hemispheres in a symmetric way, they
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show genetic anticipation and the size of the CAG expansion correlates with disease 
severity and age of onset (for a review see Ross, 2002). In many of these CAG 
repeat disorders neuronal intranuclear inclusions have been described, which 
contain the protein encoded by the abnormal gene and ubiquitin.
Disorder Mode of 
inheritance
Locus Protein Normal
CAG
repeats
Mutant
CAG
repeats
HD Dominant 4p Huntingtin 11-34 37-120
DRPLA dominant 12p Atrophin 1 7-25 49-85
SBMA X-linked Androgen receptor 11-33 40-62
SCA1 Dominant 6p Ataxin 1 25-36 41-81
SCA2 Dominant 12q Ataxin 2 17-29 36-52
SC A3 Dominant 14q Ataxin 3 13-36 62-82
SCA6 Dominant 19p Ataxin 6 4-16 21-27
SCA7 Dominant 3p Ataxin 7 7-17 38-130
SCA17 Dominant 6q27 TATA binding 
protein
29-42 47-55
Table 4.1. Neurological CAG repeat disorders. HD: Huntington’s disease. DRPLA: 
dentatorubropallidolysian atrophy. SBMA: spinobulbar muscular atrophy. 
SCA1,2,3,6,7,17: spinocerebellar atrophy types 1,2,3,6,7,17.
4.1.7. The R6/2 and other mouse models of HD 
The R6/2 HD mouse model
The identification of the gene mutation causing HD enabled the generation of mouse 
models of the disease. The first such model was the R6/2 mouse (Mangiarini et al.,
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1996). The R6/2 mouse is transgenic for exon 1 of the human HD gene with -145 
CAG repeats under the control of the human HD promoter (Davies et al., 1997; 
Mangiarini et al., 1996). The transgene is expressed ubiquitously at both the mRNA 
and protein level including brain and skeletal muscle. Initially the mice develop 
normally; at the age of about 8 weeks they exhibit a progressive neurological 
phenotype with features very similar to HD. Mice have a complex movement 
disorder including choreiform movements, stereotypical movements, tremor, and 
they have seizures (Mangiarini et al., 1996). From about week 6 they start to loose 
weight, a feature also observed in HD. The disease progresses rapidly and mice 
usually die at about 14 weeks of age. Pathologically, brains of transgenic mice 
weigh less than control brains but appear grossly normal. Histologically, even before 
the onset of symptoms neuronal intranuclear inclusions containing the expanded 
polyQ repeat and ubiquitin are present in cortex at 3.5 weeks and striatum at 4.5 
weeks (Davies et al., 1997).
In the R6/2 transgenic mouse model of HD, nuclear ubiquitinated huntingtin 
aggregates were described in cardiac and skeletal muscle, kidney, liver, adrenal 
glands and pancreas (Sathasivam et al., 1999). In muscle, the occurrence of 
inclusions correlated with the onset of muscle atrophy. Further histochemical 
analysis of muscle sections from animals with end stage disease revealed a 
reduction in muscle fibre diameters compared with control littermates but no 
evidence to suggest an underlying myopathic or neuropathic process (Sathasivam 
et al., 1999). In the R6/2 mouse the formation of nuclear ubiquitinated huntingtin 
inclusions suggests that muscle cells express and modify the human transgene in a 
similar way to neurones.
Other HD mouse models
Other R6 lines also contain exon 1 of the human HD gene under the control of the
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human HD promoter sequences but with different CAG repeat lengths; the R6/1 line 
has 115 and the R6/5 line has 128-156 repeats. The phenotype is similar to that of 
the R6/2 line, however, with a later onset than the R6/2 (4-5 months in R6/1 
hemizygotes, 9 months in homozygous R6/5). Schilling and colleagues developed 
mouse lines with a longer N-terminal fragment (171 aminoacids compared to 91 
aminoacids in the R6 lines) and 18, 44 or 82 CAG repeats under the control of the 
prion protein promoter (Schilling et al., 1999). Lines with 82 CAG repeats developed 
a progressive neurological phenotype similar to the R6 lines, and life span was 
shorter. Laforet and colleagues designed lines with a N-terminal fragment encoding 
for 1000 aminoacids containing either 18, 46 or 100 CAG repeats (Laforet et al.,
2001). Lines with 18 CAG repeats were indistinguishable from normal controls while 
lines with 46 or 100 CAG repeats developed a neurological phenotype during their 
life span characterised by impairment in either clasping, gait, general activity or 
rotarod performance (Laforet et al., 2001).
Other mouse models express the mutant form of the whole human huntingtin 
gene. The first such mouse lines were established by Reddy et al with 16, 48 or 89 
CAG repeats under the control of the CMV promoter (Reddy et al., 1998). Lines with 
48 CAG repeats that were expressing higher level s of the transgene than the 
endogenous gene and those with 89 CAG repeats showed a progressive 
neurological phenotype with hyperactivity and a movement disorder (Reddy et al.,
1998). In another model full-length human huntingtin was introduced within a human 
yeast artificial chromosome (YAC). Mouse lines contained 18, 46 or 72 CAG 
repeats; only lines with 72 CAG repeats developed a mild neurological phenotype 
characterised by mild dark-phase hyperkinesias whereas the line with 46 CAG 
repeats was no different to the line with 18 CAG repeats (Hodgson et al., 1999). 
Another approach to generating mouse models targets the mouse huntingtin gene 
directly either replacing the exon 1 sequence with a CAG repeat length that is
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pathogenic in humans (Lin et al., 2001; Shelbourne et al., 1999) or generating a 
hybrid gene in which the human exon 1 containing expanded CAG repeats replaces 
the mouse exon 1 (Levine et al., 1999; Wheeler et al., 2000). These “knock-in” mice 
express between 50 and 150 CAG repeats; however, only one line with 150 CAG 
repeats developed a clear progressive neurological phenotype (Lin et al., 2001). 
Comparing the mouse models to date reveals the difficulties to model a disease with 
onset in mid-life in an animal with a much shorter life span than humans. The R6/2 
model accelerates the manifestation of the disease in two ways: it uses very long 
CAG repeat lengths that in humans are associated with a young onset of the 
disease; and it uses N-terminal fragments of human huntingtin which may bypass 
the initial step of the pathophysiology (see section 4.1.5.) and lead to an earlier 
onset of the disease. On the other hand, this may also be associated with a 
phenotype and pathological changes that are different from the human disease. A 
model expressing the full-length mouse huntingtin gene manipulated using the 
“knock-in” approach is theoretically more likely to be a faithful model of HD; 
however, this approach seems so far less reliable in generating a mouse with an 
early onset of the phenotype.
4.1.8. Pathogenic mechanisms in HD
4.1.8.1. Genetic gain of function
Several lines of evidence suggest that the mutation in the huntingtin gene confers a 
toxic gain of function. Targeted disruption of the homologous mouse gene, either of 
exon 5 (Nasir et al., 1995), exon 4 (Duyao et al., 1995) or the promoter region 
(Zeitlin et al., 1995) revealed that mouse embryos with targeted disruption of both 
genes (nullizygous) were developmentally retarded and died in utero. This suggests 
that huntingtin is important for normal development. Heterozygous mice carrying 
one disrupted and one normal allele appeared normal (Nasir et al., 1995). However,
190
abnormalities were detected on specific tests of cognition and motor function similar 
to those animals with lesions in the striatum. This might indicate that huntingtin is 
particularly important for basal ganglia development (Nasir et al., 1995). The 
mutation does not inhibit transcription or translation since mutant huntingtin can be 
detected on Western blots of protein extracted from brain and peripheral tissue 
(Trottier et al., 1995a). This indicated that there is no loss of the protein or mRNA 
that could lead to subsequent cell dysfunction. Patients homozygous and 
heterozygous for the mutant huntingtin gene have an almost identical phenotype 
suggesting that the normal allele is not important (Wexler et al., 1987). It is therefore 
likely that the abnormal allele is responsible for a novel CAG-length-dependent 
feature leading to cell dysfunction and death of specific neuronal subpopulations. 
The gene product, mutant huntingtin with an expansion of polyglutamine repeats 
(polyQ), might in itself have toxic properties leading to impairment of important 
neuronal function such as ATP production, or it may interfere with the function of 
other specific proteins, e.g. transcription factors, thus indirectly affecting neuronal 
function (Figure 4.1.).
On the other hand, huntingtin was also shown to enhance the production of 
neurotrophic factors such as brain derived neurotrophic factor suggesting that it 
might also have a neuroprotective function (Cattaneo et al., 2001). In particular, it 
was shown that wild-type huntingtin inhibits apoptosis at the level of procaspase 9 
(Rigamonti et al., 2001). These authors demonstrated that huntingtin had no effect 
on cytochrome c release following proapoptotic insults but inhibited activation of 
procaspase 9 (Rigamonti et al., 2001). These downstream consequences for normal 
huntingtin function may be related to the interaction of mutant huntingtin with wild- 
type huntingtin, which can be sequestered into aggregates that had been seeded by 
mutant N-terminal fragments (Busch et al., 2003). Thus, a mutation in huntingtin 
may not only lead to a toxic gain of function but also to a loss of function.
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4.1.8.2. Formation and toxicity of polyQ aggregates
4.1.8.2.1. PolyQ aggregate formation
Analysing the structure of polyglutamine peptides Perutz demonstrated that 
polyglutamines are able to form p-pleated sheets. These sheets in turn can link 
together to form a polar zipper structure, which gains in stability with longer 
polyglutamine repeat length (Perutz, 1995; Perutz et al., 1994). In support of this 
concept, in vitro studies with recombinant N-terminal huntingtin fragments revealed 
aggregate formation with polyQ size in the pathological range (51 -122) but not in the 
normal range (20 and 30 repeats) (Scherzinger et al., 1997). Electron microscopy 
showed that aggregates had a fibrillar structure similar to p-amyloid (Scherzinger et 
al., 1997). In addition, Scherzinger et al demonstrated that the formation of these 
aggregates critically depended upon protein concentration and incubation time; in a 
self-initiated process aggregate formation depended upon the formation of a nucleus 
that serves as a seed for aggregate propagation (Lansbury, 1997; Scherzinger et 
al., 1997).
PolyQ aggregates were subsequently described in vivo. Nuclear and 
extranuclear (in neuronal processes and axonal terminals) huntingtin aggregates 
have been found in brains of HD patients and R6/2 HD transgenic mice (Davies et 
al., 1997; DiFiglia et al., 1997; Gutekunst et al., 1999; Li et al., 1999; Schilling et al.,
1999). In addition, a number of studies provided evidence that the number of 
aggregates formed correlated with the severity of the disease phenotype. In the 
cortex of HD patients the number of aggregates correlated with CAG repeat number, 
which has been used as an approximate measure for disease severity (Becher et 
al., 1998). In R6/2 HD transgenic mice the formation of neuronal intranuclear 
huntingtin aggregates preceded clinical manifestation of a movement disorder 
(Davies et al., 1997); aggregate formation was also found to be associated with cell 
death in HEK293 and neuroblastoma cell culture models of HD (Cooper et al., 1998;
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Martindale et al., 1998), and the association of aggregate formation and neuronal 
loss was observed in other CAG repeat disorders (Ellerby et al., 1999; Paulson et 
al., 1997; Sato et al., 1999).
Toxic fibrillar aggregates can form from non-pathogenic polyQ repeat lenghts 
(Perutz et al., 1994; Scherzinger et al., 1999; Yang et al., 2002). In vitro the initiation 
of aggregate formation was found to depend upon a critical concentration of polyQ 
containing aggregate precursor and was associated with a lag time (Chen et al.,
2002). Thus, it is conceivable that it is the polyQ size that determines the likelihood 
that aggregates form within an individuals’ lifespan, and, hence, whether the 
individual will have the disease (pathological polyQ size) or not (non-pathological 
polyQ size). In addition, other factors influencing the concentration of huntingtin, and 
the length of time that huntingtin is free in the cytoplasm, and thus prone to 
aggregation, might also contribute to aggregate formation.
4.1.8.2.2. Huntingtin aggregates: full-length versus N-terminal fragment
In HD patients nuclear and cytoplasmic aggregates were shown to contain only N- 
terminal fragments (DiFiglia et al., 1997). A number of HD models, both cell culture 
and animal, have indicated that truncated polyQ fragments may be more toxic than 
the full-length protein (Davies et al., 1997; Hackam et al., 1998; Hodgson et al.,
1999; Reddy et al., 1998; Schilling et al., 1999). The R6/2 HD mouse model 
contains a very short N-terminal huntingtin fragment (exon 1) causing a marked 
disease phenotype and neuropathological changes (see section 4.1.7.). This 
contrasts to a transgenic mouse with full-length huntingtin transgene where animals 
had a later onset of symptoms and survived longer (Reddy et al., 1998) and the 
more diffuse cytoplasmic huntingtin staining in normal human brain (DiFiglia et al., 
1995; DiFiglia et al., 1997; Sharp et al., 1995). It would thus appear that indeed N- 
terminal huntingtin fragments are of paramount importance to the formation of
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aggregates, possibly by forming a seed with subsequent nucleation-dependent 
aggregate formation as discussed above.
The hypthesis of N-terminal fragments as central to the generation of 
aggregates in HD would imply that mutated huntingtin was more readily cleaved 
than wild-type huntingtin. The results of a recent study that examined huntingtin 
protein from patients with HD, transgenic HD mice and cell culture models of HD 
questioned this view (Dyer and McMurray, 2001). This study revealed that in vitro 
mutant huntingtin was more resistant to proteolysis than wild-type. In addition, N- 
terminal cleavage products were found to result from cleavage of normal huntingtin, 
and not the mutant form, but were then sequestered by mutant huntingtin (Dyer and 
McMurray, 2001). These results indicated that the consequences of mutant 
huntingtin expression may extend beyond those known to be caused by expression 
of N-terminal fragments alone.
4.1.8.2.3. Huntingtin aggregates: nuclear versus cytoplasmic toxicity
Nuclear polyQ aggregates represent a typical pathological feature of HD that is 
observed both in the nucleus and in the cytoplasm, and in particular in neurites and 
axonal terminals. It is not clear whether the nuclear or the cytoplasmic localisation of 
aggregates is more relevant to HD pathogenesis.
Recent cell culture studies have re-examined the issue of polyQ aggregate 
toxicity (Chen et al., 2001; Chen and Wetzel, 2001; Yang et al., 2002). In these 
studies, polyQ peptides (either Q20 or Q40) were constructed with two lysine 
residues to confer solubility and a fluorescence tag at the N-terminus to enable 
visualisation. In vitro, both polypeptides could be induced to form fibrillar aggregates 
after cold shock and at high concentrations. These aggregates were readily taken 
up by cultured cells in which they were localised in the cytoplasm. In order to 
examine the relevance of localisation of aggregates the polyQ peptides were fitted
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with a nuclear localisation signal. Aggregates from these modified polyQ peptides 
passed the nuclear membrane and entered the nucleus. Irrespective of the original 
polyQ repeat length, aggregates caused substantial cell death when directed to the 
nucleus but were not toxic when present in the cytoplasm. Control experiments 
using preformed aggregates from bacterial cold-shock protein showed that 
aggregates also entered the nucleus but were not toxic. These experiments illustrate 
that polyQ aggregates are toxic within the nucleus, regardless of whether they 
formed from normal polyQ or pathogenic polyQ repeat length, but that the polyQ 
sequence is not required for entry into the nucleus.
As discussed in section 4.1.8.2.1., in addition to nuclear aggregates there is 
convincing evidence for huntingtin aggregates in neuronal processes and axonal 
terminals. In HD brains neuropil aggregates were more common than nuclear 
aggregates and were abundantly present before the onset of symptoms (Gutekunst 
et al., 1999). It is possible that neuropil aggregates precede dystrophic neurites, 
which are both observed as the disease progresses (DiFiglia et al., 1997). Neuropil 
aggregates correlated with disease severity in R6/2 transgenic mice (Li et al., 1999) 
and full-length huntingtin expression in mice resulted in neuropil aggregates and 
axonal degeneration in early stages of disease (Li et al., 2001). Aggregate formation 
in neurites and neuropil could lead to pathological interactions with cytoplasmic 
huntingtin-interacting proteins (see section 4.1.4., Figure 4.1.) as these could 
become sequestered within polyQ aggregates. These interacting proteins, e.g. HIP1 
or HAP1, are involved in endocytosis, vescle trafficking and recycling, as well as 
microtubule-dependent transport and neuronal survival (Engelender et al., 1997; Li 
et al., 1998b; Li et al., 2002; Marcora et al., 2003). These functions may be 
compromised as an indirect consequence of cytoplasmic inclusion formation 
possibly leading to impaired synaptic function including neurotransmitter release
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(Figure 4.1.). This may cause e.g. excitotoxicity due to abnormal glutamate 
homoeostasis (Cepeda et al., 2001; Li et al., 2003).
4.1.8.2.4. Huntingtin aggregates: unresolved issues
Taken together there is now good evidence to suggest that aggregates are indeed 
toxic and that there is a close link between aggregate formation and pathogenesis. 
On the other hand, in cultured striatal neurones transfected with mutant full-length 
huntingtin, cytoplasmic aggregate formation was inversely related to cell death 
casting doubt upon a causal role for huntingtin aggregate formation in the 
pathogenesis of HD (Saudou et al., 1998). This raises the question whether 
aggregate formation always has to be toxic or whether it can be protective.
It remains unclear whether aggregate formation in vivo is initiated by the 
generation of N-terminal fragments of mutant huntingtin since there is evidence to 
suggest that mutant huntingtin may actually be more resistant to cleavage. 
Alternatively, the N-terminal fragment from normal huntingtin proteolysis could 
sequester full-length mutant huntingtin. Huntingtin aggregates form in the nucleus 
and the cytoplasm (Figure 4.1.). There is evidence indicating that both these 
aggregate localisations have downstream consequences presumable via the 
interaction with transcription factors or synaptic proteins respectively. It is not clear 
whether nuclear or cytoplasmic aggregates cause more neuronal damage, or 
whether neurones degenerate as a consequence of a mixture of both (Figure 4.1.).
There are several more unresolved issues regarding aggregate formation. 
One relates to the size the inclusions have to reach in order to be toxic, i.e. whether 
they have to be visible by light microscopy or not. Recent studies have described 
polyQ protofibrils as possible precursors of mature fibrils (Poirier et al., 2002) and, 
using a novel technique, huntingtin aggregates that were not detected using light 
microscopy were found within numerous so called aggregation foci in post mortem
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HD brains but not in control brains (Osmond et al., 2002). Another important 
question is whether aggregates have to form in the neurones that are most 
susceptible to cell death, i.e. in the striatum. In HD brains more aggregates have 
been described in the cerebral cortex than in the striatum (DiFiglia et al., 1997; 
Gutekunst et al., 1999). If aggregates caused the cells in which they form to die one 
would expect more cell death in the cerebral cortex than in the striatum. It is 
possible that aggregates distinct from those detected by immunohistochemistry play 
a greater role (as discussed above) or that synaptic dysfunction leads to functional 
consequences downstream of the affected neurone (Figure 4.1.).
4.1.8.2.5. The effect of aggregate prevention
As discussed above there is evidence to suggest that the formation of huntingtin 
aggregates is toxic and is correlated to disease progression. Thus treatment to 
prevent aggregate formation or enhance aggregate removal could be beneficial in 
HD. In in vitro models several studies investigated whether such treatment had an 
effect on the disease phenotype. Treatment of R6/2 HD transgenic mice with 
caspase-1 inhibitors reduced aggregate formation, and this was associated with 
improvements in the disease phenotype (Chen et al., 2000; Ona et al., 1999); other 
treatments, all of which reduced aggregate load and improved the phenotype, 
consisted of switching-off the mutant huntingtin transgene in mice expressing a 
tetracyclin regulatable mutant huntingtin fragment (Yamamoto et al., 2000), 
inhibition of aggregate formation with Congo red in a HD mouse model (Sanchez et 
al., 2003), or the expression of anti-aggregation peptides in a Drosophila model of 
polyQ disease (Kazantsev et al., 2002). These results indicated that prevention of 
aggregate formation or removal of existing aggregates can improve the phenotype 
in transgenic animal models of HD, which suggests that these aggregates were 
toxic. However, it is not known whether similar treatment of patients with HD would
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have such an effect. There may be important species differences, and, in addition, 
some of the mouse models contained human N-terminal huntingtin fragments rather 
than the full-length mutant huntingtin that is present in humans. Dispite these 
reservations the results in these animal models are encouraging for the quest to find 
treatment for patients with HD.
4.1.8.2.6. Extraneuronal aggregate formation
The presence of huntingtin aggregates in non-neuronal tissues has not been 
systematically investigated in patients with HD. In SBMA, another CAG repeat 
disorder intranuclear aggregates of androgen receptor protein were observed in 
skin, heart, testis and kidney but not in spleen, liver or muscle (Li et al., 1998a). In 
the R6/2 transgenic mouse model of HD, nuclear inclusions were described in 
cardiac and skeletal muscle, kidney, liver, adrenal glands and pancreas 
(Sathasivam et al., 1999). In muscle, the occurrence of inclusions correlated with the 
onset of muscle atrophy. Further histochemical analysis of muscle sections from 
animals with end stage disease revealed a reduction in muscle fibre diameters 
compared with control littermates but no evidence to suggest an underlying 
myopathic or neuropathic process (Sathasivam et al., 1999). In the R6/2 mouse 
these findings indicate that in tissues other than brain that express the human 
transgene the critical concentrations of polyQ for aggregate formation are present.
In addition, what seems to be important for causing neurones to die, namely nuclear 
localisation of huntingtin fragment aggregates, is also observed within extraneuronal 
tissues, in particular muscle. Since the CAG size in the R6/2 mouse exceeds that of 
even juvenile onset human HD cases it remains unknown whether the findings in the 
mouse model will be reproduced in human HD patients.
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4.1.9. Programmed cell death
In HD transgenic mouse models, both the R6/2 (Mangiarini et al., 1996) and full- 
length huntingtin models (Reddy et al., 1998), neuronal cell death was found to 
involve apoptotic pathways. The caspase family of proteases (cysteine-dependent, 
aspartate-specific proteases) play a major role in the execution of apoptosis 
(Alnemri et al., 1996; Hengartner, 2000). A number of studies provide evidence for 
an involvement of caspases in HD. Transcriptional caspase-1 gene up-regulation 
was described early in the HD disease process (Ona et al., 1999); this may be the 
result of nuclear translocation of N-terminal fragments of mutant huntingtin (Li et al., 
2000b). There is evidence to suggest that later on this could be followed by 
increased transcription of the caspase-3 gene with subsequent activation of the 
caspase-3 protein (Chen et al., 2000). Huntingtin itself was found to be a substrate 
of caspase-1 and caspase-3 (Goldberg et al., 1996; Wellington et al., 1998) with 
subsequent huntingtin cleavage and the generation of huntingtin fragments (Ona et 
al., 1999) (Figure 4.1.). Since huntingtin fragments enter the nucleus this may in turn 
maintain up-regulation of caspase-1 and caspase-3 activation but may also deplete 
the available huntingtin (Chen et al., 2000; Ona et al., 1999; Rigamonti et al., 2000; 
Rigamonti et al., 2001; Zuccato et al., 2001) with a subsequent loss of huntingtin 
function.
Several findings in mouse models of HD have been reproduced in human 
HD brains. In striatum of HD patients activation of caspases 1, 3, 8 and 9 as well as 
the release of cytochrome c from mitochondria has also been documented (Kiechle 
et al., 2002; Ona et al., 1999; Sanchez et al., 1999) (Figure 4.1.).
4.1.10. Mitochondrial involvement and impairment of energy metabolism
Evidence for mitochondrial involvement in HD comes from post mortem, in vivo and 
in vitro studies (Figure 4.1.). A defect in mitochondrial respiratory chain complex II
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and III was found in putamen and caudate with an additional complex IV defect in 
putamen in HD brains (Browne et al., 1997; Gu et al., 1996; Mann et al., 1990; 
Tabrizi et al., 1999). Further support for the hypothesis that complex II and III of the 
mitochondrial respiratory chain might be selectively affected came from animal 
models of HD using complex II inhibitors 3-nitropropionic acid or malonate (Beal et 
al., 1993; Brouillet and Hantraye, 1995; Brouillet et al., 1995). In addition, striatal 
cells derived from a knock-in mouse model of HD were found to be more vulnerable 
to 3-nitropropionic acid than the selective complex I inhibitor rotenone (Ruan et al.,
2004). In the same study some evidence suggested that mitochondria’s calcium 
handling might be compromised in accord with data from HD patient lymphoblasts 
(Panov et al., 2002). Furthermore, there were indications for impaired cerebral 
energy metabolism (Koroshetz et al., 1997), and elevated lactate levels correlating 
with CAG repeat length were reported in HD occipital cortex and striatum (Jenkins et 
al., 1998).
A few studies examined respiratory chain function in extraneuronal tissues.
In HD muscle, a decrease in complex I activity was found in the biopsies of three 
patient (Arenas et al., 1998) whereas mitochondrial respiratory chain activities were 
normal in HD platelets (Gu et al., 1996) and fibroblasts (Tabrizi et al., 1999). HD 
lymphoblasts showed increased sensitivity of mitochondrial membrane 
depolarisation and MTP-opening to cyanide, a complex IV inhibitor, and the 
apoptosis inducing agent staurosporine (Sawa et al., 1999). This indicates that the 
underlying disease mechanism in HD may render mitochondria more vulnerable to 
exogenous mitochondrial toxins. Taken together these results suggest that in 
extraneuronal tissues there is less complex II or III deficiency compared to the brain 
but rather a reduction, or increased sensitivity to toxins, of complex I or IV. 
Interestingly, 31P magnetic resonance spectroscopy revealed a reduced ratio of 
phosphocreatine to inorganic phosphate in symptomatic HD patients both at rest
200
and in the recovery period after exercise (Lodi et al., 2000). This suggests that 
mitochondrial respiratory chain dysfunction at a molecular level may be mirrored by 
the deficit in in vivo mitochondrial oxidative metabolism as shown by Lodi and 
colleagues (Lodi et al., 2000).
4.1.11. Oxidative stress and excitotoxicity
HD brains and HD models have been investigated for evidence of oxidative stress 
and excitotoxicity. In HD patients oxidative damage was found in mtDNA in human 
HD parietal but not frontal cortex or cerebellum (Polidori et al., 1999) (Figure 4.1.); 
however, another study failed to document oxidative damage to lipids, proteins or 
DNA in caudate, putamen and frontal cortex in 10 HD patients (Alam et al., 2000). 
Most of the evidence to support the involvement of oxidative stress in HD comes 
form HD models. Increased lipid peroxidation was observed in striatum of the R6/1 
huntingtin transgenic mice with 116 CAG repeats (Perez-Severiano et al., 2000). 
Isolated striatal and cortical synaptosomes of rat brains treated with the complex II 
inhibitor 3-nitropropionic acid (3-NP) showed decreased oxidative damage with free 
radical scavengers suggesting that 3-NP caused striatal degeneration involved 
oxidative stress (La Fontaine et al., 2000).
There is also evidence for increased nitration in HD mouse models 
suggestive of excitotoxicity (Tabrizi et al., 2000b). Huntingtin was found to interact 
with a protein called postsynaptic density protein 95 (PSD-95) that modulates the 
arrangement and the activity of postsynaptic receptors. Mutant huntingtin interacted 
less with PSD-95; this enhanced the sensitivity of NMDA and kainate receptors, 
which may promote receptor activity and could cause excitotoxic damage as a 
consequence (Sun et al., 2001) (Figure 4.1.). An NMDA receptor antagonist and 
over-expression of normal huntingtin ameliorated this (Sun et al., 2001). This 
hypothesis is supported by in vitro findings in HEK293 cells transfected with both
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mutant huntingtin and NMDA receptors that were more susceptible to NMDA 
exposure than controls (Zeron et al., 2001), and electrophysiological studies in HD 
mouse models, which revealed altered synaptic activity and an increase in NMDA 
glutamate receptor activity (Cepeda et al., 2001; Zeron et al., 2002). Within neurites 
mutant huntingtin might interfere with glutamate uptake into vesicles thus increasing 
cytoplasmic glutamate levels and the risk to incur excitotoxic damage (Li et al., 
2000a; Li et al., 2003) (Figure 4.1.).
Figure 4.1. Possible relationship of disease mechanisms in HD. Much of how the 
pieces of the pathogenetic puzzle fit together in HD remains speculative. Normal 
huntingtin seems to be predominantly cytoplasmic possibly associated with the 
cytoskeleton, and vesicle transport and function. It is likely subject to processing in 
the cytoplasm leading to the generation of huntingtin fragments. Extended CAG 
repeat sequences translate into a mutant protein with excessive polyQ repeats that 
render huntingtin or in particular its N-terminal fragments more prone to the 
assumption of a (3-pleated sheet structure, and subsequent aggregate formation. 
Aggregate formation can take place in the cytoplasm or in the nucleus. In the 
cytoplasm this may lead to a toxic gain of function either through the full-length 
protein or the N-terminal fragment including the activation of the caspase cascade, 
interference with mitochondrial function and excitotoxicity, or depletion of functional 
normal huntingtin. Within the nucleus, mutant huntingtin and aggregates very likely 
interfere with gene transcription thus exerting a deleterious effect on neurones, and 
possibly other extreneuronal tissues. This may affect cell function, e.g. of cells 
harbouring aggregates in the cerebral cortex. This may lead to abnormal stimulation 
of striatal cells, possibly involving excitotoxicity, or to a decrease in the delivery of 
trophic factors with subsequent damage to striatal cells.
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4.2. Rationale and aim
Ubiquitinated huntigtin inclusions are a common feature in HD and R6/2 transgenic 
mouse cells. The formation of huntingtin aggregates has been suggested to play an 
important pathological role but the factors that influence huntingtin aggregate 
formation in postmitotic cells is not understood. Huntingtin aggregates have been 
observed in skeletal muscle of the R6/2 transgenic mouse model it was 
hypothesised that huntingtin inclusion formation may be a feature of myoblast 
cultures from these animals. Furthermore, differentiation into postmitotic myotubes 
may serve as a useful postmitotic model to investigate the biochemical mechanisms 
downstream of mutant huntingtin expression, which influence huntingtin inclusion 
body formation.
It was the aim of this work to establish myoblast cultures from R6/2 and littermate 
control mice and to differentiate them into myotubes. The R6/2 transgenic mouse 
model was used as a model of N-terminal huntingtin expression to study inclusion 
formation in myoblasts and differentiated myotubes. This study further investigated 
which factors might modify inclusion formation, and it examined downstream 
consequences of N-terminal huntingtin over-expression and inclusion formation.
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4.3. Results
4.3.1. Analysis of R6/2 myoblast cultures
Myoblast cultures were freshly established from 12-week-old R6/2 mice and 
littermate controls as described (see section 2.2.4.). Myoblasts were plated onto 
glass coverslips coated with laminin; in preliminary experiments to optimise culture 
conditions laminin coating was found to facilitate myoblast growth better than gelatin 
(2% (v/v in PBS) or collagen (data not shown). After one week in culture cells 
reached about 60% confluency, and after around 10 days the cultures were over­
confluent. Therefore, after 1 week in culture growth medium was replaced by 
differentiation medium to induce myotube formation. Myotubes were detected using 
morphological criteria (multinucleated syncithium as the result of myoblast fusion). 
This was confirmed by staining the cultures with an antibody against desmin, the 
intermediate filament specific of muscle cells (Figure 4.2A, C, E, G, I, J).
4.3.2. Myoblast and myotube culture
Within the first week in growth medium (data not shown) and after one week in 
differentiation medium, double labelling indicated that desmin positive cells 
(myoblasts and myotubes) from both control (Figure 4.2A) and R6/2 (Figure 4.2C) 
cultures immunostained intensely for huntingtin (Figure 4.2B and D respectively), 
while huntingtin immunoreactivity was very weak in desmin negative cells (Figure 
4.2B and D). However, because the anti huntingtin antibody recognised both mouse 
and human huntingtin it was not possible to distinguish between the truncated 
human and the normal mouse huntingtin in the R6/2 cultures. The intensity of 
huntingtin staining in the myotubes diminished with increasing time post fusion, so 
that after 4 weeks in differentiation medium, huntingtin immunoreactivity was similar 
in desmin positive and desmin negative cells (Figure 4.2E, F and Figure 4.2G, H for 
control and R6/2 respectively).
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Qualitatively it was clear that in all cultures established there were 
consistently more myotubes in the R6/2 cultures (Figure 4.2J) than the controls 
(Figure 4.21). Semi-quantitative assessment of the cultures after 1 week in 
differentiation medium confirmed that the number of desmin positive cells 
(myoblasts and myotubes) in the R6/2 cultures was consistently greater than in the 
control cultures (Mann-Whitney U-test, p<0.0001; Figure 4.3A). Flowever, the total 
number of cells in each culture did not differ significantly between control and R6/2 
cultures (Figure 4.3B). In addition, desmin positive cells in the R6/2 cultures 
contained significantly more nuclei compared to control cultures (Mann-Whitney U- 
test, p=0.0011; Figure 4.3C).
Cytoplasmic inclusions positive for ubiquitin (Figure 4.2K) and huntingtin 
(Figure 4.2L) were observed in R6/2 but not control cultures (Figure 4.2M and N) 
after 3 weeks in differentiation medium, but only in non-myotube cells. Qualitatively, 
the incidence of these cytoplasmic inclusions was relatively static between 3 and 6 
weeks following differentiation.
After 6 weeks in differentiation medium dual labelling revealed nuclear 
inclusions immunoreactive for ubiquitin (Figure 4.20) and huntingtin (Figure 4.2P) in 
less than 10% ofR6/2 myotubes as assessed semi-quantitatively (mean 7.8; range 
6.7-8%), but not control myotubes (Figure 4.2M, N). However, nuclear inclusions 
were not observed in all the nuclei within a positive myotube (Figure 4.20). Nuclear 
inclusions staining positively for both huntingtin and ubiquitin were also occasionally 
observed in groups of desmin negative cells in R6/2 cultures (Figure 4.2Q, 1R), and 
occasionally multiple nuclear inclusions were present in a single nucleus (Figure 
4.2S, T). Occasionally vacuoles were observed in desmin negative cells, which grew 
in larger clusters (Figure 4.2U) and showed intense extra nuclear huntingtin 
immunoreactivity (Figure 4.2V).
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When the cultures were grown in serum free medium, after 6 weeks virtually 
all the myotubes and all their nuclei showed huntingtin (Figure 4.2W) and ubiquitin 
(Figure 4.2X) positive nuclear aggregates as assessed semi-quantitatively (mean 
92; range 89-96%). In addition, the number of non-myotube cells harbouring nuclear 
inclusions was increased (Figure 4.2W). However, cytoplasmic inclusions were less 
frequent (Figure 4.2W).
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Figure 4.2. Immunocytochemistry of myoblasts and myotubes of R6/2 mouse and 
control muscle cultures. Myoblast differentiation and inclusion body formation in 
control (A, B, E, F, I, M, N) and R6/2 (C, D, G, H, J, K, L, O - X) myoblast cultures. 
Cultures were immunostained for desmin (A, C, E, G, I, J, U, green staining), 
huntingtin (B, D, F, H, K, M, O, Q, S, V, W, red staining) or ubiquitin (L, N, P, R, T,
X, green staining). Nuclei were stained with DAPI (blue). Cultures were grown in 
differentiation medium (A -V) or serum free medium (W, X) for 1 week (A, D, I, J), 4 
weeks (E-H, U, V) or 6 weeks (K-T, W, X).
After 1 week of culture in differentiation medium, myoblasts and myotubes in 
both control and R6/2 cultures stained positively for desmin (green staining, A and C 
respectively, arrows) and strongly for huntingtin (red staining, B and D respectively, 
arrow). There was no detectable huntingtin staining in desmin negative cells (A-D, 
arrow heads). However after 4 weeks in culture huntingtin immunoreactivity 
diminished markedly in both control (F) and R6/2 cultures (H), while desmin 
immunoreactivity remained very clear (E and G). The number of desmin positive 
myoblasts and myotubes was qualitatively greater in R6/2 (J) than the control (I) 
cultures.
In R6/2 cultures cytoplasmic inclusions immunoreacted with huntingtin (K) 
and ubiquitin (L) following 3 weeks in differentiation medium. No cytoplasmic or 
nuclear inclusions were observed at any time in controls (M and N). After 6 weeks of 
culture, R6/2 myotubes showed single nuclear inclusions positive for huntingtin (O, 
pink, arrow) and ubiquitin (P, white, arrow). After 6 weeks in culture occasional, 
groups of non-myotube cells exhibited single nuclear inclusions with huntingtin (Q) 
and ubiquitin (R) cross-reactivity. Some individual non-myotube cells exhibited 
multiple nuclear inclusions positive for huntingtin (S) and ubiquitin (T). After 2 weeks 
of culture, clusters of desmin negative cells (U, arrows) showed cytoplasmic 
vacuoles and stained intensely for huntingtin (V, arrows).
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Culture in serum-free medium enhanced the formation of huntingtin (W) and 
ubiquitin (X) positive nuclear inclusions in both myotubes and non-myotube groups 
of cells (W and X arrows). Cytoplasmic huntingtin (W, arrow head) and ubiquitin (X, 
arrow head) positive inclusions were infrequently present. Scale bar: 20 pm in A-F, 
M, N, U-X; 50pm in G-J and 10pm in K, L and O-T.
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Figure 4.3. Semi-quantitative analysis of control and R6/2 myoblast cultures. Cells 
were immunostained for desmin and co stained with the nuclear dye DAPI to 
determine cell numbers after 2 weeks of culture in differentiation medium. A. The 
number of desmin positive cells was greater in R6/2 cultures than in controls (solid
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bar versus open bar, *p<0.0001, Mann-Whitney U test, see section 2.12.). B. 
Comparison of the total number of nuclei revealed no statistical difference between 
controls (open bars) and R6/2 cultures (solid bars). C. The number of nuclei per 
myotube / myoblast was increased in the R6/2 (solid bars) muscle cultures in 
comparison with the control cultures (open bars) (solid versus open bar, *p=0.0011, 
Mann-Whitney U test). Values are expressed as means ±SEM. N=4 representative 
areas were evaluated on a cover-slip in each of n=3 control and n=3 R6/2 myoblast 
cultures.
4.4. Discussion
4.4.1. Huntingtin immunostaining
In both control and R6/2 mouse muscle cultures high levels of huntingtin 
immunoreactivity were apparent in the first weeks after the addition of differentiation 
medium. Only a proportion of cells immunoreacted with the huntingtin antibody; 
these cells were predominantly multi-nucleated myotubes but the occasional 
myoblast could be identified. It was not possible to distinguish between the mouse 
and human protein using immunocytochemical staining; however, the intensity of 
huntingtin staining in individual cells and the localisation of huntingtin 
immunoreactivity to the cytoplasm was similar in the control and R6/2 cultures.
While this suggests that protein levels in those cells expressing the mutant human 
transgene, i.e. R6/2 cultures, were similar to the control cells that expressed the 
mouse huntingtin gene alone this does not allow a comparison of gene expression 
levels or a quantitative comparison of huntingtin protein levels. In order to draw 
these comparisons mRNA studies, and Western blot respectively, would have been 
useful. However, this was not possible in these cultures since they did not contain a 
homogenous population of cells that all immunoreacted with the huntingtin antibody. 
Thus the results of any such analysis would have been derived from a sample with a
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mixture of different cells of which only a proportion would have stained huntingtin 
positive. This would have made these results very difficult to interprete.
4.4.2. Huntingtin and myotube differentiation
In both the cell cultures form the R6/2 transgenic mice and the control cultures 
huntingtin immunoreactivity was observed in cells that also stained with a desmin 
antibody. The intermediate filament desmin is expressed in conjunction with muscle- 
specific gene products, such as myogenin and myoD (Weintraub, 1993), and serves 
as an indicator for the maturity of cells growing in the myoblast cultures (Bennett et 
al., 1979). Concomitant desmin expression indicated that huntingtin was specifically 
expressed in differentiating myoblasts and myotubes. Further support for the 
association of huntingtin with myoblast differentiation was derived from the 
differential intensity of huntingtin immunostaining overtime. Immunostaining for 
huntingtin was very intense within the first two weeks of culture and thereafter 
decreased in intensity. Thus more huntingtin protein was likely present within 
myoblast and myotubes at the time of differentiation after which levels declined. This 
might indicate that huntingtin plays a role in the differentiation process of muscle. In 
accord with a possible role of huntingtin in differentiation huntingtin has been shown 
to be important for haematopoiesis (Metzler et al., 2000), and knock-out of the 
huntingtin gene in mice was found to be lethal in utero (Zeitlin et al., 1995). This 
suggests huntingtin may have a more general role in cell maturation. However, how 
precisely huntingtin regulates differentiation, and whether there are differences 
between cell types, remains unknown.
At the level of the individual cell the association of huntingtin staining with 
desmin immunoreactivity did not differ between cell cultures derived from the R6/2 
mice or those from control mice, and the time course of the intensity of huntingtin 
staining was similar. However, the number of desmin positive myotubes was
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consistently greater in the R6/2 cultures compared to the control cultures. Since the 
R6/2 derived myoblast cultures differed from the controls in the expression of the 
human N-terminal huntingtin transgene this suggests that increased expression of 
the N-terminal human huntingtin transgene may have promoted myoblast 
differentiation. It is likely that mutant huntingtin associated promotion of myotube 
differentiation was due to a gain of function and not to a loss of normal huntingtin 
function. This is supported by a report showing that targeted inactivation of 
huntingtin in forebrain and testis of mice resulted in neurodegeneration of this brain 
area and sterility (Dragatsis et al., 2000). However, it is not clear whether this effect 
was due to the expanded CAG repeats in the N-terminal human huntingtin 
transgene or due to the expression of the human transgene per se irrespective of 
the mutation. This question could have been addressed in myoblast cultures from 
control mice containing the wild-type human N-terminal huntingtin transgene; 
however, since such animals were not available this was not possible in the context 
of this thesis.
The function of huntingtin remains incompletely understood. Huntingtin is 
expressed ubiquitously in both the central nervous system and peripheral tissues 
(Trattier et al., 1995b) suggesting it has a general housekeeping role. In human and 
rat brains huntingtin has been associated with neuronal vesicles, and has been 
suggested to be involved in endocytosis, vesicle trafficking and microtubules as well 
as the regulation of transcriptional activity (DiFiglia et al., 1995; Gutekunst et al., 
1995; Sharp et al., 1995; Velier et al., 1998). Huntingtin undergoes proteolysis, 
which generates N-terminal fragments that presumably can diffuse freely into the 
nucleus (see section 4.1.5.). Huntingtin has also been shown to interact with 
numerous proteins including proteins involved in gene transcription, intracellular 
trafficking and vesicle function (for a review see Li and Li, 2004). The N-terminal
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region of huntingtin seems to bind many of these proteins, and the length of the 
polyQ repeat can modify the affinity of huntingtin to the interacting proteins.
It is not known if this includes proteins that are relevant for myoblast 
differentiation. Abnormal polyQ repeat length in R6/2 derived myoblast cultures may 
have altered the affinity of huntingtin to its interacting proteins including myoblast 
differentiation proteins thus facilitating myotube differentiation. However, since the 
control myoblast cultures expressed full-length normal mouse huntingtin it is not 
clear whether the enhancement of myotube formation in the R6/2 mouse myoblast 
cultures was due to the extended polyQ size or the fact that N-terminal huntingtin 
fragments were over-expressed. N-terminal fragments can freely diffuse into the 
nucleus whereas full-length huntingtin remains in the cytoplasm. If the effect of N- 
terminal huntingtin fragments on myotube differentiation was mediated by 
interactions in the nucleus this could explain the observation that full-length mutant 
huntingtin presumably in the cytoplasm disrupted cellular signalling mediated by 
epithelial growth factor and nerve growth factor receptors in PC-12 cells thus 
blocking neuronal differentiation (Song et al., 2002). In support of this hypothesis 
mutant huntingtin was found to be more resistant to proteolysis, which would mean 
that less N-terminal fragments are generated (Dyer and McMurray, 2001). How this 
relates to R6/2 transgenic mice and the loss of muscle bulk in these animals 
remains unclear.
4.4.3. Inclusion formation
In HD patients, striatal medium spinal neurones degenerate relatively selectively, 
and both patient and HD transgenic mice brains exhibit nuclear and cytoplasmic 
polyQ aggregates (Davies et al., 1997; DiFiglia et al., 1997; Gutekunst et al., 1999;
Li et al., 1999; Schilling et al., 1999). There is evidence to suggest that these polyQ 
inclusions are toxic (see section 4.1.8.2.) but a number of issues regarding their
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localisation (nuclear versus cytoplasmic), their composition (N-terminal fragments 
versus full-length huntingtin) and their impact on neuronal function remain 
unresolved (see section 4.1.8.2.4.). In HD, it is not known whether PolyQ 
aggregates form in extraneuronal tissues. In SBMA, an X-linked CAG repeat 
disorder, androgen receptor aggregates were observed in skin, heart, testis and 
kidney but not in spleen, liver or muscle (Li et al., 1998a). However, muscle atrophy 
is commonly observed in patients and HD transgenic mice, in particular in the later 
stages of the disease (Sathasivam et al., 1999). Muscle from R6/2 transgenic mice 
expressing the N-terminus of the human HD gene with more than 150 CAG repeats 
exhibited huntingtin intranuclear inclusions similar to those found in HD and R6/2 
brain tissue (Sathasivam et al., 1999). The role that these inclusions play in muscle 
remains unclear.
The presence of polyQ aggregates in muscle of R6/2 mice suggested that 
R6/2 myoblast cultures could be useful to study the role of huntingtin inclusions in 
postmitotic cells. The R6/2 transgenic mice model over-expression of human N- 
terminal huntingtin with large CAG repeat size (-145 repeats). This is a good model 
of HD in that it reproduces important pathological features of the human disease, in 
particular the formation of nuclear huntingtin inclusions, and a progressive 
neurological phenoty p including a movement disorder with early onset (Davies et al., 
1997; Mangiarini et al., 1996). A limitation of the model is that issues regarding the 
differential involvement of N-terminal fragments and full-length huntingtin cannot be 
easily addressed. In addition, there is no control mouse model available that 
expresses the wild-type human N-terminal transgene. This means that it is not 
possible to distinguish effects of over-expression of the mutation in the transgene 
form those due to over-expression of N-terminal fragments alone.
In R6/2 muscle cultures the presence of ubiquitin positive huntingtin 
aggregates was identified in a proportion of myotubes 6 weeks after differentiation
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but inclusions were absent in other cells present in the culture. Interestingly, this 
time course corresponded with the appearance of nuclear inclusions in brain and 
muscle of R6/2 mice (Davies et al., 1997; Sathasivam et al., 1999). The absence of 
nuclear inclusions in other cells present in the culture corresponds with the absence 
of inclusions in skin in the mouse model (Sathasivam et al., 1999). This suggests 
that pathogenetic events in R6/2 myotubes parallel those in fully differentiated R6/2 
mouse muscle and neuronal cells. Why nuclear inclusions formed only in myotubes 
is not clear. Myotubes differed from non-myotube cells in their level of huntingtin 
immunoreactivity suggesting that the formation of inclusions could be due to the 
relative higher concentration of mutant huntingtin in myotubes. This is in accord with 
concentration dependent initiation of aggregate formation in vitro (Chen et al., 2002). 
It is possible that in myotubes, but not in non-myotubes, the concentration of polyQ 
containing aggregate precursor exceeded the critical concentration needed to form 
aggregates (Chen et al., 2002).
Extra-nuclear ubiquitinated huntingtin aggregates were observed 3 weeks 
after the addition of differentiation medium, but only in desmin-negative cells. At 
earlier stages, similar looking cells exhibited large vacuoles. While vacuoles have 
been observed in fibroblast cultures from R6/2 mice (Sathasivam et al., 2001), no 
evidence of huntingtin inclusion formation was detected. It is possible that inclusions 
may have formed in the R6/2 fibroblasts with prolonged culture. In contrast to 
myotubes no nuclear inclusions were observed in those cells that contained 
cytoplasmic inclusions. In HD brains both nuclear and cytoplasmic inclusions occur 
(DiFiglia et al., 1997), and there is also support for synaptic dysfunction due to 
cytoplasmic aggregates (Cepeda et al., 2001; Li et al., 2000a; Zeron et al., 2001; 
Zeron et al., 2002). The vacuoles that were observed in non-myotube cells, and in 
fibroblasts, could therefore be a consequence of cell dysfunction due to cytoplasmic
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inclusion formation. It is possible that the disappearance of cells with vacuoles over 
time was due to the death of these cells. However, this remains speculative.
In the R6/2 myblast cultures cell death was not quantitatively assessed. 
Nonetheless, on microscopy there was no overt loss of cells over the 6 weeks of 
culture. In vitro evidence indicated that nuclear polyQ aggregates are toxic (Chen et 
al., 2001; Chen and Wetzel, 2001; Yang et al., 2002), so that a loss of cells 
containing inclusions could have been expected. The molecular mechanisms 
underlying HD pathogenesis are not completely understood. The presence of 
nuclear and cytoplasmic accumulation of mutant N-terminal huntingtin fragments is 
universally acknowledged, however, their role in disease pathogenesis remains 
controversial (Gutekunst et al., 1999; Li et al., 2000a; Wellington et al., 2000). There 
is considerable evidence suggesting huntingtin aggregate formation plays a direct 
role in the induction of cell dysfunction and death (as discussed in detail in the 
introduction to this chapter). However, in vitro evidence in cultured striatal neurones 
showed that while the translocation of N-terminal fragments to the nucleus induced 
apoptosis the degree of apoptosis depended on the ability of the cells to form 
nuclear inclusions suggesting that inclusion formation may also have a protective 
role (Saudou et al., 1998). In addition, full-length mutant huntingtin appears to be 
more resistant to proteolysis and was found to sequester N-terminal cleavage 
fragments from normal huntingtin within aggregates (Dyer and McMurray, 2001). In 
the R6/2 transgenic HD mouse huntingtin positive inclusions formed in neuronal 
nuclei and the neuropil in some brain areas before the age of 4 weeks (Davies et al., 
1997; Li et al., 1999). This is observed prior to neuronal death, which is not apparent 
under 14 weeks of age and limited to selected brain areas (Turmaine et al., 2000) 
suggesting a causal relationship between inclusion formation and neuronal death in 
this model.
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4.4.4. Serum deprivation enhanced inclusion formation
The modulation of aggregate formation can be promising as a treatment for patients 
with HD. Several studies in animal models of HD have shown that treatment 
consisting of caspase 1 inhibition (Chen et al., 2000; Ona et al., 1999), Congo-red 
(Sanchez et al., 2003), anti-aggregation peptides (Kazantsev et al., 2002), or by 
switching-off the mutant huntingtin gene (Yamamoto et al., 2000) can reduce 
aggregate formation and improve the phenotype of these animals. In addition, in 
cells transfected with expanded polyQ, huntingtin antibodies against the N-terminus 
of huntingtin have been shown to reduce aggregate formation (Lecerf et al., 2001), 
while aggregates were more frequent following inhibition of the proteasome (Jana et 
al., 2001; Wyttenbach et al., 2000).
Aggregate formation in R6/2 muscle cultures increased in response to stress 
inflicted by 6 weeks of serum deprivation. This is in agreement with the observation 
that serum deprivation increased aggregate formation in rat striatal cells (Wellington 
et al., 2000). It is possible that serum contains factors that protect against inclusion 
body formation or enhance their degradation, or that lack of serum induces 
pathways that lead to enhanced huntingtin transport into the nucleus and 
aggregation. Serum deprivation has been used as a model to induce apoptosis 
(Navas et al., 2002; Rukenstein et al., 1991), and mitochondrial membrane 
permeabilisation and oxidative stress have been reported as a consequence of 
serum deprivation in vitro (Colombaioni et al., 2002a; Colombaioni et al., 2002b; 
Joza et al., 2001; Navas et al., 2002; Pandey et al., 2003). Thus the stress conferred 
by serum deprivation may have increased the formation of huntingtin aggregates in 
the R6/2 myotubes. However, an increase in proteasome protease activity was also 
reported following serum deprivation in hepatocytes (Pandey et al., 2003). This is 
difficult to reconcile with the increase in aggregate formation observed in the R6/2 
myotubes and rat striatal cells (Wellington et al., 2000) since with an increase in
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proteasome activity more effective clearance of aggregates would be expected. 
However, it is possible that similar to cultured striatal neurones (Saudou et al., 1998) 
the formation of aggregates may have been protective to the R6/2 myotubes. This 
would be in agreement with the absence of gross cell death over the 6 weeks of 
serum deprivation.
4.5. Conclusion
In this thesis chapter it was demonstrated that R6/2 myotubes can be used as a 
non-neuronal post-mitotic cell culture model exhibiting nuclear huntingtin inclusions 
very similar to those observed in R6/2 HD mouse brains. The number of inclusions 
was influenced by environmental conditions suggesting that this model could be 
useful to study the pathophysiology of huntingtin aggregate formation and could 
serve as a tool to examine treatment strategies designed to influence aggregate 
formation.
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CHAPTER 5.
PRNP codon 129 polymorphism in sporadic inclusion body myositis 
muscle (sIBM)
5.1. Introduction
5.1.2. Clinical and histopathological characteristics of sIBM
Sporadic inclusion body myositis (sIBM) is the most common muscle disorder 
affecting patients 50 years and older (Griggs et al., 1995). Patients suffer from 
atrophic usually painless but insidiously progressing weakness afflicting mainly 
proximal and distal muscles of arms and legs. The diagnosis of sIBM is made on 
muscle biopsy. Histologically, sIBM is characterised by endomysial inflammation 
with non-necrotic muscle fibres being invaded by mononuclear lymphocytes and by 
vacuoles lined with granular material (rimmed vacuoles) (Griggs et al., 1995). 
Amyloid deposits can be identified with Congo red staining using polarised light or 
fluorescence (Figure 5.1 D). Electron microscopy demonstrates intranuclear or 
cytoplasmic amyloid-like fibrills with a diameter of 6-1 Onm or paired helical 
tubulofilaments with 15-21nm diameter. Immunocytochemical techniques reveal that 
the inflammatory cells are mainly macrophages and CD8+ cytotoxic/suppressor T- 
cells (Figure 5.1 B). In addition, invaded and non-invaded muscle fibres express 
class 1 major histocompatibility complex (MHC-1) antigens on their surface.
Hereditary inclusion body myopathy differs from sIBM in that there is no 
inflammation on muscle biopsy and clinically the disease spares the quadriceps 
muscle (Argov and Yarom, 1984; Sadeh et al., 1993). Inclusion body myopathy is 
inherited as an autosomal recessive disorder with linkage analysis suggesting that it 
may be the same entity as Nonoka distal myopathy, a disorder linked to 
chromosome 9 (Argov et al., 1997; Ikeuchi et al., 1997).
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5.1.3. Pathogenesis of sIBM
The pathogenesis of sIBM remains unknown. The prominent inflammatory changes 
with invasion of non-necrotic muscle fibres by lymphocytes suggest that sIBM might 
be a primary inflammatory muscle disease similar to polymyositis. This is in accord 
with a quantitative analysis showing that fibres invaded by inflammatory cells were 
more frequent than those with amyloid deposits or rimmed vacuoles (Pruitt et al., 
1996). However, immunosuppressive treatment, including immunoglobulins, does 
not lead to significant clinical improvement (Amato et al., 1994; Barohn et al., 1995; 
Dalakas et al., 1997). It has been reported that CK levels drop following 
immunosupression for up to 24 months, and compared to pre-treatment the post 
treatment muscle biopsies showed fewer inflammatory changes. However, the 
number of vacuolated fibres and fibres with amyloid deposits increased (Barohn et 
al., 1995). This would be in keeping with the hypothesis that sIBM is a primary 
degenerative disease with secondary inflammatory changes. In support of this 
hypothesis accumulation of proteins characteristic for Alzheimer’s disease has been 
reported within vacuolated muscle fibres. These proteins include p-amyloid, C- and 
N-terminal epitopes of p-amyloid precursor protein, apolipoprotein E, a1- 
antichymotrypsin, ubiquitin, hyperphosphorylated tau, neurofilament heavy chain, a- 
synuclein and prion protein (Askanas et al., 1993a; Askanas et al., 1993b; Askanas 
et al., 2000; Askanas et al., 1994a; Askanas et al., 1994b; Griggs et al., 1995; 
Mendell et al., 1991). Increased levels of mRNA for the acetylcholine receptor, p- 
amyloid precursor protein and PrP have also been reported (Griggs et al., 1995; 
Sarkozi et al., 1994; Sarkozi et al., 1993). This may suggest that the deposits of 
these proteins are linked to their increased transcription. However, it is not clear 
whether any of these changes are primary or secondary to another, as yet unknown, 
pathological event.
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While the pathogenesis of sIBM remains elusive, increased transcription and 
accumulation of fi-amyloid possibly facilitated by factors related to ageing might be 
an important early event in sIBM pathogenesis (Askanas and Engel, 2001). The 
remarkable similarities between the pathological changes observed in sIBM and 
Alzheimer's disease give rise to the hypothesis that abnormal protein folding plays 
an important part at least in the mechanisms downstream of the (unknown) 
causative factor(s). Thus, the accumulation of numerous proteins including the PrP 
and ubiquitin in inclusions in sIBM might link this disease to neurodegenerative 
diseases where protein folding and aggregation seem to be at the forefront of the 
pathogenetic process (Sherman and Goldberg, 2001).
5.1.4. The prion protein
The PRNP, a housekeeping gene with 3 exons on chromosome 20, encodes the 
PrPc with highest expression levels observed in neurones (Oesch et al., 1985). 
Initially, the PrPc is synthesised as a 253-aminoacid polypeptide. Soon after 
translation begins the first 22 aminoacids (signal peptide) are cleaved. A C-terminal 
glycosylphosphatidylinositol anchor, added in the post-translational processing, 
facilitates glycolipid linkage to cell membranes. PrPc contains 2 N-linked 
glycosylation sites and a naturally occurring polymorphism at codon 129.
PrPc is a cell surface glycoprotein of unknown function (Prusiner, 2001). 
PrPc, a glycosylphosphatidylinositol-anchored cell surface glycoprotein, is mainly 
expressed in the central nervous system, but is also, to a lower extent, produced in 
lymphocytes (Cashman et al., 1990) and stromal cells of lymphoid organs such as 
tonsil, spleen and gut associated lymphoid tissue (Kitamoto et al., 1991), and 
muscle where it was found at the neuromuscular junction (Gohel). PrPc has been 
linked to neuronal copper metabolism (Brown et al., 1997) and synaptic 
transmission (Collinge et al., 1994).
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5.1.5. Transmissible spongiform encephalopathies
In the transmissible prion diseases, or transmissible spongiform encephalopathies 
(TSE), a misfolded conformation of PrPc, a detergent-insoluble and proteinase K 
resistant isoform of the prion protein, termed PrPsc, results in the conversion of 
normal PrPc encoded by the host into the insoluble and aggregate-prone PrPsc. PrPc 
and PrPsc do not differ in their primary aminoacid sequences; the conformational 
change from a high a helix and a low p sheet content of PrPc to a relatively high p 
sheet content in PrPsc (>30%) has been linked to low solubility of PrPsc and its 
propensity to from fibrils and amyloid (Pan et al., 1993). In cell free systems it was 
shown that once PrPsc has formed it can serve as a template to promote the 
conversion of PrPc to PrPsc (Kocisko et al., 1994).
The mechanisms leading from the conversion of PrPc to PrPsc on to 
neurodegeneration are incompletely understood. Studies in mice showed that 
mouse neurones that were not expressing PrPc were well and immune to the toxicity 
of PrPsc accumulation and deposition (Brandner et al., 1996; Bueler et al., 1993; 
Bueler et al., 1992). This suggests that an interaction between the transmitted PrPsc 
and the normal host PrPc is necessary to cause disease.
The most common human form of TSE is Creutzfeld-Jacob disease (CJD). 
Patients with sporadic CJD commonly present with a rapidly progressive dementia, 
myoclonus and cerebellar ataxia. The majority of patients die within one year of 
disease onset. Iatrogenic forms of CJD have been observed in patients following 
neurosurgery, corneal grafts, dura mater implantation, treatment with human 
cadaveric pituitary growth hormone and gonadotrophins, and direct infection with 
stereotactic electroencephalogram electrodes. Up until 2000, world-wide a total of 
267 patients with iatrogenic CJD have been reported (Brown et al., 2000).
Another form of TSE was observed in the Fore linguistic group in Papua New 
Guinea in the context of ritualistic cannibalism, termed Kuru (Gajdusek, 1977;
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Gajdusek and Zigas, 1957; Zigas and Gajdusek, 1957). In 1996, the first case of 
new variant CJD was reported (Will et al., 1996). The clinical presentation differs 
from sporadic CJD in that patients are much younger (median age at death 29 
years) and often initially suffer from psychiatric symptoms including anxiety, 
withdrawal or insomnia weeks or months before cognition becomes impaired and 
abnormal movements occur (Spencer et al., 2002). A link with the agent causing 
bovine spongiform encephalopathy (BSE) was established on epidemiological, 
biochemical and histological grounds suggesting that the human disease is caused 
by the prion responsible for BSE (Aguzzi, 1996; Aguzzi and Weissmann, 1996;
Bruce et al., 1997; Hill et al., 1997a).
5.1.6. Genetic prion diseases
Mutations of PRNP have been associated with hereditary prion neurodegenerative 
diseases. Three main forms of autosomal dominantly inherited prion disease are 
distinguished: familial CJD, Gerstmann-Straussler-Scheinker syndrome and fatal 
familial insomnia. Gerstmann- Straussler-Scheinker syndrome differs from CJD in 
it’s clinical presentation; most commonly patients have the P102L (where Proline is 
substituted at position 102 by Lysine) PRNP mutation, which leads to slowly 
progressive cerebellar ataxia and cognitive decline (Hsiao et al., 1989). However, 
other phenotypes have been described associated with various other PRNP 
mutations (Collins et al., 2004).
5.1.7. PRNP codon 129 polymorphisms
A polymorphism occurs naturally at codon 129 of PRNP, which can encode for 
methionine or valine leading to methionine/valine (MA/), methionine/methionine 
(M/M) or valine/valine (V/V) genotypes. Normal populations across the world differ 
markedly with respect to the frequencies of PRNP codon 129 alleles (Tables 5.1 and
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2). However, within Western Europe several studies documented very similar 
frequencies (Table 5.1); about 50% are homozygous (40% M/M and 10% V/V) and 
50% are heterozygous (Table 5.1).
Western European controls M/M (%) V/V (%) M/V (%)
(Owen et al., 1990), n=106 39 (36) 13 (12.3) 54 (50)
(Schulz-Schaeffer et al., 1996), n=74 31 (41) 10(13) 33 (44)
(Deslys et al., 1994), n=69 25 (36) 7(10) 37 (53)
(Laplanche et al., 1994), n=92 38 (41) 9(9) 45 (48)
(Lampe et al., 1999), n=57 23 (40) 5(8) 29 (50)
(Zimmermann et al., 1999), n=300 129 (43) 25 (8.3) 146 (48.7)
Pooled, n=698 285 (40.8) 69 (9.9) 344 (49.3)
Table 5.1. Frequency distribution of PRNP codon 129 polymorphisms in the normal 
population in Western Europe.
Other control populations M/M V/V M/V
Papua New Guinea controls (Cervenakova et al., 32% 24% 43%
1998)
Japanese controls (Doh-ura et al., 1991) 92% 0% 8%
Table 5.2. Frequency distribution of PRNP codon 129 polymorphisms in non- 
European control populations.
Homozygosity for methionine or valine at codon 129 of the PRNP was 
suggested to be a predisposing factor in the iatrogenic and sporadic cases of CJD 
(Collinge et al., 1991; Palmer et al., 1991). In contrast to the normal population in 
Western Europe close to 90% of sporadic CJD patients (Brown et al., 2000; Windl et 
al., 1996), between 80 and 90% of iatrogenic CJD cases (Brown et al., 1994; Brown
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et al., 2000; Johnson and Gibbs, 1998) and 100% of cases with new variant CJD 
(Spencer et al., 2002; Will et al., 1996), Andrews http://www.cid.ed.ac.uk/vcidq.htm) 
are homozygous (Table 5.3).
In the iatrogenic CJD cases, those associated with dura mater implants were 
predominantly methionine homozygotes (Brown et al., 2000), whereas in those 
cases associated with growth hormone treatment the main increase in homozygosity 
frequency seems to stem from cases homozygous for valine (Brown et al., 2000) 
(Table 5.3). Why there appears to be a differential increase in homozygosity 
frequencies for either methionine or valine in iatrogenic CJD remains unclear. 
Methionine homozygosity predominates in sporadic CJD and in new variant CJD 
(Table 5.3). Taken together this suggests that homozygosity at PRNP codon 129 
increases the risk for these forms of CJD while heterozygosity seems to reduce this 
risk. This is consistent with studies in the Fore people of Papua New Guinea; 
methionine homozygosity seems to be a relevant susceptibility factor in Kuru where 
it is associated with a shorter incubation period, shorter duration of illness and 
younger age at onset of the disease (Cervenakova et al., 1998; Lee et al., 2001b). 
Since the ritualistic consumption of brains has been abandoned the number of 
cases of Kuru has decreased. However, Kuru is still observed in older patients 
suggesting a longer incubation period. Contemporary Fore survivors are 
predominantly heterozygous for PRNP codon 129 polymorphism (Mead et al.,
2003). This is consistent with the hypothesis that codon 129 heterozygosity protects 
from Kuru, which in turn may have led to selection of a heterozygous codon 129 
genotype in the Fore people (Mead et al., 2003). In new variant CJD all of 143 
definite or probable cases (with 137 deaths) reported to date 
(http://www.cid.ed.ac.uk/fiqures/htm) were homozygous for methionine suggesting 
that methionine homozygotes were particularly susceptible to transmission of BSE.
In agreement with human data, in mice expressing human codon 129 encoding for
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methionine the inoculation with BSE and new variant CJD prions induced a 
neuropathological and molecular phenotype similar to human new variant CJD 
(Asante et al., 2002). It remains unknown whether heterozygotes will develop new 
variant CJD after longer incubation periods; thus although UK surveillance data 
(Andrews http://www.cid.ed.ac.uk/vcidq.htm) and assumptions based on modelling 
data (d'Aignaux et al., 2001; Valleron et al., 2001) indicate that new variant CJD 
may have peaked already it remains uncertain whether the future will see a second 
wave of cases amongst heterozygotes.
How codon 129 homozygosity increases the vulnerability to CJD is not 
understood. Since the host PrPc needs to interact with the PrPsc it is possible that 
the aminoacid composition encoded by PRNP codon 129 plays an important, albeit 
currently unknown, role in the cellular events following PrPsc infection. In vitro 
studies suggest that methionine at codon 129 may be more susceptible to a 
conformational switch from a helix to p sheet than valine (Petchanikow et al., 2001). 
Codon 129 status may also influence post translational changes in PrPc. In sporadic 
CJD patients, PRNP codon 129 status was shown to correlate with different types of 
PrPsc, as differentiated on Western blot after limited proteinase K digestion by 
fragments with different molecular mass and intensity, which reflect un- mono- and 
di-glycosylated forms (Collinge et al., 1996; Wadsworth et al., 1999). It is not known 
how PRNP codon 129 polymorphisms translate into the link that has been observed 
to disease duration and neuropathological characteristics in CJD (Hauw et al., 2000; 
Hill et al., 2003; Parchi et al., 1997; Parchi et al., 1999; Parchi et al., 2000).
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Prion disease groups M/M V/V M/V
Historical Fore people with Kuru (Cervenakova et al., 1998; 53% 20% 27%
Lee et al., 2001b)
Historical Fore survivors (males 20 years and younger) 0% 35% 65%
(Cervenakova et al., 1998; Lee et al., 2001b)
Contemporary Fore survivors (women 50 years and older) na na 77%
(Mead et al., 2003)
Classic sporadic CJD (Windl et al., 1996), n=58 83% 9% 9%
Classic sporadic CJD (Brown et al., 2000), n=832 71% 16% 13%
New variant CJD (Spencer et al., 2002; Will et al., 1996), 100% 0% 0%
httD://www.cid.ed.ac.uk/fiaures/htm). n=143
Iatrogenic CJD combined (Brown et al., 2000), n=128 57% 23% 20%
Iatrogenic (growth hormone) CJD (Brown et al., 2000), n=82 48% 32% 21%
Iatrogenic (dura mater) (Brown et al., 2000), n=43 74% 7% 19%
Table 5.3. Frequency distribution of the PRNP codon 129 polymorphisms in Kuru, 
sporadic CJD, new variant CJD and iatrogenic CJD. Na: not available.
5.1.8. Extraneuronal PrPsc
The pathological form of the prion protein, PrPsc, has, quite like PrPc, been found 
mainly in the central nervous system. However, the examination of other tissues of 
patients with sporadic CJD has revealed PrPsc in other tissues that express PrPc, 
including a substantial proportion of muscle samples (Glatzel et al., 2003), and in 
patients with new variant CJD tonsil biopsy can be used as a diagnostic test (Hill et 
al., 1999; Hill et al., 1997b). Following the inoculation of scrapie strains adapted to 
hamster and mice PrPsc propagation was shown in muscle albeit at only about 5- 
10% of brain levels (Bosque et al., 2002; Thomzig et al., 2003).
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5.1.9. Prion protein and sIBM
The prion protein is one of the proteins described within vacuolated muscle fibres of 
sIBM muscle biopsies. There is evidence for increased transcription of PRNP from 
mRNA and increased expression of the prion protein from immunohistochemistry 
studies (Askanas et al., 1993b; Sarkozi et al., 1994). These studies did not 
differentiate between PrPc and PrPsc.
Mice transgenic for wild-type PRNP developed spongiform degeneration of 
the brains but also demyelination of peripheral nerves and a necrotising myopathy 
(Westaway et al., 1994). Similar to sIBM occasional ragged-red fibres were 
observed but contrary to the characteristic inflammatory changes in muscle biopsies 
of sIBM the muscle of transgenic mice did not show any lymphocytic infiltration, and 
no PrPsc was detected (Westaway et al., 1994). The results of this study indicate 
that over-expression of wild-type PRNP might be toxic to muscle; however, at least 
in mice the muscle histology differed from sIBM.
Apart from one case report an association of sIBM and CJD has not been 
reported. This single patient was recently reported with both sporadic CJD and a 
muscle disorder with many pathological features indicative of sIBM (Kovacs et al.,
2004). In this patient muscle disease preceded the onset of neurological symptoms 
by about ten years. The patient presented with dysphasia as the first symptom to 
indicate a disease afflicting the central nervous system and he survived for more 
than three years thereafter. Thus, clinically a number of unusual features were 
present in addition to typical symptoms and signs, and pathological changes, of 
sporadic CJD. The authors showed PrPsc present in both brain and muscle with 
levels in muscle reaching about 30% of those in brain (Kovacs et al., 2004). 
However, in another study the normal PrPc but not the prion disease isoform PrPsc 
was detected in sIBM muscle (Zanusso et al., 2001).
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The potential connection between PrP and sIBM led Lampe and colleagues 
to study the frequency of methionine homozygosity of codon 129 of PRNP in sIBM 
(Lampe et al., 1999). They studied the PRNP codon 129 polymorphism in 22 
Western European patients with a clinical and histological diagnosis of sIBM and 57 
controls without neurological disease (Table 5.4). This showed that 14 patients were 
M/M homozygous (64%), 7 (32%) were M/V heterozygous and 1 patient was V/V 
homozygous (5%). Analysis of frequency distribution compared to the results of their 
own control group did not reveal a significant difference; however, a comparison 
with pooled data from normal controls in 3 Western European countries showed that 
the M/M polymorphism was more common in their patients (p=0.023).
M/M (%) V/V (%) M/V (%)
sIBM, n=22 14 (63) 1 (4) 7(31)
Controls, n=57 23 (40) 5(8) 29 (50)
Pooled controls, n=398 156 (39) 44(11) 198 (50)
Table 5.4. Results of the study by Lampe and colleagues.
5.2. Rational and aim
There is good evidence to suggest that sIBM is a degenerative disorder with many 
pathological similarities to degenerative brain disorders, in particular Alzheimer’s 
disease. It is not clear how to view the involvement of the prion protein in the 
pathogenesis of sIBM. There is clear evidence that expression of PrPc is increased 
in muscle of patients with sIBM, and PrPc, in particular in vacuolated muscle fibres in 
sIBM. Patients with CJD contain PrPsc in muscle and mice transgenic for PrPsc 
developed not only a spongiform encephalopathy but also a necrotising myopathy 
with some similarities to sIBM histologically. Since homozygosity for either 
methionine or valine at the naturally occurring polymorphism at PRNP codon 129 is
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associated with an increased susceptibility to sporadic, iatrogenic and new variant 
CJD a previous study examined the PRNP codon 129 polymorphism in sIBM 
patients (Lampe et al., 1999). Lampe and colleagues suggested that homozygosity 
for methionine was more common in patients with sIBM; however, the number of 
sIBM patients in their study was small (22). Therefore, it was the aim of this study to 
examine the PRNP codon 129 polymorphism in a larger number of patients with 
sIBM to identify if the relationship persists.
5.3. Results
5.3.1. Patients
The DNA of a muscle biopsy specimen was analysed in muscle from 41 white 
Western European patients (14 women, median age 62 years, range 49-74). All 
patients were given a diagnosis of sIBM on the basis of clinical and histopathological 
characteristics according to the published criteria (Griggs et al., 1995).
5.3.2. Histology
All biopsies showed morphological changes characteristic for sIBM. On 
Haematoxylin and Eosin (H+E) stains, muscle biopsies showed a mixture of 
inflammatory changes with non-necrotic muscle fibres invaded by mononuclear 
lymphocytes (Figure 5.1 A, arrows); immunostaining with antibodies to CD8+ 
revealed that the majority of lymphocytes were cytotoxic T-cells (red staining in 
Figure 5 .1B). On H+E stains and Gomori trichrome stains biopsies had numerous 
vacuoles rimmed by basophilic (on H+E, Figure 5.1 A, arrow heads), or fuscinophilic 
(on Gomori trichrome, Figure 5.1 C, arrows) granular material, “rimmed vacuoles".
On Congo red stained sections congophilic material suggests the presence of 
amyloid (Congo red stain, red fluorescence, Figure 5.1D). The morphological 
features of all biopsies were similar.
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Figure 5.1. Histology of sporadic inclusion body myositis. A. H+E stain 
showing endomysial infiltration of lymphocytes with invaded non-necrotic 
muscle fibre (arrows). Some fibres also contain small “rimmed vacuoles 
(arrow heads). B. Immunohistochemistry with an antibody to CD8+ (red stain) 
indicated that a large proportion of the inflammatory cells are cytotoxic 
T-lymphocytes. C. Gomori trichrome stain shows numerous “rimmed vacuole" 
(arrows). D. Congo red stained section under fluorescent light indicates the 
presence of amyloid. Scale bar in A-C=50|im, in D=25|nm.
5.3.3. PRNP codon 129 polymorphism
PCR amplification of PRNP gene resulted in a 755bp band on agarose gel 
electrophoresis. The restriction enzyme NsP\ cuts at codon 129 when it encodes 
methionine and also at codon 155. Thus in case of a methionine allele NsP\ digests 
the 755bp PCR product into three bands of 352, 328 and 75bp (schematic drawing 
in Figure 5.2). In case of a valine allele, NsP\ digestion results in the 352bp band 
and a 427bp band (Figure 5.2). MaeII cuts at codon 203 and at codon 129 when it 
encodes valine. Thus the 755bp PRNP PCR product will be digested into three DNA 
fragments (350, 220, 185 bp) in case of a valine and into two bands (185 and 
570bp) in case of a methionine allele at codon 129. Thus, MaeII restriction digestion 
in an individual with heterozygosity yields 4 bands (185, 220, 350 and 570bp, M/V in 
Figure 5.2), methionine homozygosity results in the three DNA fragments of the 
methionine allele (185, 220 and 350bp, M/M in Figure 5.2) and valine homozygosity 
gives 2 bands of the valine allele (185 and 570bp, V/V in Figure 5.2).
Restriction digests using NsP\ did not yield consistent results with most 
samples not being cut (left lane of each pair in Figure 5.3). Thus the results with 
A/sPI were not deemed reliable. The samples were therefore interpreted using MaeII 
alone (Table 5.5). 41 patients muscle samples were analysed; the results of 17 are 
shown in Figure 5.3. 21 were homozygous for methionine (51.2 %, M/M in a 
representative gel run after restriction digest of PRNP gene PCR product shown in 
Figure 5.3) and one patient for valine (2.4 %; V/V in Figures 5.2 and 5.3); 19 
patients were heterozygous (46.4 %; M/V in Figure 5.2 and 5.3).
M/M (%) V/V (%) M/V (%)
sIBM, n=41 21 (51.2) 1 (2.4) 19(46.4)
Pooled controls, n=698 285 (40.8) 69 (9.9) 344 (49.3)
Table 5.5. Frequency distribution of PRNP codon 129 polymorphism in sIBM 
patients.
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uncut
Marker I NsP\ Mae II
800bp-------  *  -  m
2 5 £ -------     427bp    570bP400bp-------       352bp    350bp
200bp  328bp ____  ____  ——— 220bp
100bp--------------------------------      75bp 185bp
M/M V/V M/V M/M V/V M/V
Figure 5.2. Schematic drawing of the restriction fragment length following digestion 
of the 755bp PRNP open reading frame PCR product with the restriction endonucl­
eases NsPI or Maell. M/M: methionine homozygous. V/V: valine homozygous.
M/V: heterozygous.
Marker
\ 4
1 2 3 4 5 6 7 8
M/V M/V M/M M/V M/V M/M M/M M/M
800bp
600bp
400bp
200bp
M/M M/M M/M M/V M/M M/M M/M V/V M/V
800bp
600bp
400bp
200bp
Figure 5.3. Restriction digest of PRNP PCR product. 2% agarose gel showing two 
lanes for eachsample for a total of 17 samples. On the left of each pair, unsuccessful 
NsPI digestion of PCR amplification of the PRNP results in the 755bp PRNP band 
while the right lane shows examples for Methionine/Valine (M/V), Methionine/ 
Methionine (M/M) and Valine/Valine (V/V) phenotypes after digestion of the PCR 
product with the restriction endonclease Maell. M/M: methionine homozygous.
V/V: valine homozygous. M/V: heterozygous. The numbers 1-17 each represent 
one sIBM patient.
These results were compared with those from 6 studies in Western European 
countries (Table 5.5). When combined these studies demonstrated that 40.8 % of 
individuals had the Met/Met and 9.9% had the ValA/al phenotypes whereas 49.3 % 
were heterozygous (Table 5.5). The statistical analysis addressed the question 
whether in sIBM patients homozygosity, i.e. M/M or V/V, was more common than 
heterozygosity compared with published results from 6 studies in Western European 
countries (Table 5.5). To this end Fisher’s exact test was used, which compares 
frequencies of homozygosity, or heterozygosity in patients with, or without, sIBM in a 
2 X 2  frequency table. The two-sided p value was 0.2497 considered not significant 
(Odds ratio 1.419, 95%CI 0.785-2.832).
We went on to repeat this analysis combining our data with the data of 
Lampe and colleagues, and with data from 16 more patients reported by Lampe and 
co-workers (Lampe et al., 2001), Table 5.6). Comparing frequencies of 
homozygosity with heterozygosity revealed no statistically significant difference 
between patients with sIBM and controls (Fisher’s exact test, p=0.2353, Odds ratio 
1.355, 95%CI 0.8456-2.17 using the approximation of Woolf). When comparing the 
frequencies of M/M homozygotes with M/V heterozygotes there was a trend towards 
a higher frequency in the sIBM group (Fisher’s exact test, p=0.0869, Odds ratio 
1.536, 95%Cl 0.984-2.488).
Study (sIBM) M/M (%) V/V (%) M/V (%)
Pooled controls, n=698 285 (40.8) 69 (9.9) 3 4 4  (49.3)
This study, n=41 21 (51.2) 1 (2.4) 19(46.4)
(Lampe et al., 1999), n=22 14(63) 1 (4 ) 7(31)
(Lampe et al., 2001), n=16 7 (43.8%) 2 (12.5%) 7 (43.8%
Pooled, n=79 42 (53.2) 4(5.1) 33 (41.8)
Table 5.6. Frequency distribution of PRNP codon 129 polymorphism in patients with 
sporadic inclusion body myositis.
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5.4. Discussion
It was the aim of this study to re-examine the relationship between the PRNP codon 
129 polymorphism and sIBM. A previous study reported in 22 patients that the M/M 
polymorphism was more frequent in sIBM than in Western European controls 
(Lampe et al., 1999). The results presented in this thesis did not demonstrate a 
significant difference in homozygosity of codon 129 of the PRNP between patients 
with sIBM and the combined results of several studies in normal control subjects 
from Western European countries.
This discrepancy could have been caused by different frequencies of the 
PRNP codon 129 polymorphism in the control populations used in the respective 
studies. However, the genotype distribution of the PRNP codon 129 polymorphism 
is relatively consistent comparing the different studies in Western European 
controls. Between 44 and 53% of individuals were M/V heterozygous and between 
46 and 54% were homozygous (Table 5.1). This contrasts to studies in other 
populations such as the Japanese or the Fore people in Papua New Guinea (Table 
5.2). Therefore, differences in PRNP codon 129 polymorphism frequencies between 
the controls cannot explain the different results.
In the present study 41 patients were examined for the PRNP codon 129 
polymorphism compared with the 22 patients in the previous study (Lampe et al., 
1999). Thus, the smaller number of patients in the Lampe et al study may have led 
to a chance selection of patients with methionine homozygosity. To assess an even 
larger number patients we performed a meta-analysis on the pooled data of both 
studies, and data on a further 16 sIBM patients reported by Lampe and colleagues 
(Lampe et al., 2001). The results indicated that the M/M polymorphism compared 
with heterozygosity was not significantly more frequent in sIBM patients. However, 
there was a trend towards higher M/M frequency in sIBM patients.
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This type of analysis (comparing M/M with M/V) does not take the V/V 
homozygous cases into account. Studies in transmissible spongiform 
encephalopathies indicated that homozygosity in general, i.e. either M/M or V/V, is 
more frequent (Table 5.3). We therefore compared frequencies of homozygosity 
with heterozygosity in our meta-analysis. This did not reveal any significant 
differences between the patients with sIBM and controls. Therefore, the results 
presented here suggest that sIBM is not linked to homozygosity of the PRNP codon 
129 polymorphism. It is possible that the accumulation of PrPc in sIBM muscle is a 
non-specific event. This notion would be in accord with a recent report that showed 
increased expression of PrPc in other inflammatory muscle diseases (polymyositis 
and dermatomyositis) and neurogenic muscle atrophy (Zanusso et al., 2001).
This does not exclude the possibility that the prion protein plays a role in 
sIBM. However, so far there is no evidence that the insoluble form of PrP, PrPsc, 
occurs in sIBM, and the results presented in this thesis chapter do not support the 
notion that a potential susceptibility factor for transmissible prion diseases, codon 
129 homozygosity, is more common in patients with sIBM. In light of the small 
number of patients evaluated and the recent observation of both CJD and sIBM in 
the same patient (Kovacs et al., 2004), more research is warranted to investigate 
this issue in more detail.
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6. Future work 
Parkinson’s disease
Dispite the advances that have been made in understanding Parkinson’s disease 
several important issues regarding the pathophysiology remain incompletely 
understood and need to be the subject of future work. It is still not clear why there is 
selective dopaminergic cell death in PD and why it takes decades, even in the 
young onset genetic forms of parkinsonism, for the disease to develop. In sporadic 
PD, future work needs to clarify the relationship between the various pathways that 
have been identified in PD (e.g. mitochondrial involvement, UPS) and how these 
pathways are influenced by and linked to genetic factors to try and differentiate the 
primary event that initiates the disease process from effects further downstream. 
Unless at least some of these fundamental issues regarding the cause of 
dopaminergic cell death in PD are better understood treatment of PD will likely 
remain symptomatic, and it will be difficult to identify pre-symptomatic patients and 
to develop markers of disease progression. The knowledge about pathways that 
contribute to PD can, however, provide the basis for potential treatment strategies 
once the disease has manifested itself. For instance, it has become clear that the 
UPS is involved in the disease process. Modification of the UPS may be one way to 
try and stop disease progression.
Powerful animal models are the key to progress in a number of these areas. 
Toxin models such as the MPTP model have provided valuable insight into PD, and 
the identification of several genes that cause familial forms of PD has enabled the 
generation of genetic disease models. These models documented that a-synuclein 
over-expression can cause a variety of neuropathological changes. However, none 
of the genetic mouse models to date has been able to recapitulate the most striking 
pathological feature of the human disease, i.e. selective degeneration of
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dopaminergic neurones. A major challenge will therefore remain the generation of a 
genetic animal model that does show selective dopaminergic cell death.
Huntington’s disease
Unlike in PD, the genetic basis for HD has been identified and the genetic test for 
the HD gene can be used for pre-symptomatic testing. This is an important pre- 
requesite in order to identify patients at risk to develop HD; these are the patients 
that would benefit most from any treatment that could be designed to prevent 
neuronal degeneration. However, it is not known how the disease develops in a 
given patient with positive predictive testing. This means that it remains unclear 
when the expression of mutant huntingtin begins to affect neuronal function and 
when neurones start to degenerate. Thus future work needs to identify biomarkers 
of disease activity, which would also be invaluable for treatment trials.
A number of suitable animal models have been generated since the HD 
gene has been found. These models have provided valuable insight into the 
consequences of the expression of the extended polyQ size in the huntingtin 
protein. One of the most prominent features in these models was the development 
of inclusions that contain the N-terminus of huntingtin with polyQ. There is good 
evidence to suggest that these inclusions are toxic and treatment aimed at 
preventing or reversing inclusion formation improved the phenotype in transgenic 
animals. Thus similar trials in human HD patients could be promising. However, 
future work needs to increase our understanding of the normal function of huntingtin 
and of the complex interactions of mutant huntingtin with wild-type huntingtin and 
the whole array of huntingtin-interacting proteins. This could form the basis for the 
identification of genes and drugs that could restore normal huntingtin function or 
alter toxicity of mutant huntingtin. Such modifiers of huntingtin function or toxicity 
could also identify novel treatments for HD patients.
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Appendix 1 
Western blotting
5 X dissociation buffer
• 6m I glycerol
• 2g SDS
• 5mg bromophenol blue
• 1ml 1M Tris-HCI (pH 6.5)
The ingredients were mixed in a 50ml screw top tube; 2ml double distilled H20  were 
added and the mixture dissolved in a hot water bath (~80°C). The total volume of 
10ml was made up with double distilled H20. p-mercaptoethanol was added after 
protein estimation because it interferes with the BCA protein determination assay.
Electrophoresis buffer
• 28.8g glycine
• 6g Tris (Trizma base)
• 2g sodium dodecylsulfate (SDS)
Make up to a final volume of 2 litres with double distilled H20.
Towbin’s blotting buffer (25mM Tris, 192mM glycine, 20% methanol)
• 7.57gTris
• 36.04g glycine
• 500ml methanol
Make up to a final volume of 2.5 litres with H20, adjust pH to 8.3 and refridgerate.
284
Gel recipes for one pair of mini-gels (0.75mm spacers) using the BioRad Mini-
Protean system
STACKING SEPARATING
3% 10% 12.5% 15%
3.75mM Tris-HCI (pH 8.6) - 920(0.1 920pl 920pl
0.5M Tris-HCI (pH 6.5) 500pl - - -
40% aery lam ide-bis (37.5:1)1 450pl 2.5ml 3.1ml 3.7ml
Urea 1.8g 3.25g 3.25g 3.25g
20% SDS 25pl 46 pi 46pl 46 pi
Double distilled H20 3.25ml 4.1ml 3.5ml 2.9ml
TEMED1 3pl 6pl 6 pi 6 pi
10% ammonium persulfate 25pl 44 pi 44 pi 44 pi
1 from BioRad
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Appendix 2.
g-svnuclein cell culture models
A number of studies have investigated the effects of wild-type, G209A or G88C a- 
synuclein over-expression in vitro (Table A1). Studies differ in the cell lines used, the 
vector used for transfection and the mode of transfection, i.e. transient, stable or 
stable and inducible (see section 1.1.7.4). The literature on over-expression of wild- 
type, or G209A or G88C mutant, a-synuclein revealed variable results. The 
following tables differentiate the effects of a-synuclein, either wild-type or mutant, 
transfection on processes that are relevant in PD, i.e. viability, oxidative stress, the 
UPS and aggregate formation, and mitochondrial function (for a summary see 
Tables A2 and A3).
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Cell type Transfection Reference a-synuclein Number
Mouse hypothalamic Stable (Hsu et al., 2000) Wild-type 1
GT1-7
SH-SY5Y Stable (Kanda et al., Wild-type 2
2000), G209A, G88C 3
BE(2)-M17 Stable (Ko et al., 2000), Wild-type 4
neuroblastoma G88C 5
PC-12 cells Stable, doxy- 
cycline switch
(Tanaka et al., 
2001)
G88C 6
PC-12 cells Stable (Stefanis et al., Wild-type 7
2001) G209A 8
SH-SY5Y Stable (Junn and Wild-type, 9
Mouradian, 2002), G209A, G88C 10
human foetal dopaminer­ Transient (Xu et al., 2002) Wild-type, 11
gic neurones, SH-SY5Y Stable, inducible G88C, G209A 12
HEK293 Transient (Engelender et al., 
1999)
Wild-type 13
SH-SY5Y Transient (Kalivendi et al., 
2004)
Wild-type 14
COS-7 Transient (Lee et al., 2004) Wild-type 15
Differentiated SH-SY5Y Transient (Lee et al., 2004) Wild-type 16
SH-SY5Y Transient (Lee et al., 2004) Wild-type 17
SH-SY5Y Transient (Kalivendi et al., 
2004)
Wild-type 18
primary cortical rat Transient (Saha et al., 2004) Wild-type 19
neurones G88C, G209A 20
TSM1 neuronal Stable (da Costa et al., Wild-type 21
2000) G209A 22
HEK293 stably trans­ Transient (Tanaka et al., Wild-type 23
fected with synphilin-1 2004) G88C, G209A 24
MN9D (murine Stable (Jensen et al., Wild-type, 25
mesencephalic) 2003) G88C, G209A 26
SK-NM-C Stable, inducible (Lee et al., 2001c) Wild-type, 27
BE-M17 neuroblastoma Stable (Ostrerova-Golts Wild-type, 28
et al., 2000) G88C, G209A 29
Table A1. Cell culture models of a-synuclein over-expression.
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Process Effect Cell line and reference number (see Table 3.3)
Viability -» SH-SY5Y (2), PC-12 (7)
I BE-M17 neuroblastoma (28)
Susceptibility to t SK-NM-C (27)
staurosporine I TSM1 neuronal (21)
Oxidative stress t Mouse hypothalamic GT1-7 (1)
-> SH-SY5Y (14)
Susceptibility to H20 2 -> SH-SY5Y (2)
I SK-NM-C (27)
Aggregates t Mouse hypothalamic GT1-7 (1), BE-M17 
neuroblastoma (28), COS-7 (15), differentiated SH- 
SY5Y (16)
UPS and aggregates -» PC-12 (7), SH-SY5Y (17), HEK293 with synphilin 
(23)
MRC function -> SH-SY5Y (18)
I Mouse hypothalamic GT1-7 (1)
Susceptibility to MPP+ -> SH-SY5Y (2)
t SH-SY5Y (18)
I MN9D (murine mesencephalic) (25)
Susceptibility to rotenone t COS-7 (15), differentiated SH-SY5Y (16)
Susceptibility to dopamine t SH-SY5Y (9), human foetal dopaminergic 
neurones and SH-SY5Y (11)
Table A2. Effect of wild-type a-synuclein over-expression in cell culture models, 
t :  increase, i :  decrease. no change.
Process Effect Cell line and reference number (see Table 3.3)
Viability -> BE-M17 neuroblastoma (5)
I PC-12 (6,8), HEK293 with synphilin (24), BE-M17 
neuroblastoma (29)
Susceptibility to H20 2 t SH-SY5Y (3)
Susceptibility to menadione t BE-M17 neuroblastoma (5)
UPS I PC-12 (6,8),
Aggregates t HEK293 with synphilin (24); BE-M17 
neuroblastoma (29)
Susceptibility to MPP+ t MN9D (murine mesencephalic) (25)
Susceptibility to dopamine t SH-SY5Y (10), human foetal dopaminergic 
neurones and SH-SY5Y (12)
Table A3. Effect of mutant a-synuclein over-expression in cell culture models. 
T: increase. decrease. no change.
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Appendix 3.
Sequences of pIND.a-syn and plND.G209A-a-syn constructs amplified from DNA 
extracts of WTsyn cell lines, or MUTsyn cell lines respectively.
WTsyn 1: a t g a t c a t g c a g t c g a c g c g a a c a -g c -g c t a c g t a t c a t g a t a g t c c t a g c t c a t a c -a c -t -g -
TG AGCGTCGTTC AGT A-CTAGCT GAT CG AA-CACC-GT CAC A-CGCA-CT CAT C-CGGCC AT--A-T C-G-A-T-GT CT- 
A-TCGTCG ATG AT C-ACT ATT - A-GT C AC-T C AC-CG-A-TAC-T-CGTT GCT CG AAT-T-AT GT C ACGTT G- 
CGCGTG ACTGGT GC-AT GT CGC A-T -AT-AT GAT CT-CCT GCTT CG ACT-A--AGT-C-T G AT-T-A-T C -G  AT-AT G-AC- 
AT-ACTGTACC-GTCGGCAG--CG-AGATCA-G-TATACGATACAT-GATG-AC-TGTCGCTCT-CAAT- 
G ACGTATGTG-CT C G -T  C-GC-AT CACGCG A-AG AT-A-G-T -G CAT GT CG ACT C A— CGCT-A-T--C-GGCG-TG- 
CGTG-C ACT GTAT G AG-C-T GT C A-CG-C-GT-T--ATTA-C AT GTT-TT-T-GT-A-G A-G A-G-C-CGCCACGT-T - 
G AATGGA-GA-T ACC-C-ACAGAG-CC—C—G—CTT CTTTTTTGG AAATTT-
TTT C AACAAGTTACCG AG AAAG AAG AACT CAC ACACAGCTAGCGTTT AAACTT AAGCTT G GT ACCG AC AGT GT G 
GTGTAAAGGAATTCATTAGCCATGGATGTATTCATGAAAGGACTTTCAAAGGCCAAGGAGGGAGTTGTGGCTG 
CTGCTGAGAAAACCAAACAGGGTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTTCTCTATGTAGGCTC 
CAAAACCAAGGAGGGAGTGGTGCATGGTGTGGCAACAGTGGCTGAGAAGACCAAAGAGCAAGTGACAAATGT 
TGGAGGAGCAGTGGTGACGGGTGTGACAGCAGTAGCCCAGAAGACAGTGGAGGGAGCAGGGAGCATTGCAG 
CAGCCACTGGCTTT GT CAAAAAGGACCAGTTGGGCAAGAAT G AAGAAGGAGCCCCACAGGAAGGAATTCT GG A 
AG ATATGCCTGTGG ATCCT G AC AAT G AGGCTT AT GAAATGCCTT CT G AGG AAGGGT AT C AAG ACTACG AACCT G 
AAGCCTACCCA-TA-CGACG-TCCCAGACTACGCTTGATCA-CTAGTCCAGTGTGGTGGAATTCTGCAGATAT-C- 
CAGCACACGT G--CGGGCGT C-T CGA
W T s y n  2: t a g t c a -c c --t a -g t -c a g t g c g t a -g c t -a -g c a -c g c a t c a --g -t -c -t g c a -t a c - t a c a t c -
AT CG ACT-G--CT-G-AG-T-GG ACGT A-TAT CA-T CGT-A--T-AT GT C-AC-TGC AGT AC AT ATTAATA-T - 
CACGTCGTGCT C-A-CT GCG AGT G A -G T C-AC AT-T-GC A-CT AT CT C A-C-T C-AT -CAT C-GT CAG AAGTAC A-T C-- 
T CT C-G AC AG-T -CG-T CG-AT GT AT C-TAG AT--GTAC ACGT GTCGTC ATATGG C AC AT G A-T—AT CAT GCAT-A-T G- 
T--C-AT CT GATGC-AT CT-CTTAT CT CT G-CGCG-T-TGCT AGT ACATT ATATCT GT CG-C-GCCT G-CG-CGCT -G- 
T CGCT-G-CT-C-A-T G-CGT CGT -CAC-GTGTTCG-CC-TGCG-TCGCCCAT CT CGCTT G-CGTTTT-TT-T-G--G-GC- 
G A-T-C-GT CC-C-T-G-GGG-GG--G--G-CC-C-AGGCCC-CC-T-C-C-G-C-
CTT CTTTT G AG AAAATTT CTTT CAACAAGTTACCG AG AAAG AAG AACT C ACACAC AGCTAGCGTTT AAACTTAAG 
CTTGGTACCGACAGTGTGGTGTAAAGGAATTCATTAGCCATGGATGTATTCATGAAAGGACTTTCAAAGGCCAA 
GGAGGGAGTTGTGGCTGCTGCTGAGAAAACCAAACAGGGTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGG 
TGTTCTCTATGTAGGCTCCAAAACCAAGGAGGGAGTGGTGCATGGTGTGGCAACAGTGGCTGAGAAGACCAAA 
G AGCAAGTG ACAAAT GTTGG AGGAGCAGTGGT GACGGGTGTGACAGCAGTAGCCCAGAAGACAGTGGAGGGA 
GCAGGG AGCATTGCAGCAGCCACTGGCTTT GT CAAAAAGGACCAGTTGGGCAAGAAT GAAGAAGGAGCCCCA 
CAGGAAGGAATTCTGGAAGATATGCCTGTGGATCCTGACAATGAGGCTTATGAAATGCCTTCTGAGGAAGGGT 
AT CAAGACT ACGAACCT GAAGCCTACCCA-TA-CGACG-TCCCAGACTACGCTT GAT CA- 
CT AGT CCAGT GTGGTGGAATT CT GCAG ATAT-C-CAGCAT CAGT G-GCGG ACAC--T-GAG
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WTsyn 3: c a g t c -g t g c t a g -c a t t t c -a -c g a --g t c t -g a c t -g -a c t - t c c g t --c -t -c t c — t - a — t -c a -g -t —
GAT GCT AGTT C-T GG AGT C A -T  CAT-T CGCATACT-CT C-A-G-TAGTAGCTT C-T-CAT GCTGCACG-CT-CTCCT-C- 
C A-CG-AC-TA-C-G A-T CGCTT--CAGT CT-CTACT-AC-ACT-C--TCGT-T— T C--AGG-AT C-T C-AT-CGCCTAC A- 
CTC-T - AG-TCG-TT CT C A-T-T ATT C-AG ATAA-T-CT -C--GCC ACT C-CG CT -AC-TA-GT-CT CA--T CT G C-A- 
C ATACTA-CG AT -A—C-T G-T GT C-ACACA—T CG-T-A-TA-C-T ATA-T AT CGC—C AT CG-AT G AG-C-TGC AAT CT-T- 
ATCT -GT G AGT CAGG AT -AAGT CTA-CACCCAT CGT C-CGCCCCCG—GCCCGCC-GC-CGCG-G-GCCCA--CC—A- 
G-G-A-CTT CTTTGT AGAAAATTT-
TTTT CACAAGTTACCG AGAAAG AAGAACT CACACAC AGCTAGCGTTTAAACTT AAGCTT GGTACCG AC AGT GTG
GTGTAAAGGAATTCATTAGCCATGGATGTATTCATGAAAGGACTTTCAAAGGCCAAGGAGGGAGTTGTGGCTG
CTGCTGAGAAAACCAAACAGGGTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTTCTCTATGTAGGCTC
CAAAACCAAGGAGGGAGTGGTGCATGGTGTGGCAACAGTGGCTGAGAAGACCAAAGAGCAAGTGACAAATGT
TGGAGGAGCAGTGGTGACGGGTGTGACAGCAGTAGCCCAGAAGACAGTGGAGGGAGCAGGGAGCATTGCAG
CAGCCACTGGCTTTGTCAAAAAGGACCAGTTGGGCAAGAATGAAGAAGGAGCCCCACAGGAAGGAATTCTGGA
AG ATATGCCTGTGG ATCCT G AC AAT G AGGCTTAT G AAATGCCTT CT G AGG AAGGGT AT C AAG ACTACG AACCT G
AAGCCTACCCA-TA-CGACG-TCCCAGACTACGCTTGATCA-CTAGTCCAGTGTGGTGGAATTCTGCAGATAT-C-
CAGCACCAGT G-T CGGGGGTA-T -GA
MUTsyn 1: TATCATCATGCT-CGTGTAACGTCA-T-C-AG-TCAT-CA-GT-CAT-A--TCT-C-TCACTCGTGCATTG- 
TATGCGATGCATG-CATA-TCTGTAC-TGAT-GCTAG-CCGACG-TC-GT-A-CGTCGTAGCA-TA-TCATACATGAC- 
ACG AG ATT -AT GCT -CG-ATTT-GT AT AA-T-T AT CAT CAT AT A-
GTCTACGTATGCATAATATCGATCAGTCAGTCTCGATGACTCGCGCGCCTGTTCATGTAGTCG-AGCATATA- 
T CT CGC A-T GG-TCGT CG AT CT CTT AT GT CAT CAACGT-TCGCTAG C ACT CT -AT C-T-GCT CTTATAT CT -AG-T-GC- 
ATG-ATAGCGAGCA-CTGATGT-G--C-CGA-TC-GTCGCAC-GC-AGA-CTGGCA—TG-TGTCTAG-TC—TCACT-G- 
CT—G ACC-G-T CGCAGCAC-GC-TT AGTCA-T ATATTAG AAG AT CT CTC-TTA- 
ATT AT ATT GT AGT C ATT C AG AGATT-CT CC AC AT CT-CAGT AGT-CG- 
TGCCGCGAGGGGGACGGGGGGGGGGCACTTCTTTTG-GATATTTT-
TTT CAACAAGTT ACCG AG AAAG AAG AACT CAC ACAC AGCTAGCGTTTAAACTT AAGCTTGGT ACCG AC AGT GT G 
GTGTAAAGGAATTCATTAGCCATGGATGTATTCATGAAAGGACTTTCAAAGGCCAAGGAGGGAGTTGTGGCTG 
CTGCT GAGAAAACCAAACAGGGT GTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTT CTCTAT GTAGGCT C 
CAAAACCAAGGAGGGAGTGGTGCATGGTGTGACAACAGTGGCTGAGAAGACCAAAGAGCAAGTGACAAATGTT 
GG AGGAGCAGTGGT G ACGGGT GTGACAGCAGT AGCCCAGAAGACAGTGGAGGGAGCAGGGAGCATTGCAGC 
AGCCACTGGCTTTGTCAAAAAGGACCAGTTGGGCAAGAATGAAGAAGGAGCCCCACAGGAAGGAATTCTGGAA 
G ATAT GCCT GTGGAT CCT GACAAT G AGGCTTAT GAAATGCCTT CT GAGGAAGGGTATCAAG ACTACGAACCT GA 
AGCCTACCCA-TA-CGACG-TCCCAGACTACGCTTGATCA-CTAGTCCAGTGTGGTGGAATTCTGCAGATAT-C- 
CAGCAGCAGT G-GCGGG-GCT CT CG AG
MUTsyn 2: a g t c a t c t c a g t a t c -
GACTCTCAGTGCTATGAGCTGCGTATGCTTCGATCATCGTATTTGCATCGAGTCGTTAGATCTCGTACGACTCA 
T G ACGT CG-T CT AT CACGT CG-T CTACATGGAG-C-GAT C-
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GTCGCACTGCACTTCTTGTAGCAGCATCTTAATCCTGCAGATAT-GTAGCATCATCTAA-TAGC- 
ATGTCT C ACT CACCTT CGCAG AT CGCT GTAGTTAT CTAT GAT-CGT-G-TA-CTC-TA-C ATAGTA-T GT AC- 
TTGTATT CGTATCGGTGTAT -ATACACGT GT ACTACGTAT CTAT CT CCA-CTACATAC A-CGCACACGC AT C AG- 
CAGT C-AT ACG A-CT GTCGT CAT CATATAT AAGTAGC AT GATT CG ATAT CAGT AT AG AT - 
GCTGCAGTGTTTGAATATATGGCTACGTAG-TAT-GTCTATCTATCTATTATGGATGACGGTATGAC- 
GAGCGCGC ACCGACCGC ACGG AT ACC-CG AG AAGGGACAG-G-G-G-T C-T -CTTT-G-GAAA-TTTT-TT - 
AACAAGTTACCGAGAAAGAAGAACTCACACACAGCTAGCGTTTAAACTTAAGCTTGGTACCGACAGTGTGGTGT 
AAAGGAATTCATTAGCCATGGATGTATTCATGAAAGGACTTTCAAAGGCCAAGGAGGGAGTTGTGGCTGCTGCT 
GAGAAAACCAAACAGGGTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTTCTCTATGTAGGCTCCAAAA 
CC AAGGAGGGAGTGGTGCATGGTGT GACAACAGT GGCT G AGAAGACCAAAGAGCAAGT GACAAATGTT GGAG 
GAGCAGTGGT G ACGGGTGT G ACAGCAGT AGCCCAGAAGACAGTGGAGGG AGCAGGGAGCATT GCAGCAGCC 
ACTGGCTTTGTCAAAAAGGACCAGTTGGGCAAGAATGAAGAAGGAGCCCCACAGGAAGGAATTCTGGAAGATA 
TGCCTGTGGATCCTGACAATGAGGCTTATGAAATGCCTTCTGAGGAAGGGTATCAAGACTACGAACCTGAAGC 
CTACCCA-TA-CG ACG-T CCCAG ACTACGCTT GAT CA-CTAGT CC AGT GTGGT GG AATT CT GCAG ATAT-C- 
CAGCAGCAGT G-GCGGGCGCT-T-GAGT
MUTsyn 3: CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCACCCCCTCCCCCCCGCCC-
CTCCCTCCCCCCCACCCCCCCCCCCATC-CTCCATCCCCCCCCCCCCC-TCCTCC-CCC-
GCCCCCCCCCCCCCCCCCCCCCCCCCCCCTCCCCCCT-
T CCCCCCCCTCT CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCT CAGCCCCCACC-CT CCTTTT G- 
G AAATTTT-TTT C-
AC AAGTT ACCG AG AAAG AAG AACT CACAC AC AGCT AGCGTTTAAACTT AAGCTTGGTACCG ACAGT GTGGTGTA 
AAGGAATT CATTAGCC AT GG ATGT ATT CAT GAAAGGACTTT CAAAGGCCAAGG AGGG AGTT GTGGCT GCTGCT 
GAGAAAACCAAACAGGGTGTGGCAGAAGCAGCAGGAAAGACAAAAGAGGGTGTTCTCTATGTAGGCTCCAAAA 
CCAAGGAGGGAGTGGT GCATGGTGT GACAACAGTGGCT GAGAAG ACCAAAGAGCAAGT GACAAAT GTT GGAG 
GAGCAGTGGTGACGGGTGTGACAGCAGTAGCCCAGAAGACAGTGGAGGGAGCAGGGAGCATTGCAGCAGCC 
ACT GGCTTT GT C AAAAAGG ACCAGTT GGGC AAG AAT G AAGAAGG AGCCCCACAGGAAGG AATT CT GG AAG ATA 
TGCCT GTGG AT CCT GACAAT G AGGCTTAT G AAAT GCCTT CT G AGGAAGGGTAT CAAG ACT ACG AACCT GAAGC 
CTACCCA-TA-CGACG-TCCCAGACTACGCTTGATCA-CTAGTCCAGTGTGGTGGAATTCTGCAGATAT-C- 
CAGCAC-AGGT-GCAGA
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Mutations of the a-synuclein gene have been identified 
in autosomal dominant Parkinson’s disease (PD). 
Transgenic mice overexpressing wild-type human a- 
synuclein develop motor impairments, intraneuronal 
inclusions and loss of dopaminergic terminals in the 
striatum. To study the mechanism of action through 
which mutant a-synuclein toxicity is mediated, we 
have generated stable, inducible cell models 
expressing wild-type or PD-associated mutant (G209A) 
a-synuclein in human-derived HEK293 cells. Increased 
expression of either wild-type or mutant a-synuclein 
resulted in the formation of cytoplasmic aggregates 
which were associated with the vesicular (including 
monoaminergic) compartment. Expression of mutant 
a-synuclein induced a significant increase in sensi­
tivity to dopamine toxicity compared with the wild-type 
protein expression. These results provide an explana­
tion for the preferential dopaminergic neuronal 
degeneration seen in both the PD G209A mutant a- 
synuclein families and suggest that similar mecha­
nisms may underlie or contribute to cell death in 
sporadic PD.
INTRODUCTION
Parkinson’ s disease (PD) is characterized by the loss o f 
dopaminergic neurons in the substantia nigra pars compacta 
and by the formation o f Lewy bodies in a proportion o f 
surviving neurons. The identification o f mutations in several 
different genes in fam ilia l parkinsonism (1—4), increased 
concordance amongst identical tw ins when studied w ith 
fluoro-dopa positron emission tomography (5), or i f  onset is 
before 50-years-old (6), and the increased fam ilia l frequency 
o f PD (7) all support the proposition that there may be a signif­
icant genetic contribution to the aetiology o f this disease. 
Mutations in the a-synuclein gene have now been identified in 
several PD families (1,2,8), although they are not common 
causes o f either fam ilia l (9) o r sporadic PD (10,11). The pres­
ence o f a-synuclein has also been demonstrated in Lewy 
bodies in the brains o f sporadic PD patients (12) suggesting the 
possibility that aggregation o f  this protein may be relevant to
disease pathogenesis. In a recent report, transgenic mice over­
expressing w ild-type human a-synuclein developed deficits in 
motor performance, a-synuclein containing neuronal intra­
nuclear and intracytoplasmic inclusions and loss o f dopamin­
ergic terminals in the striatum, proportional to the degree o f 
a-synuclein expression (13). W e have developed stable, induc­
ible human-derived cell lines expressing wild-type or mutant 
(G209A) a-synuclein to investigate the morphological and 
biochemical consequences o f wild-type and mutant protein 
expression.
RESULTS
There was only very weak expression o f a-synuclein in the 
pIND .a-syn- or pIND.a-syn/G209A-transfected cells in the 
absence o f ponasterone A  (Fig. 1A) and likewise no or only 
weak expression in the pIND.zero cells. This suggests that the 
background expression o f  pIN D .a-syn and pIND .a-syn/ 
G209A cells is the result o f the host gene and not due to 
leakage o f the introduced gene constructs. Furthermore, the 
level o f a-synuclein expression (w ild-type or mutant) was 
proportional to the concentration o f ponasterone A  used w ith 
the inducible cell lines (Fig. 2). Thus, the production o f a- 
synuclein protein by these cell lines was tightly controlled by 
ponasterone A.
Treatment o f the pIN D .a-syn or pIND.a-syn/G209A cell 
lines w ith 5 p.M ponasterone A  fo r 48 h led to the formation o f 
intracellular aggregates containing a-synuclein (Fig. 1B-D). 
No difference in the number or location o f aggregates formed 
was observed between cells expressing w ild-type or mutant a- 
synuclein (Fig. 1C and D). a-synuclein did not co-localize 
w ith markers fo r the cell nucleus, Golgi, mitochondria or lyso- 
somes (Fig. 1C-F and H). Neither the w ild-type (data not 
shown) nor mutant a-synuclein deposits stained for ubiquitin 
(Fig. 1G). However, co-localization o f both wild-type (data not 
shown) and mutant a-synuclein was observed with vesicle- 
associated membrane protein (V A M P ), indicating that a- 
synuclein was associated w ith  intracellular vesicles (Fig. II). 
Staining fo r vesicular monoamine transporter (V M A T  1) 
showed that a proportion o f  vesicles were positive fo r both this 
protein and a-synuclein (Fig. 1 J).
The expression o f w ild-type or mutant a-synuclein did not 
cause any significant level o f excess cell death (Fig. 3). This
+These authors contributed equally to this work
8To whom correspondence should be addressed. Tel: +44 207 830 2012; Fax: +44 207 431 1577; Email: schapira@rfhsm.ac.uk
2684 Human M olecu lar Genetics, 2000, Vol. 9, No. 18
suggests that in  the time-frame o f expression used (96 h) 
neither w ild-type nor mutant a-synuclein proteins were toxic.
In view o f the like ly co-localization o f a-synuclein w ith 
dopamine-containing vesicles and the known toxicity o f 
dopamine through its production o f reactive oxygen species
(14,15), we investigated the effect o f wild-type and mutant a- 
synuclein expression on dopamine toxicity. Following treatment 
w ith ponasterone A  (5 ( iM ) fo r 48 h before and during the 48 h o f 
dopamine exposure, pIND.zero cell lines showed a significant 
increase in cell death w ith  0.75 and 1 m M  dopamine (P = 0.0002
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Figure 2. Western blots showing the induction o f a-synuclein expression with 
ponasterone A. pIND (pIND.O), pIND.a-syn (IC ) and pIND.a-syn/G209A  
(15M) transfected cell lines were grown, cell extracts prepared and western 
blots performed as described. Porin immunoreactivity was equal in all lanes 
and indicated equivalent protein loading (A). Both a-synuclein and HA anti­
bodies detected a band representing the a-synuclein-HA complex at -2 0  kDa 
with 5 pM ponasterone A in the wild-type and mutant a-synuclein cell lines 
but not in the pIND.zero lines (B and C ). In  all these three cell lines there was 
no detectable a-synuclein protein expression without ponasterone A. Increas­
ing concentrations of ponasterone A (0.1, 0.5, 1.0, 3.0 and 5 p M ) resulted in 
greater expression of the mutant protein (D). Similar results were obtained 
with the wild-type pIND.a-syn cell lines (data not shown).
for both) confirming the tox ic ity  o f  dopamine in these cells 
(Fig. 3). These concentrations o f dopamine are equivalent to 
those reported in the cell bodies o f dopaminergic neurons (16).
Increasing dopamine concentrations resulted in excess cell 
death in the lines expressing either w ild-type or mutant a-synu- 
clein. At 0.5 mM dopamine both w ild-type and mutant a- 
synuclein expression caused increased cell death compared w ith 
pIND.zero lines (P = 0.05 and P  =  0.007, respectively) but there 
was no significant difference in susceptibility between the two 
a-synuclein lines. A t higher concentrations o f dopamine, 
however, mutant a-synuclein expression caused significantly 
greater cell death than w ild-type (P =  0.0003 and P =  0.02 for 
0.75 and 1 mM dopamine, respectively). There was no signifi­
cant difference in cell toxic ity between pIND.zero and wild-type 
a-synuclein lines at these concentrations.
DISCUSSION
a-synuclein has been shown to bind to vesicles, be transported 
by the fast component o f axonal transport in  rat optic nerve and 
co-localize w ith  synaptophysin in  the presynaptic terminal 
(17,18). The G88C mutant form  o f a-synuclein had decreased 
vesicle binding compared w ith  the mutant G209A or w ild-type 
forms in this rat model. Our fluorescent immunocytochemical 
studies showed that, in  human cultured cells, w ild-type and 
mutant forms o f  human a-synuclein are also associated w ith  
the vesicular component w ith in  cells, including those vesicles 
expressing the monoamine transporter. Overexpression o f 
human w ild-type a-synuclein in a transgenic mouse model 
demonstrated accumulation o f  a-synuclein aggregates in the 
rough endoplasmic reticulum  o f  cingulate cortex neurons (13) 
indicating that a-synuclein aggregates may also be located 
outside vesicles. In  some cells o f our model, increased expres­
sion o f w ild -type or mutant a-synuclein w ith ponasterone A 
led to diffuse, as opposed to aggregated, protein deposits. W hy 
some cells did and others did not form  aggregates was unclear. 
The observation that a-synuclein aggregates were not ubiquin- 
ated in our cell system was surprising. However, i t  may be that 
the time-scale fo r ub iquitination to be detected was too brief. 
Term inally differentiated cells are needed to assess whether 
ubiquitination occurs after more prolonged a-synuclein 
expression.
In our model, neither w ild-type nor mutant G209A a-synu- 
clein expression resulted in cell death. In a transient transfection 
model o f G209A mutant a-synuclein expression in HEK293 
cells, however, excess cell death was observed (19). The differ­
ence in these results may lie in the level o f protein expression—  
the transient transfections perhaps producing greater levels o f 
mutant protein. Nevertheless, our results are in accord w ith those 
o f the mouse model o f overexpression o f human w ild-type a- 
synuclein in which there was no evidence o f excess cell death 
(13).
Based on our results, we suggest that at least part o f the 
tox ic ity  o f  mutant a-synucle in is mediated via its enhancement 
o f dopamine tox ic ity . The mice overexpressing human w ild- 
type a-synuclein developed intraneuronal inclusions, but no 
increased cell death o f  tyrosine hydroxylase (TH)-positive 
neurons (13). However, at 12 months, those mice w ith the 
highest a-synuclein expression levels had reduced striatal TH 
activity, decreased density o f  TH-positive terminals and a 
defic it in  motor performance. Thus long-term wild-type a-
Figure 1. Immunocytochemical localization of a-synuclein in HEK293-derived cell lines. HEK293-derived cell line ECR293 was transfected with pIND, pIND .a- 
syn or pIND.a-syn/G209A. Wild-type or mutant a-synuclein clonal lines were chosen where >70% of cells expressed the induced protein. Immunocytochemistry 
was performed with antibodies to a-synuclein (A -D , green fluorescence), the Golgi network (E ), MitoTracker (F), ubiquitin (G ), lysosomes (H ), vesicle-associ­
ated membrane protein (VAMP) (I) and vesicular monoamine transporter (V M A T 1) (J). The cell nucleus was stained with propidium iodide as described. Nuclei 
were clearly visible but there was negligible background expression o f a-synuclein (green fluorescence) in HEK293 cells with the wild-type or mutant constructs 
(A). Induction with ponasterone A increased expression of both wild-type (data not shown) and G209A mutant a-synuclein (B) with the formation o f cytoplasmic 
but no nuclear aggregates for both wild-type (C) and mutant (D ) a-synuclein. Dual staining with green fluorescence for the Golgi network (E) and lysosomes (H) 
showed separate localization for mutant (red fluorescence) and wild-type (data not shown) a-synuclein. Co-staining with the MitoTracker (red fluorescence) 
showed that a-synuclein was not localized in the mitochondria (F). This was confirmed with the CO I subunit o f cytochrome oxidase (data not shown). Dual label­
ling studies indicated that neither the mutant a-synuclein (red) nor wild-type a-synuclein (data not shown) aggregates stained for ubiquitin (green) (G). a-synu­
clein (red) did co-localize with VAM P (green) (I)  as shown by the merged fluorescence (yellow) and with VM AT-1 (red) with green fluorescence for a-synuclein 
(J) although this was not exclusive to the distribution of either of the vesicle stains. Bars: (A and B) 20 pm; (C—J) 10 pm.
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Figure 3. Cell death in pIND.zero (open bars), pIND.a-syn (black bars) and pIND.a-syn/G209A (hatched bars) cell lines with increasing concentrations of 
dopamine. Incubations and quantitation of cell death were undertaken as described. In the absence o f dopamine, there was no significant cell death in any cell line 
with 5 pM ponasterone A treatment over 96 h. A ll concentrations o f dopamine used resulted in a significant increase in cell death. At 0.75 and 1.0 mM dopamine, 
the degree of cell death was significantly greater in the mutant a-synuclein cell line than in either the pIND.zero or pIND.a-syn lines (P = 0.0003 and P = 0.02, 
respectively).
synuclein overexpression is toxic. O ur model would predict 
that overexpression o f mutant G 209A a-synuclein in such 
mice would induce a more rapid and intense loss o f striatal TH- 
positive terminals and loss o f dopamine-containing neurons, 
with an earlier onset o f motor dysfunction. In this context, it  is 
interesting to note that those fam ilies w ith  the G209A mutation 
develop PD at a much earlier mean age than those w ith  id io ­
pathic PD and also have a more accelerated course w ith  death 
an average 9.7 years after onset (20). Our results are also 
consistent with the Drosophila  model o f w ild -type and mutant 
a-synuclein expression in which there is aggregate formation, 
relative selective dopaminergic cell loss and locomotor 
dysfunction (21). Furthermore, expression o f human G209A 
mutant but not w ild-type a-synuclein selectively led to apop- 
tosis of dopamine neurons in  rat prim ary mesencephalic 
cultures (22). Both the mutant and w ild-type forms o f human 
a-synuclein enhanced the tox ic ity  o f 6-hydroxydopamine. 
Similar results were also seen at low  concentrations o f  the pre­
aggregated fibrillogenic 61-95 kDa fragment o f  a-synuclein in 
the same model system (23).
At present the mechanism by which mutant a-synuclein 
increases dopamine tox ic ity  is not known, a-synuclein is 
highly expressed in human brain presynaptic terminals (24) 
and in rat substantia nigra pars compacta (25), and is also a 
major component in the Lewy bodies o f  dopamine-containing 
neurons in PD brains (12). Thus, a-synuclein is expressed at
sites o f  high dopamine content and it may function to modulate 
dopamine release (26).
Dopamine-induced cell death has been confirmed in a 
number o f systems (27-29). Dopamine is unstable and is 
readily oxidized to the dopamine quinone and generates super­
oxide and hydrogen peroxide. Dopamine can also covalently 
m odify free cysteine, cysteine in glutathione and cysteinyl resi­
dues in  protein (30). Sulphydryl groups on cysteines are often 
associated w ith  active sites on proteins and thus their modifica­
tion could alter function irreversibly. Interestingly, the forma­
tion o f S-cysteinyl dopamine on protein is associated w ith  the 
loss o f monoaminergic striatal terminals in dopamine-induced 
tox ic ity  (31). Thus, dopamine tox ic ity  may be mediated via 
increased reactive oxygen species generation and by direct 
protein m odification.
In  our expression model, the synergistic toxic effect o f mutant 
a-synuclein and dopamine occurs relatively rapidly. Dopamine- 
mediated free radical and sulphydryl group damage may 
increase the predisposition fo r mutant a-synuclein to form 
aggregates, a suggestion supported by the finding that a-synu- 
clein aggregation was increased by ferric ion or by ferrous ion in 
the presence o f hydrogen peroxide (32). However, during the 
time course o f our experiments, increased aggregation o f w ild- 
type or mutant a-synuclein was not observed at light m icro­
scopic level in our cell system. The toxic ity o f dopamine may be 
increased by failure to compartmentalize it w ith in vesicles. The
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damaging effects o f dopamine would therefore be increased i f  
mutant a-synuclein interfered w ith  the function o f  the 
monoamine transporter, thereby increasing intracytoplasmic 
concentrations and the potential fo r cell damage sufficient to 
cause cell death. This hypothesis would be consistent w ith  the 
results o f our study, the defective modulation o f  dopamine 
release and significant decrease in striatal dopamine levels in a-  
synuclein knockout mice (26), as w e ll as the observations 
described above in the G209A PD families. A  defect o f 
dopamine compartmentalization could promote a slow but 
progressive loss o f striatal terminals and nigral neurons. The 
overexpression o f w ild-type a-synuclein m ight lead to a sim ilar 
effect, but over a longer period— such as seen in  the human 
wild-type a-synuclein transgenic mice described above (13).
The relevance o f these data fo r patients w ith  id iopathic PD 
without a-synuclein mutations m ight lie  in  the potential fo r 
wild-type a-synuclein to be the target protein fo r a variety o f 
pathogenetic pathways includ ing dopamine tox ic ity , oxidative 
stress and possibly m itochondrial dysfunction. The gradual 
accumulation o f auto-oxidation products may promote a-synu- 
clein aggregation, Lewy body form ation and cell death over 
prolonged periods.
MATERIALS AND METHODS
Generation of cell model
Total RNA was isolated as described by Chomczynski and Sacchi
(33) from lymphoblasts from a male PD patient w ith the G209A a- 
synuclein mutation (a kind g ift from M . Polymeropoulos, NIH, 
Bethesda, MD) and control lymphoblasts with wild-type a- 
synuclein (from ECACC, Wiltshire, UK). cD N A was generated by 
RT-PCR using the cDNA Cycle k it (Invitrogen, Groningen, The 
Netherlands) according to the manufacturer’s instructions. The 
High Fidelity system (Roche/Boehringer, Mannheim, Germany) 
was used for all subsequent PCR. Full-length a-synuclein cDNA 
was amplified using 5' CATTCGACGACAGTGTGGTGT-3' 
(nucleotides 16-37) as a forward primer and 5 'C TG C TG AT- 
GGAAGAC1TCGAG-3' (nucleotides 586-607) as a reverse 
primer. In a subsequent PCR, the open reading frame o f a- 
synuclein and its 31 nucleotide 5' untranslated region was amplified 
using 5'-AAGGTACCGAC AG TG TG G TG TAAAG G AAT-3 ' as a 
forward primer (nucleotides 26-44 w ith a 5' Kpnl site) and 5'- 
AATGATCAAGCGTAGTCTGGGACGTCGTATGGGTAGG- 
CTTCAGGTTCGTAGTCTTAC- 3' as a reverse primer [nucleo­
tides 456-478 with a 3' haemagglutinin (H A ) epitope coding 
sequence and Bell site]. Both mutated G209A and wild-type a - 
synuclein amplified fragments were restricted w ith  K pn l and 
Bell and ligated into the K pn l and Bam H l sites o f  p IN D  (Inv itro ­
gen). The correct sequence was confirmed by B ig Dye 
automated sequencing (A B I 310; Perkin Elmer, Warrington, 
UK). HEK293 cells w ith stable transfection o f the pVgRxR 
plasmid (ECR 293; Invitrogen) were grown at 37°C in  a 
humidified atmosphere containing 5% C 0 2 in  growth medium 
consisting o f Dulbecco’s m odified Eagle’ s medium (D M E M ) 
and 4.5 pg/1 glucose, 10% fetal ca lf serum, 50 U /m l penicillin, 
50 |ig/ml streptomycin, 400 pg/m l Zeocin, 50 (ig/m l uridine and 
110 (ig/ml sodium pyruvate. ECR293 cells were transfected with 
5 pg of pIND constructs containing either no insert or inserts 
encoding wild-type a-synuclein w ith a C-terminal H A  epitope 
(pIND.a-syn) or G209A mutant a-synuclein with a C-terminal
H A  epitope (pIND.a-syn/G209A) using the Escort (Sigma, Poole, 
U K ) lipofection method according to the manufacturer’ s instruc­
tions. Twenty-four hours post-transfection, stable clones were 
selected in the presence o f  400 fig /m l G418 and stable cell lines 
generated from  indiv idual clones. A ll cells resistant to G418 
fo llow ing  transfection w ith p IN D  were used as a control cell line 
(pIND.zero cells). Clonal cell lines transfected with either 
pIN D .a-syn or pIND .a-syn/G 209A were treated w ith 5 pM  
ponasterone A  fo r 48 h and screened by immunocytochemistry 
fo r the expression o f a-synucle in -H A construct using an 
antibody to H A  (1:200 dilution; Boehringer). D N A  was 
extracted from  each cell line and the a-synuclein insert was 
amplified using p IN D  m ultip le  cloning site forward and reverse 
sequencing primers (Invitrogen) and sequenced as above to 
confirm  the correct sequence.
Immunocytochemistry
Cells were harvested w ith  Versene (1:5000; Gibco BRL, 
Paisley, U K ) and plated out on glass coverslips in a 35 mm dish 
w ith 2 m l o f medium. They were allowed to settle fo r 24 h before 
induction o f  a-synuclein expression w ith 5 | iM  ponasterone A. 
A fte r 48 h o f protein expression the coverslips were washed in 
phosphate-buffered saline (PBS). Cells were fixed fo r 20 min in 
4% (w /v) paraformaldehyde and then fo r 15 m in at -20°C  in 
methanol. A ll the fo llow ing incubations took place in a humid 
chamber at 37°C. Fixation was followed by blocking w ith 10% 
normal goat serum in PBS for 1 h followed by incubation w ith 
the primary antibody fo r 3 h. A fte r three washes in PBS, primary 
antibodies raised in  mouse were developed fo r 1 h w ith respec­
tive goat anti-mouse Alexa 488 conjugates (1:200; Molecular 
Probes, Eugene, OR) whereas the rabbit or goat primary anti­
bodies were detected w ith goat anti-rabbit or donkey anti-goat 
A lexa 568 conjugates, respectively (1:1000; Molecular Probes). 
A fte r three washes in  PBS, coverslips were mounted on glass 
slides in C itifluo r w ith  1 pg/m l DAPI. Dual labelling consisted 
o f an incubation w ith  the rabbit or goat primary antibody and the 
appropriate fluorescent secondary antibody, followed by a 
mouse monoclonal antibody and anti-mouse fluorescent 
secondary antibody. The fo llow ing  primary antibodies were 
used: a-synuclein either mouse monoclonal antibody (mAb) 
(1:200; Zymed, San Francisco, C A) or rabbit polyclonal anti­
body (1:2000; Chemicon, Temecula, CA), H A  (mAb anti-HA, 
1:200; Roche/Boehringer), cytochrome c oxidase (m Ab anti- 
C O X I subunit, 1:200; M olecular Probes), lysosomes (m Ab anti- 
lysosomal associated membrane protein 1, 1:400; PharMingen, 
San Diego, CA), Golgi (m Ab anti-Golgi zone, 1:200; 
Chemicon), V A M P  (m Ab), anti-V AM P  (1:200; Chemicon), 
V M A T  1 (goat polyclonal antibody, an ti-V M A T 1, 1:50; Santa 
Cruz Biotechnology, Santa Cruz, C A) and ubiquitin (mAb anti- 
ubiquitin, 1:300; Chemicon). In addition, cells were labelled 
w ith propidium iodide (1 pg /m l) and Mitotracker (CMXRos-H2, 
3 (iM ; M olecular Probes). Slides were evaluated w ith a krypton- 
argon laser (M RC 600; BioRad, Hercules, CA) attached to an 
Olympus BH2-RFCA fluorescence microscope.
Western blotting
Cells were plated at 40% confluency and allowed to settle for 
24 h before the addition o f  ponasterone A  (0-5 pM ). A fte r 48 h 
the cells were scraped, washed in  PBS and solubilized in 
100 m M  T ris -H C l, 8% (w /v) SDS, 24% (w/v) glycerol, 0.5%
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(v/v) mercaptoethanol, pH 6.9, containing a cocktail o f protease 
inhibitors. Samples were heated at 37°C fo r 10 min, centrifuged 
at 16 060 g for 10 min, separated on a 15% polyacrylamide gel 
containing SDS and transferred to PVDF membrane (Immo- 
bilon-P; M illipore, Bedford, M A ) fo llow ing standard techniques
(34). Equal protein loading was verified by comparison w ith a 
gel stained w ith Coomassie in parallel. Blots were blocked using 
10% (w/v) proprietary m ilk  powder, incubated w ith  anti-HA rat 
mAb (1:3000; Boehringer) as primary and sheep anti-rat Ig -  
horseradish peroxidase (HRP) (Fab fragments, 1:3000; 
Boehringer) as the secondary antibody. Blots were also 
incubated w ith anti-a-synuclein m Ab (1:4000; Zymed) and anti- 
porin (1:25 000; Calbiochem, Nottingham, U K ) mouse mono­
clonal antibodies as primary and rabbit anti-mouse HRP 
(1:3000; BioRad) as secondary antibody. A ll blots were devel­
oped by chemiluminescence detection (NEN, L ife  Science 
Products, Boston, M A ).
Cell death experiments
Cells were harvested w ith  Versene (1:5000; Gibco BRL), 
counted w ith a haemocytometer and plated out at a density o f 
-62  500 cells/well o f a 12-w e ll plate. A fte r 1 day, 5 | iM  ponas­
terone A  was added. A fte r 48 h the medium was replaced w ith  
phenol-red free medium containing ponasterone A  (0-5  |iM ) 
and dopamine (0-1000 pM ) fo r 48 h. The supernatant o f each 
well was aspirated, the cells washed w ith  PBS and harvested 
by the addition o f Versene and 10% (v/v) T riton  X-100. Pairs 
o f supernatant and cells o f the same w e ll were stored at -80°C  
until assayed for lactate dehydrogenase (LD H ) spectrophoto- 
metrically (35) or using a L D H  C yto tox ic ity  Detection k it 
(TaKaRa Biomedicals, Tokyo, Japan). The ratio o f  L D H  
activity in the supernatant to the total LD H  activ ity  was taken 
as the percentage o f cell death. Protein was determined w ith  
the BCA k it (Pierce, Rockford, IL )  using bovine serum 
albumin as standard.
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